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Abstract 
Colorectal cancer has a 9.8% cumulative incidence rate, making it the third most common 
cancer in the Western world.  Despite a 50-60% response rate in patients to current 
cancer therapies, drug resistance and tumour relapse remain a concern.  While current 
therapies reduce the tumour mass, they possibly fail to eradicate a unique population of 
pluripotent tumour resident cells.  These cells, known as cancer stem cells, may have 
similar properties of self-renewal and proliferation to embryonic and adult stem cells, as 
they also express a number of key pluripotent transcription factors, including amongst 
others, NANOG, OCT3/4 and SOX2.   Furthermore, since discreet groups of such stem 
cells are proposed to essentially drive tumourigenesis, they present as potential novel 
targets for cancer therapy.  This study aimed to isolate a putative CSC population from 
the advanced colon adenocarcinoma cell lines HT29 and DLD1 and to assess the 
therapeutic effects of the epigenetic drugs Valproic acid and Zebularine on pluripotent 
gene expression.   
As cancer stem cells may be isolated from general tumour cell populations due to their 
expression of unique cell surface markers, this study began with an investigation of the 
existence of putative cancer stem cells in human colorectal adenocarcinoma cell lines.  
Using flow cytometry, the surface expression of the stem cell-specific biomarkers, 
CD133 and EpCAM were evaluated in each of the SW1116, HT29 and DLD1 cell lines; 
these being representative of early-, mid- and late-stage colon adenocarcinomas, 
respectively.  In the SW1116 cell line, 88.70 percent of cells were EpCAM
+
, in the HT29 
cell line, 94.10 percent of cells were EpCAM
+
, and in the DLD1 cell line, 89.50 percent 
of cells were EpCAM
+
.  Moreover, CD133 was expressed together with EpCAM within a 
subpopulation of each cell line: 2.33 percent of cells were CD133
+
/EpCAM
+ 
within the 
SW1116 cell line; 5.11 percent of cells were CD133
+
/EpCAM
+
 within the HT29 cell line; 
while the DLD1 cell line contained some 10.30 percent of CD133
+
/EpCAM
+
 expressing 
cells.  These results suggest that the raised frequency of CD133 expression may well be 
associated with increased tumour stage.     
It was then of particular interest to evaluate the in vitro growth properties and clonogenic 
potential of CD133
+
/EpCAM
+ 
cells derived from the more advanced HT29 and DLD1 
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cell lines.  To accomplish this, magnetic cell separation was used to isolate a pure 
population of CD133
+
/EpCAM
+
 cells from each of these cell lines (CD133
+
/EpCAM
+ 
cells were not isolated from the SW1116 cell line, as this represents an early stage, non-
metastatic colon adenocarcinoma). A 98.60 and 98.00 percent purification of 
CD133
+
/EpCAM
+
 cells was obtained from the HT29 and DLD1 cell lines, respectively.  
CD133 was shown to be an important surface marker to isolate putative colorectal cancer 
stem cells, as an in vitro sphere formation assay showed that 21 percent of cells from 
each of the cell lines had clonogenic potential.  Moreover, using indirect 
immunofluorescence, confocal microscopy localised CD133 and EpCAM expression to 
the cell membrane and within the cytoplasm of both HT29 and DLD1 derived cancer 
stem cells.  While the cytoplasmic expression of CD133 may indicate cell invasiveness, it 
is nevertheless cell surface expression of both CD133 and EpCAM that are considered to 
be markers of putative cancer stem cells.  
As epigenetic mechanisms such as methylation of gene promoters and histone activity are 
involved in the regulation of stem cell transcriptional programs and in the regulation of 
self-renewal and differentiation, it was of particular interest to evaluate gene and protein 
expression of the pluripotency associated transcription factors, NANOG, OCT3/4 and 
SOX2 in the CD133
+
/EpCAM
+   
HT29 and DLD1 derived cancer stem cells.   These cells 
were treated with varying concentrations of a histone deacetylase inhibitor, Valproic acid 
and a DNA methyltransferase inhibitor, Zebularine, respectively; and their modulatory 
effects on protein expression of NANOG, OCT4 and SOX2 were assessed by confocal 
microscopy and on gene expression by quantitative real-time PCR analysis.  Confocal 
microscopy showed that 2.5mM and 5mM Valproic acid up-regulated nuclear NANOG 
and OCT4, respectively in HT29 putative cancer stem cells; whereas 250µM and 500µM 
Zebularine up-regulated nuclear NANOG equally, and 500µM Zebularine up-regulated 
nuclear OCT4 in these cells (p≤0.05).  The modulatory effects of these drugs on nuclear 
NANOG and OCT4 expression in DLD1 putative cancer stem cells were inconclusive 
(p>0.05).  Interestingly, nuclear SOX2 protein expression was unaffected by either drug 
in both HT29 and DLD1 derived cancer stem cells.  Statistical analyses of NANOG and 
OCT4 gene expression data indicated no significant change in mRNA transcript levels.  
Surprisingly, SOX2 mRNA transcripts were undetectable in both HT29 and DLD1 
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putative cancer stem cells.  A subsequent study showed that its absence was characteristic 
of these cells.  Thus, a mechanistic model was proposed, wherein particular post-
translational modifications of SOX2 regulate the negative feed-back loop in HT29 and 
DLD1 putative cancer stem cells.   
In summary, Valproic acid and Zebularine modulate nuclear NANOG and OCT4 protein 
expression in HT29 putative cancer stem cells.  As altered expression of either 
transcription factor is reported to induce differentiation in embryonic and adult stem cells, 
this similarly may induce differentiation in the HT29 derived cancer stem cells.  Further 
research is needed to confirm whether Valproic acid and Zebularine induce 
differentiation, as these drugs may sensitise these cells to current anti-cancer therapies 
and possibly prevent tumour relapse.  
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CHAPTER 1  
INTRODUCTION 
Cancer is a worldwide burden in both the developed and developing world.  In 2008, as 
many as 12.7 million cancer cases, and 7.6 million cancer deaths were estimated to have 
occurred.  Colorectal cancer has a 9.8% cumulative incidence rate making it the third most 
common cancer in the Western world (Jemal et al., 2009).  It is estimated that colorectal 
cancer will cause as many as 26 270 male- and 24 040 female-deaths in the United States 
in 2014 (Cancer Facts and Figures, 2014).  In 2007, The South African National Cancer 
registry had statistics on colorectal cancer prevalence in South Africans, for men it was 
4.47% and women 3.59%.  The age standardised incidence rate was 7.12 per 100 000 men 
and 4.34 per 100 000 women; whereas, the lifetime risk of developing colorectal cancer 
before the age of 74 was 1/115 men and 1/199 women.  The lifetime risk was highest in 
Caucasian men (1/50) and women (1/85), followed by Asian men (1/59) and women (1/90) 
(Table 1.1).  Although these figures may seem somewhat small compared to those of the 
Western world, they are indeed significant.  To demonstrate their significance, women 
living in Uganda and Zimbabwe have a lower risk of developing cancer by the age of 65 
compared with Western Europe; however, the risk of cancer related death is almost 
doubled (Ferlay et al., 2004).  This emphasises the need to study cancer prevention 
strategies and to design novel anti-cancer therapeutics to treat colorectal cancer in African 
populations. 
Table 1.1: The lifetime risk (ages 0-74 years) of developing colorectal cancer per 
population group in South Africa.          
Population Males Females 
Caucasian 1/50 1/85 
Asian 1/59 1/90 
Coloured 1/63 1/100 
Black 1/314 1/434 
All 1/115 1/199 
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The standard treatment for patients with localised colorectal cancer requires surgery to 
remove the cancer; whereas, the treatment for patients with advanced metastatic disease 
involves chemotherapy and/or radiotherapy following surgery (DeSantis et al., 2014).  
Adjuvant chemotherapy and/or radiotherapy may also be utilised to treat localised disease, 
but this is dependent on the patient and the grade of the tumour.  The chemotherapeutic 
agents used include: 5-Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan and combinations 
thereof, for example, FOLFOX (5-Fluorouracil, Leucovorin and Oxaliplatin) and FOLFIRI 
(5-Fluorouracil, Leucovorin and Irinotecan) (de Gramont et al., 2000; Falcone et al., 
2007).  In some instances, these drugs may be combined with the targeted therapeutic 
agents Bevacizumab or Cetuximab, these being monoclonal antibody derived inhibitors of 
vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), 
respectively (Hurwitz et al., 2004; Giantonio et al., 2007; Saltz et al., 2008; Van Cutsem et 
al., 2009; Dranitsaris et al., 2010).  However, despite a 50-60% response rate in patients to 
these chemotherapeutic agents, drug resistance and tumour relapse remains a concern 
(Paldino et al., 2014). 
It has been suggested that a subpopulation of tumour cells, the tumour initiating cells or 
cancer stem cells (CSCs), are highly resistant to these chemotherapeutic agents and are 
responsible for tumour relapse following therapy (Visvader et al., 2008; Lin , 2014).  In 
this regard, it is thought that CSCs may actively evade cytotoxic or radiotherapy, and 
further, that quiescent CSCs may possibly be more resistant to therapy.  If correct, this 
implies that there may be a need to develop novel therapies that target these CSCs 
specifically (Visvader & Lindeman, 2012).  Therefore, in this thesis, a putative colorectal 
CSC subpopulation will be isolated from two invasive colon adenocarcinoma cell lines to 
determine the potential regulatory effect(s) that the epigenetic drugs Valproic acid (VPA) 
and Zebularine (ZEB) have on pluripotent marker gene expression in these cells.  Since 
CSCs are highly resistant to current cancer therapies, it is thought that altering the 
expression of key pluripotent genes that maintain “stemness” in these cells would induce 
cell differentiation and make them more susceptible to current therapy (Chiou et al., 2010; 
Gudas & Wagner, 2011; Ibrahim et al., 2012; Munoz et al., 2012; Zhang et al., 2012; Chen 
et al., 2013; Shiozawa et al., 2013). 
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1.1 The Adenoma-carcinoma Sequence 
At a molecular level, colorectal cancer is known to arise from the sequential accumulation 
of multiple mutations in a single cell target.  The sequence of genetic and epigenetic events 
leading to the initiation and progression of tumourigenesis in the colon is referred to as the 
adeno-carcinoma sequence, as shown in Figure 1.1 (Fearon & Vogelstein, 1990).  The 
transformation of normal colonic epithelium to an adenoma occurs over a period of 5-20 
years, and its progression to a carcinoma occurs anywhere from 5-15 years, as seen in 
Figure 1.1.  There are two major pathways associated with the adenoma-carcinoma 
sequence, these being chromosomal instability (CSI) and microsatellite instability (MSI) 
(Grady & Carethers, 2008).  These events are driven by the dysregulation of numerous 
signalling cascades implicated in colorectal cancer metastasis (see Figure 1.2). 
 
 
Figure11.1. Colorectal tumour progression and the points where oncogene and tumour 
suppressor gene mutations occur.  Initially, an epithelial cell acquires a mutation in the 
tumour suppressor gene APC, followed by DNA hypomethylation.  This is followed by a 
sequential accumulation of mutations in the oncogenes K-RAS, RAF and PIK3CA and the 
tumour suppressor genes (TSG) TP53 and Transforming growth factor beta (TGF-β).  
Additionally, there is a loss of chromosome 18q, where several other tumour suppressor 
genes such as SMAD4 are located (Weinberg, 2007). 
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Figure21.2. Cell signalling pathways involved in the tumourigenesis and metastasis of 
colorectal cancer.  The dysregylation of these signalling cascades contribute to the 
chromosomal and microsatellite instability involved in the adenoma-carcinoma sequence 
(Qiagen).  
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1.1.1 Chromosomal Instability 
CSI in the colon is characterised by the allelic loss of the chromosomal regions 5q 
(Adenomatous polyposis coli; APC), 18q (Mothers against decapentaplegic homolog 4, 
SMAD4) and 17p (Tumour protein 53; TP53) (Weinberg, 2007).  Additionally, 
deoxyribonucleic acid (DNA) hypomethylation and alterations in the oncogenes Rat 
sarcoma (RAS), Rapidly accelerated fibrosarcoma (RAF) and Phosphatidylinositol-4,5-
bisphosphate 3-kinase (PIK3CA) occur (Weinberg, 2007).  The functional roles of these 
genes, and their loss-of-function, are briefly discussed below.   
1.1.1.1 Loss of APC 
Loss of APC function occurs in more than 80% of sporadic colorectal cancers (Morin et 
al., 1997).  APC, located on chromosome 5q, functions as a negative regulator of the 
canonical Wingless type (WNT) signalling pathway, and is additionally a regulator of 
apoptosis and cell-cycle progression (Fearon & Vogelstein, 1990; Goss & Groden, 2000).  
In the absence of WNT signalling, APC and Axis inhibition protein 1 (AXIN) bind to 
newly synthesised β-catenin. A destruction complex consisting of Casein kinase I (CKI) 
and Glycogensynthase kinase-3 (GSK-3) phosphorylate β-catenin at Serine and Threonine 
residues on its amino acid terminus.  Phosphorylated β-catenin recruits ubiquitin ligase 
(Beta-transducin repeat containing protein; b-TrCP) resulting in its degradation (Reya & 
Clevers, 2005).  Therefore, loss of APC function results in the accumulation of β-catenin in 
the nucleus where it activates the transcription of its target genes (Markowitz & 
Bertagnolli, 2009).  Since APC plays a role in many cell regulatory functions, it is not 
surprising that the loss of APC function is considered to be a driver of colorectal 
tumourigenesis. 
1.1.1.2 Loss of SMAD4 
The tumour suppressor gene SMAD4, located on chromosome 18q, is a mediator in the 
Transforming growth factor beta (TGF-β) and Bone morphogenetic protein (BMP) 
signalling pathways (Dupont et al., 2009).  The binding of TGF-β ligands to type II 
receptors recruits type I receptors, which phosphorylate receptor-regulated SMAD2 and 3 
(R-SMAD) (Massagué et al., 2005; Roy & Majumdar, 2012).  R-SMAD associates with 
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SMAD4 and together this complex translocates to the nucleus where it activates the 
transcription of its downstream target genes to regulate cell proliferation, differentiation 
and apoptosis (Heldin et al., 1997; Duff & Clarke, 1998; Roy & Majumdar, 2012).  In the 
BMP signalling pathway, SMAD4 associates with receptor-regulated SMAD1 and 5, 
where it too activates the transcription of genes involved in regulating cell proliferation, 
differentiation and apoptosis (Medvedev et al., 2008).  The loss of SMAD4 is frequently 
found in 30-40% of colorectal cancers and its loss is also associated with liver metastases 
(Miyaki et al., 1999; Kodach et al., 2008).  Furthermore, it promotes the “switching” of 
TGF-β tumour suppressor activity to tumour promoter activity (Zhang et al., 2010).  
Voorneveld et al. (2014) also showed that in the absence of SMAD4, BMP signalling 
enhances both cell invasion and metastasis through its activation of SMAD4-independent 
BMP signalling pathways. 
1.1.1.3 Loss of TP53 
TP53 (also known as p53) is a tumour suppressor gene located on chromosome 17p.  It is 
considered to be the “guardian of the genome” due to its functional role in regulating cell 
cycle progression, as well as its ability to stimulate DNA repair and promote cellular 
apoptosis (Lane, 1992).  TP53 mutations are highly abundant in colorectal cancer (Sameer, 
2013).  While mutations in this gene result in the loss of tumour suppressor activity, some 
mutations may however result in a gain-of-function phenotype (Leslie et al., 2002).  Gain-
of-function attributes include increased genomic instability, enhanced cell migration and 
invasion, as well as resistance to pro-apoptotic signals (Oren & Rotter, 2010). 
1.1.1.4 RAS, RAF and PIK3CA Mutations 
RAS is a mediator in the Mitogen-activated protein kinase (MAPK) and 
Phosphatidylinositide 3-kinase (PI3K) signalling pathways that are implicated in 
controlling cell growth and survival (Courtney et al., 2010; Nandan et al., 2011).  The 
MAPK signalling pathway is activated upon the binding of ligands to tyrosine kinase 
receptors resulting in their activation via phosphorylation.  Activated receptors activate 
RAS proteins which have GTPase activity (Zenonos & Kyprianou, 2013).  Activated RAS 
initiates a sequential phosphorylation cascade whereby it activates RAF which further 
activates Methyl ethyl ketone (MEK), and subsequently MAPK (Zenonos & Kyprianou, 
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2013).  Phosphorylated MAPK is translocated to the nucleus where it activates 
transcription factors involved in maintaining cell proliferation (Ubeda et al., 1999; Nandan 
et al., 2011). 
The PI3K signalling pathway becomes activated upon the binding of ligands to tyrosine 
kinase receptors (Zenonos & Kyprianou, 2013).  PI3K is recruited to the phosphorylated 
receptors and its catalytic domain Phosphatidylinositide 3-kinase subunit alpha (P110α) 
phosphorylates Phosphatidylinositol 4,5-bisphosphate (PIP)-2 to PIP3 (Pacold et al., 2000; 
Courtney et al., 2010).  PIP3 then recruits PDK1 and AKT resulting in AKT 
phosphorylation, which regulates cell proliferation, survival and migration (Zenonos & 
Kyprianou, 2013).  RAS can also activate this pathway through its direct binding with 
P110α (Pacold et al., 2000).  
RAS mutations, specifically of the K-RAS isoform, are found in 40% of colorectal 
tumours.  RAS mutations prevent the hydrolysis of RAS-GTP (active RAS) to RAS-GDP 
(inactive RAS) and therefore, RAS continuously signals through the MAPK pathway 
(Zenonos & Kyprianou, 2013).  It has become of some importance clinically to identify the 
specific mutations in the K-RAS gene; these being mutations in codons 12 and 13 (about 
95% of mutations) and codons 61 and 146 (between 35 to 40% of mutations), as patients 
with these mutations are unresponsive to anti-EGFR therapy (Cetuximab/Panitumumab) 
due to the constitutive up-regulation of the MAPK pathway (Tan & Du, 2012; Zenonos & 
Kyprianou, 2013).  Furthermore, mutations of BRAF also leads to continuous MAPK 
signalling and is found in 5-10% of colorectal tumours (Zenonos & Kyprianou, 2013).  
Mutations of PIK3CA, which encodes the P110α catalytic domain of PI3K, often occur 
together with RAS mutations.  It is found in 15-20% of colorectal tumours and results in 
increased PI3K activity (Fearon, 2011).  Therefore, mutations of RAS, RAF and PIK3CA 
lead to enhanced cell proliferation, migration and survival.  
1.1.2 Microsatellite Instability 
MSI is characterised by a loss-of-function of DNA mismatch repair (MMR) genes (Grady 
& Carethers, 2008; Boland & Goel, 2010).  Microsatellites are tandem repeats of 
oligonucleotides and these are highly prone to error during DNA replication (Watson et al., 
2014).  Under normal circumstances mismatch errors are repaired by MMR proteins 
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however, these errors cannot be repaired when MMR function is lost (Fukui, 2010).  As a 
result, microsatellite errors accumulate in key regulatory genes (Marra & Boland, 1996; 
Grady & Carethers, 2008).  MSI occurs in 15-20% of sporadic colorectal cancers, and in 
more than 95% of patients with hereditary Lynch Syndrome (Grady & Carethers, 2008).  
In sporadic cases, MSI usually results due to epigenetic silencing of the MMR gene MutL 
homologue 1 (MLH1) (Papadopoulos et al., 1994).  Patients with Lynch syndrome usually 
have a germline mutation in the MMR gene MutS homologue 1 (hMSH1) or MutS 
homologue 2 (hMSH2) (Leach et al., 1993; Fishel et al., 1993).   
1.1.3 Epigenetic Instability  
Although genomic instability is a well-established mechanism in colorectal tumour 
initiation and progression, epi-mutations also play a fundamental role and may occur more 
frequently than genetic mutations (Issa, 2004; Schnekenburger & Diederich, 2012).  
Epigenetics refers to heritable changes of the genome that alter gene expression without a 
change in the primary DNA sequence (Peedicayil, 2006; Goel & Boland, 2012; Migheli & 
Migliore, 2012; Schnekenburger & Diederich, 2012).  These modifications include DNA 
methylation, histone modifications and non-coding ribonucleic acids (RNAs), and are 
briefly presented below (Migheli & Migliore, 2012). 
Altered states of DNA methylation, involving both hyper- and hypomethylation, is highly 
prevalent in colorectal cancer.  It involves the addition of methyl groups to CpG islands 
often located in the promoter regions of genes (Schnekenburger & Diederich, 2012).  This 
modifies the three-dimensional conformation of DNA to prevent its interaction with 
transcription factors resulting in gene silencing (Graff et al., 1997).  Genome-wide 
methylation profiling studies have allowed researchers to identify several aberrantly 
methylated tumour suppressor genes associated with colorectal cancer.  Cellular 
targets/functions often affected include WNT, RAS and MAPK signalling, cell cycle 
regulation, calcium and lipid metabolism, cell adhesion and migration, DNA repair and 
apoptosis (Goel & Boland, 2012; Schnekenburger & Diederich, 2012).  Furthermore, 
colorectal tumours may be classified as having a CpG methylator phenotype (CIMP), 
should these methylated CpG islands occur extensively (Curtin et al., 2011).  Toyota et al. 
(1999) proposed a role of CIMP in colorectal tumour development and to date many 
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colorectal cancers are characterised as CIMP high (Migheli & Migliore, 2012).  The 
number of effects that aberrant methylation has on cell function undoubtedly demonstrates 
its role in colorectal tumourigenesis and progression.     
Histone modifications such as histone acetylation and deacetylation, and histone 
methylation and demethylation are best characterised in colorectal cancers, but their 
patterns are less understood compared to DNA methylation (van Engeland et al., 2011; 
Goel & Boland, 2012).  Histone modifications occur at histones H2A, H2B, H3 and H4, 
which associate with 150-200bp of DNA, termed the nucleosome (Kornberg, 1974; Luger 
& Richmond, 1998; Kornberg & Lorch, 1999).  Histone tails protrude from these 
nucleosomes and are subject to post-translational modifications, including amongst others, 
acetylation, methylation, ubiquitylation, sumoylation and phosphorylation (Nakazawa et 
al., 2012; Schnekenburger & Diederich, 2012).  Of these modifications, the best 
understood ones include the acetylation of lysine residues, and methylation of lysine and 
arginine residues (Schnekenburger & Diederich, 2012).  Histone mono-acetylation is 
catalysed by histone acetylases (HATs) and lessens the association of DNA with the core 
histone proteins, whereas histone mono-, di- and tri-methylation is catalysed by histone 
methyltransferases (HMTs) and strengthens their association with DNA (Bannister & 
Kouzarides, 2011).  RNA polymerase can easily bind to DNA that is loosely associated 
with histones to allow gene expression (Figure 1.3) (Goel & Boland, 2012; Migheli & 
Migliore, 2012). 
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Figure31.3. Histone methylation and acetylation alter gene expression.  When histones are 
methylated (left) they tightly associate with DNA resulting in gene silencing.  However, 
when histones are acetylated (right) they loosely associate with DNA to allow effective 
binding of RNA polymerase for gene transcription, and hence gene expression (adapted 
from Figure 1 in McClearly-Wheeler et al., 2013, 213 p.). 
The dysregulation of histone modifications, in addition to DNA methylation, contributes to 
colorectal carcinogenesis.  The overexpression of histone deacetylases (HDACs) which 
catalyse the removal of acetyl groups are associated with enhanced cell proliferation and 
cell survival (Mariadason et al., 2008; Weichert et al., 2008).  It was shown that class I 
HDACs (HDAC1, HDAC2 and HDAC3) are up-regulated in colorectal cancer, and that 
their overexpression is associated with poor patient survival (Weichert et al., 2008; 
Ashktorab et al., 2009).  During colorectal tumourigenesis, the overexpression of HDAC2 
in particular is followed by the acetylation of lysine residue 18 at histone 3 (H3K18) and 
lysine residue 12 at histone 4 (H4K12).  As a result, these histone marks are good 
prognostic markers for predicting patient survival (Ashktorab et al., 2009).  Similarly, 
dysregulated methylation is observed in patients with colorectal cancer.  Methylation of 
histones may result in either transcriptional activation or repression depending on the 
methylated site (Cloos et al., 2008).  Tri-methylation of lysine 4 at histone 3 (H3K4me3) is 
catalysed by the trithorax group (TrxG) of proteins and is associated with transcriptional 
activation; whereas, tri-methylation of lysine 27 at histone 3 (H3K27me3) is catalysed by 
the polycomb repressive complex 2 (PRC2), a class of the polycomb group (PcG) proteins, 
and is associated with gene silencing (Seenundun et al., 2010).  Genes located between 
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these “bivalent domain” chromatin marks are transcriptionally silent but have the capacity 
to be transcriptionally activated at a later stage (Felici, 2011).  Enhancer of zeste 
2 polycomb repressive complex (EZH2), the catalytic subunit of PRC2 of the polycomb 
complex, has been reported to be overexpressed in 87% of colorectal cancers and is 
associated with poor patient survival (Bracken & Helin, 2009; Crea et al., 2011; Takawa et 
al., 2011).  Overall, the dysregulation of histone modifications contributes to colorectal 
tumourigenesis. 
Micro RNAs (miRNAs) are an additional mechanism of epigenetic regulation.  They are 
small non-coding RNAs generated from precursor RNAs that play a role in transcriptional 
and post transcriptional gene expression (Rane et al., 2007).  They anneal to 
complementary mRNA, often resulting in gene silencing.  In colorectal cancer, miRNAs 
play a role in WNT signalling, cell migration and invasion, epithelial differentiation and 
cell cycle regulation (Lujambio et al., 2007; Shi et al., 2007; Huang et al., 2008; 
Schnekenburger & Diederich, 2012).  Table 1.2 lists some miRNAs involved in colorectal 
carcinogenesis, and their functional roles.   
Altogether, epi-mutations involving the dysregulation of DNA methylation, histone 
modifications and miRNAs, contribute to colorectal tumourigenesis and therefore, the 
mechanisms involved are potential therapeutic targets, since epi-mutations are possibly 
reversible (Peltomäki, 2012).  The therapeutic targeting of epigenetic mechanisms is 
further discussed in section 1.6.   
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TableA1.2: miRNAs and their role in colorectal cancer. 
 
miRNA Function 
miRNA-145 
WNT/β-catenin signalling (Shi et al., 2007; Arndt et al., 2009; 
Sarver et al., 2009; Oberg et al., 2011) 
miRNA-135a 
miRNA-135b 
miRNA-139 
miRNA-145 
miRNA-134a 
 
Apoptosis (Arndt et al., 2009; Earle et al., 2010) 
miRNA-133b 
miRNA-195 
miRNA-34b/c p53 signalling (Vogt et al., 2011) 
miRNA-18a 
Proliferation (Arndt et al., 2009; Motoyama et al., 2009; Earle et 
al., 2010) 
miRNA-143 
miRNA-200c 
miRNA-373 Cell migration and invasion (Huang et al., 2008) 
miRNA-520c 
miRNA-141 Epithelial differentiation (Burk et al., 2008) 
miRNA-200c 
miRNA-124a 
Cell cycle regulation (Lujambio et al., 2007; Arndt et al., 2009; 
Earle et al., 2010; Tsang et al., 2010) 
 
miRNA-34a 
miRNA-192 
miRNA-215 
miRNA-675 
miRNA-126 
Migration, invasion, metastasis (Arndt et al., 2009; Earle et al., 
2010; Tsang et al., 2010) 
miRNA-200a/b/c 
miRNA-520c 
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1.2 Colonic Stem Cells - a Target of Transformation  
The colon and rectum as described by Ellis (2010) form the large intestine.  The colon can 
be subdivided into ascending, transverse, descending and sigmoid sections.  The colon was 
previously thought to play an unnecessary role in humans, but in fact the colonic epithelial 
lining is essential for nutrient absorption; also it serves as a barrier to the external 
environment and provides a microenvironment for gut microflora (Edwards 1997; 
Anderson et al., 2011).   
Colorectal cancer occurs in the epithelial lining of the colon and the rectum.  The colonic 
epithelium is constantly being renewed by stem cells (SCs) located within the bottom of 
the villus crypts (Booth & Potten, 2000; Marshman et al., 2002; Anderson et al., 2011).  
Generally, 4-6 SCs reside in the crypt base, which continuously self-renew via symmetric 
cell divisions and generate transit-amplifying cells via asymmetric cell division (Potten et 
al., 1997; Marshman et al., 2002; Barker & Clevers, 2007).  Transit-amplifying cells 
terminally differentiate to produce one of four cell types, each with a specialised biological 
function.  These differentiated cell types include: colonocytes (absorptive cells), goblet 
cells (secrete mucin), enteroendocrine cells (produce hormones) and Paneth cells (secrete 
antimicrobial molecules) (Anderson et al., 2011).  They are located in the upper third of 
the colonic crypt and are shed into the lumen every 2-7 days (Willis et al., 2008).   
Since the colonic epithelium is constantly being renewed by long-lived SCs located within 
the crypt bottom, as opposed to transit-amplifying and differentiated cells that are short-
lived, it is likely that SCs are the targets of transforming mutations (Booth & Potten, 
2000; Marshman et al., 2002; Vermeulen, et al., 2008; Wang et al., 2013a).  This would 
imply a hierarchical organisation of cells within a tumour whereby transformed SCs, better 
known as CSCs or tumour initiating cells, are capable of producing the heterogeneous 
population of cells that comprise a tumour.  This is best explained by the CSC model 
which is further discussed in section 1.2.   
The exact origin of colorectal CSCs remains unknown as they may also arise from the de-
differentiation of transit-amplifying and differentiated cells that have been subjected to 
transformation (Vermeulen, et al., 2008; Anderson et al., 2011; Wang et al., 2013a).  
However, it is likely that they arise from adult SCs as they share many common features 
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with embryonic SCs.  These common features include the ability to proliferate indefinitely 
whilst maintaining pluripotency, differentiation potential and migration capacity (Evans & 
Kaufman, 1981; Martin, 1981; Wong et al., 2008; Schoenhals et al., 2009; Kim et al., 
2010; Mizuno et al., 2010; Shats et al., 2011).  Figure 1.4 shows a colonic crypt and the 
various cell types that comprise it.  Also indicated in this figure are the likely points where 
transforming mutations, leading to the formation of CSCs, might occur. 
 
 
 
 
 
 
 
 
 
 
 
Figure41.4. The colonic crypt showing the lower SC compartment (purple), the transit-
amplifying cells (dark pink) and the differentiated cells (light pink) located in the upper 
third of the crypt.  Indicated on the right are the points where transforming mutations may 
occur in colonic crypt cells (adapted from Figure 1 in Anderson et al., 2011, 321 p.). 
1.3 The Cancer Stem Cell Model 
It has long been believed that tumours are comprised of a heterogeneous population of 
cells wherein a discrete subpopulation of CSCs are able to give rise to the remaining cells 
that comprise a tumour (Dalerba et al., 2007a; O’Brien et al., 2007; Ricci-Vitiani et al., 
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2007 and Vermeulen, et al., 2008).  This key concept forms the basis of the CSC model.  It 
differs to the conventional model that proposes tumour growth results from the self-
renewal and differential potential of every cell type present within the tumour (Willis et al., 
2008).  The hierarchical organisation of cells within a tumour, as proposed by the CSC 
model is best described by Vermeulen et al. (2008) and is illustrated in Figure 1.5.  In this 
figure, it is shown that tumourigenic CSCs derived from adult SCs, or via the de-
differentiation of somatic cells, can self-renew to maintain the SC pool.  In addition, they 
are precursors to transit-amplifying cells that further produce non-tumourigenic, 
differentiated cells.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure51.5. The cancer stem cell model and the hierarchical organisation of cells within a 
tumour (Vermeulen et al., 2008). 
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Evidence for the existence of a CSC subpopulation in tumours was first shown by Lapidot 
et al. (1994).  They reported that a subset of acute myeloid leukaemia (AML) cells, 
characterised as cluster of differentiation (CD) 34
+
/CD38
-
, could regenerate a phenocopy 
of the original leukaemia when these cells were transplanted into severe combined 
immunodeficient (SCID) mice.  However, and in contrast to CD34
+
/CD38
- 
cells, AML 
cells characterised as CD34
+
/CD38
+ 
or CD34
-
/CD38
- 
were unable to engraft tumours in 
immunodeficient mice.  Similarly, evidence that a CSC population exists in malignant 
tumours was further extended to show that a CSC population exists in solid tumours.  Al 
Hajj et al. (2003) identified and isolated breast CSCs characterised as epithelial cell 
adhesion molecule (EpCAM)
+
/CD44
+
/CD24
-/low
 and demonstrated that these cells could 
produce tumours when serially transplanted into immunodeficient mice.  Since then, 
studies have provided evidence for the existence of a CSC population in several solid 
tumours, including amongst others brain (Singh et al., 2004), colon (Dalerba et al., 2007b; 
O’Brien et al., 2007) and lung (Eramo et al., 2008). 
1.4 Characterisation of Colorectal CSCs  
A distinct profile of cell surface markers is used to characterise and isolate colorectal CSC 
populations (Horst et al., 2008; Yeung et al., 2010; Ren et al., 2013).  Currently, CD133 
(also known as prominin-1) is one of the best-characterised markers used to identify and 
isolate colorectal CSCs through its binding with the antibodies AC133 that recognises the 
CD133/1 epitope, and AC141 and 293C that recognise the CD133/2 epitope (Zhou et al., 
2007; Kemper et al., 2010 ).  It is a promising marker since its increased expression has 
been correlated with increased tumour stage and reduced overall patient survival (Shimada 
et al., 2011).  Moreover, CD133 expression has been correlated with increased WNT 
activity in putative colorectal CSCs, a driver of colorectal tumourigenesis.  Corbo et al. 
(2012) showed WNT signalling was activated in CD133
+
 Caco2 and HCT116 cells.  An 
increase in WNT activity resulted in the up-regulation of SRp20, a splicing factor whose 
activity has been linked to cell proliferation.  In a study by Mak et al. (2012), they showed 
the association of CD133 with HDAC6 enhanced β-catenin stability in Caco2 colorectal 
cancer cells.   
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Although the biological function of CD133 is unknown, this five-transmembrane 
glycoprotein is however believed to be associated with cell-cell and cell-matrix 
interactions (Miraglia et al., 1997; Yin et al., 1997; Ren et al., 2013).  This protein was 
originally discovered as a marker for neuroepithelial progenitor cells in mouse embryos, 
and later in humans as a marker of haematopoietic SCs (Weigmann et al., 1997; Yin et al., 
1997).  Figure 1.6 shows a structural model of CD133 as proposed by Miraglia et al. 
(1997).  The transmembrane protein is characterised by an extracellular N-terminus, a 
cytoplasmic C-terminus and two extracellular loops that contain glycosylation sites that 
AC133 antibodies bind to.   
 
 
 
 
 
 
 
Figure61.6. The five-transmembrane glycoprotein CD133: the glycosylated region of 
CD133, present in the extracellular region of the cell, can bind with AC133 antibodies used 
to isolate and characterise stem cells expressing the CD133 protein (adapted from Figure 1 
in Yu et al. 2011, 255 p.). 
Two independent studies by O’Brien et al. (2007) and Ricci-Vitiani et al. (2007) indicated 
that CD133 can be used as a biological marker to isolate and characterise colorectal CSCs.  
Both investigators isolated CD133
+
 colon cancer cells from primary tumours and evaluated 
their tumourigenic potential in vivo.  They reported that the transplantation of CD133
+
 
colon cancer cells, and not CD133
-
 cells could initiate tumourigenesis in 
immunocompromised mice, whilst preserving the original tumour phenotype.   
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However, and in contrast to these studies, Shmelkov et al. (2008) observed that both 
CD133 positive and negative colon cancer cells isolated from a metastatic tumour, could 
elicit tumour formation in immunocompromised mice; although, the CD133
+
 cells were 
found to be less aggressive, they did form larger tumours.  Similarly, Kawamoto et al. 
(2010) observed that both CD133 colon cancer subsets were able to elicit tumour 
formation in immunocompromised mice.  Shmelkov et al. (2008) took their study further 
and tracked the expression of CD133 in the colon.  To do so, they generated knock-in lacZ 
reporter (CD133
lacZ/+
) mice, and reported that CD133 was expressed in both 
undifferentiated and differentiated cells.  They further demonstrated that CD133 
expression was not restricted to CSCs of primary human and murine colorectal tumours.  
Based on these findings, it was concluded that CD133 expression is controversial and that 
it may not be a reliable marker when used alone to characterise and isolate colorectal 
CSCs. 
It should however be taken into consideration that Shmelkov et al. (2008) isolated CD133 
subsets from a metastatic tumour; whereas, both O’Brien et al. (2007) and Ricci-Vitiani et 
al. (2007) isolated these subsets from primary tumours (Ren et al., 2013).  During 
metastases, epithelial cells undergo epithelial-mesenchymal transition (EMT) which 
enables cells to migrate to and invade distant tissues (Tsai & Yang, 2013).  During this 
phenotypic change, cells can be induced to gain SC characteristics which may explain why 
the CD133
-
 subset was able to elicit tumour formation in vivo (Irollo & Pirozzi, 2013).  
Nonetheless, this does not explain Shmelkov’s finding that both undifferentiated and 
differentiated cells express CD133 in murine colonic epithelial tissue, as well as in human 
and murine colorectal tumours. 
Since the use of CD133 as a marker to identify putative colorectal CSCs is currently 
controversial, Kemper et al. (2010) investigated possible regulatory mechanisms of 
AC133.  As a first approach, they investigated CD133 promoter activity and mRNA 
expression in undifferentiated and differentiated cells of primary colorectal tumours.  They 
reported that its promoter activity did not differ considerably between these cell types 
however, they did find that in vitro AC133 expression decreased almost 10-fold in 
differentiated cells with unchanged CD133 mRNA expression, when compared to 
undifferentiated CSCs.  Since promoter activity could not explain differential AC133 
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recognition, they further investigated whether alternative splicing of CD133 mRNA could 
influence the expression of the AC133 epitope.  From their findings, they showed that 
alternative splicing did not contribute to differential recognition of AC133, since 
alternative splicing does not influence the extracellular loop where the AC133 epitope 
resides.  Therefore, they further investigated the glycosylation status of CD133 upon CSC 
differentiation.  Glycosylation is a translational and post-translational modification 
governed by the binding of glycan molecules to proteins (Irollo & Pirozzi, 2013).  
Surprisingly, they reported that differential glycosylation resulted in the differential folding 
of CD133 which may mask the AC133 epitope therefore, making it undetectable in 
differentiated cells.  Based on their findings, it was concluded that both CSCs and 
differentiated cells express CD133 however, it is likely that AC133 is masked during cell 
differentiation.  Furthermore, the consensus was that AC133 could be used to characterise 
and isolate CSCs when used with caution. 
Therefore, other markers have been used in combination with CD133 to better identify 
colorectal CSCs.  These markers include amongst others, CD44 (Dalerba et al., 2007b; 
Vermeulen et al., 2008; Du et al., 2008; Chu et al., 2009, Haraguchi et al., 2008; Chen et 
al., 2011), EpCAM (Langan et al., 2012; Melin et al., 2012) and CD166 (Vermeulen et al., 
2008; Fang et al., 2010), and these are discussed below.  
CD44 was initially used as a biological marker for the identification of breast CSCs, and it 
was later proposed to be a marker of colorectal CSCs (Al Hajj et al., 2003).  It is a surface 
adhesion molecule involved in cell-cell and cell-matrix interactions through its high 
affinity for binding hyaluronic acid and various components of the extracellular matrix 
(ECM), such as collagen and fibronectin (Naor et al., 1997; Sahlberg et al., 2014).  The 
CD44 gene contains twenty exons, ten of which remain unchanged.  The remaining ten 
exons are subject to alternative splicing and are referred to as variable exons (v1-v10) 
(Naor et al., 1997; Sahlberg et al., 2014).  Standard CD44 contains only the first- and last 
five- unchanged exons; however, the utilisation of the variable exons gives rise to many 
splice variants containing different combinations of v1-v10.  The functional role of these 
splice variants is poorly understood; although, certain cancers including gastrointestinal 
cancers, express variant CD44 isoforms that are thought to mediate tumour metastasis (Du 
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et al., 2008; Banky et al., 2012).  Thus, the existence of multiple CD44 splice variants 
needs to be considered as this questions its use as a reliable CSC marker. 
EpCAM, also known as ESA, is used in combination with CD133 to characterise putative 
colorectal CSCs (Fang et al., 2010).  EpCAM was discovered in 1979, and it is a 40kDa 
glycoprotein involved in cell-cell adhesion, cell-signalling, proliferation, migration and 
differentiation (Trzpis et al., 2007; Schnell et al., 2013).  It is a promising marker used to 
characterise putative CSCs, as its overexpression has been correlated with reduced overall 
survival in patients with breast (Spizzo et al., 2004), gall bladder (Varga et al., 2004), 
urothelial (Brunner et al., 2008) and colorectal (Patriarca et al., 2012) cancers.  It consists 
of three regions, an extracellular region containing three domains with several 
glycosylation sites, a transmembrane region and a cytoplasmic region known as EpCAM 
intracellular domain (EpICD) (Figure 1.7) (McLaughlin et al., 1998; Dyer, 1999; Chong & 
Speicher, 2001; Sievers et al., 2001; Dillman, 2002; Munz et al., 2009).  EpICD functions 
as an oncogenic signal transducer in the WNT signalling pathway which is activated 
following its cleavage by proteases and its release into the cytoplasm.  EpICD then forms a 
complex with β-catenin, Lymphoid enhancer-binding factor (LEF) and Four and a half 
LIM domains protein 2 (FHL2) which is translocated to the nucleus where it activates the 
transcription of genes involved in cell adhesion, proliferation and migration (Maetzel et al., 
2009; Munz et al., 2009). 
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Figure71.7. The glycoprotein EpCAM showing its extracellular, transmembrane and 
cytoplasmic domains (adapted from Figure 1 in Armstrong & Eck, 2003, 321 p.). 
CD166, also known as activated leukocyte cell adhesion molecule (ALCAM) is a 105 kDa 
transmembrane protein, and as its alternative name suggests, it mediates cell-cell adhesion 
(Weidle et al., 2010).  CD166 is a member of the immunoglobulin superfamily of 
receptors.  It consists of three domains, a short cytoplasmic domain, a transmembrane 
domain and an extracellular domain that contains five immunoglobulin-like domains 
referred to as VVC2C2C2 (Piazza et al., 2005; Weidle et al., 2010; Anderson et al., 2011).  
This protein is expressed on a number of different cells including activated T cells and 
monocytes, epithelial cells, endothelial cells and fibroblasts although, its expression is 
usually restricted to cellular subsets involved in tissue maintenance, development and 
migration (Bowen et al., 1995; Swart, 2002).  Furthermore, it has been shown to mark the 
SC niche in the colonic crypt and therefore, it is used as a marker of colorectal CSCs 
(Levin et al., 2010). 
Chen et al. (2011) evaluated the expression of the surface markers CD44 and CD133 in the 
colorectal carcinoma cell line HCT116.  They hypothesised that the use of both markers 
would further enrich for a tumour-initiating cell population.  Four subpopulations were 
identified, these being: CD44
+
/CD133
+
, CD44
+
/CD133
-
, CD44
-
/CD133
+
 and CD44
-
/CD133
-
.  They evaluated the self-renewal potential of these subsets using a colonosphere 
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assay and reported that the CD44
+
/CD133
+
 subset was the most efficient at generating 
colonospheres. 
Similarly, Wang et al. (2012) enriched a tumour initiating subpopulation of cells using 
antibodies to the surface markers CD44 and CD133.  They isolated four cellular subsets 
from the colorectal cancer cell line SW620 and showed that the subset characterised as 
CD44
+
/CD133
+
 formed colonospheres the most efficiently and with the highest 
proliferation rate; whereas, the CD44
-
/CD133
-
 subset was the least efficient with the lowest 
proliferation rate.  Furthermore, the CD44
+
/CD133
+ 
subset was more efficient at forming 
colonospheres with a higher proliferation rate when compared to the CD44
+
/CD133
-
 
subset, and the CD44
+
/CD133
-
 subset was more efficient at forming colonospheres with a 
higher proliferation rate when compared to the CD44
-
/CD133
+
 subset.  From the results of 
these two studies, it was suggested that CD44 contributes to colony formation and 
proliferation in the HCT116 and SW620 cell lines, and the addition of this marker further 
enriches for cells with a stem-like phenotype. 
Dalerba et al. (2007b) showed that a subpopulation of colorectal cancer cells with stem-
like features could be isolated based on CD44 and EpCAM surface marker expression.  
Flow cytometry analyses of these markers revealed that two distinct populations were 
present in tumours derived from six patients with primary colorectal cancer, these being 
EpCAM
high
/CD44
+
 and EpCAM
low
/CD44
-
. A subsequent tumourigenicity assay in 
immunodeficient mice showed that the cellular subset characterised as EpCAM
high
/CD44
+ 
was able to elicit tumour formation whilst maintaining a differentiated phenotype.  
Furthermore, phenotypic heterogeneity resembling the primary tumour was maintained.  
Further screening of markers in the EpCAM
high
/CD44
+
 cellular subset showed that CD166 
was co-expressed with these cells.  To determine whether it could be used as an additional 
marker to identify cells with stem-like properties, a tumourigenicity assay was again 
utilised.  The results showed tumourigenicity resided in the CD44
+
/CD166
+ 
subset 
indicating that CD166 could be used as an additional marker to further enrich for colorectal 
CSCs. 
In contrast to the above mentioned studies, Muraro et al. (2012) evaluated the stem-like 
features of putative CSC subpopulations isolated from ten established colorectal cancer 
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cell lines, and reported that neither of the putative CSC subpopulations showed stem-like 
characteristics.  They isolated putative CSC subpopulations with the following expression 
phenotypes: CD133
+
, CD166
+
/CD144
+ 
and CD44
+
/CD24
+
 however, all three cell 
subpopulations failed to elicit tumour formation in immunodeficient mice and further 
lacked increased resistance to the chemotherapeutic drugs 5-Fluorouracil, Oxaliplatin and 
Irinotecan.  It was suggested that putative CSCs isolated from established cell lines might 
not show “stemness” features as they lack the microenvironment found in vivo.  This is 
important as signals from the microenvironment modulate marker expression and 
tumourigenicity; therefore, the expression profile of putative CSCs resident in solid 
tumours could differ to those present in established cell lines cultured in vitro (Visvader & 
Lindeman, 2012).  To illustrate the effect of the tumour microenvironment on 
tumourigenicity, Rao et al. (2012) showed that murine tumour-associated macrophages 
enhanced the tumourigenicity potential of CD44
+
 colorectal tumour cells, as these cells 
produced increased levels of osteopontin, a protein that has been found to be overexpressed 
in a number of cancers, including colorectal cancer (Li et al., 2012a). 
It should be noted that the detection of surface marker expression in both cell lines and 
tumours is dependent on the type of antibody used, as different antibodies recognise 
different epitopes.  Moreover, the presence of different splice variants implies that some 
epitopes may be lost and would thus be undetectable.  With regards to CD133 detection, it 
was demonstrated by Kemper et al. (2010) that glycosylation can alter the three-
dimensional structure of CD133 thus masking the AC133 epitope.  Therefore, cells 
positive for CD133 mRNA and protein expression might not be characterised as positive 
depending on the antibody used.  
To further demonstrate the significance of using different antibodies, Sahlberg et al. (2014) 
utilised three different antibodies to determine the percentage of DLD1, HCT116 and 
HT29 cells that express CD24.  It was shown in the DLD1, HCT116 and HT29 cell lines 
that 28%, 20% and 65% of these cells expressed CD24, respectively when the clone ML5 
was used; whereas, these cells expressed 6%, 8% and 95% of CD24, respectively when the 
clone 32D12 was used.  CD24 was not detected in either of these cell lines when the clone 
SN3 A5 2H10 was used.  These data demonstrate the use of different antibodies result in 
ambiguous data, which makes it difficult to compare expression profiling studies.  
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In addition to the use of alternatively sourced antibodies resulting in disparate data, the use 
of cell lines and different techniques are also contributing factors.  Chen et al. (2011) 
reported that more than 60% of HCT116 cells co-expressed CD44 and CD133; whereas, 
Wang et al. (2012) reported that only 14.8% of these cells were CD44 and CD133 double-
positive.  Again this may be attributed to the use of different antibodies, but may also be 
attributed to the use of different culturing techniques.  In the study by Wang et al. (2012), 
Western blot analysis of CD133 protein expression in the DLD1 cell line showed the 
protein was absent however, flow cytometry analysis of surface marker expression showed 
that 12.00 ± 0.38% of these cells expressed CD133, which demonstrates that the use of 
different molecular techniques leads to different results.  Together, these studies illustrate 
the difficulties involved when comparing studies amongst researchers.  Therefore, there is 
an increasing need to identify universal markers to better characterise CSCs and to 
elucidate their cellular functions in both normal and cancerous intestinal epithelia. 
1.5 Signalling Pathways and Transcription Factors Maintain Pluripotency 
CSCs can be further characterised based on the activity of extrinsic signalling pathways 
and the expression of intrinsic pluripotent transcription factors.  Pluripotency of embryonic 
stem cells (ESCs) is defined by the ability of these cells to produce cells of the three 
germinal layers (ectoderm, mesoderm and endoderm, excluding extra embryonic tissue) 
and gametes, through the process of differentiation (Medvedev et al., 2008).  Pluripotency 
of human embryonic and adult SCs such as CSCs is maintained by the signalling pathways 
WNT, BMP, TGFβ, NOTCH and HEDGEHOG, as well as by the transcription factors 
NANOG, Octamer-4 (OCT4), Sex determining region Y (SRY)-related high mobility 
group (HMG) box 2 (SOX2), Kruppel-like factor 4 (KLF-4) and V-myc avian 
myelocytomatosis viral oncogene homolog (c-MYC) (Figure 1.8) (Medvedev et al., 2008).  
The expression of these signalling pathways and pluripotency associated transcription 
factors is modulated by epigenetic mechanisms that include DNA methylation, chromatin 
remodelling, PcG proteins and miRNAs (Orkin & Hochedlinger, 2011).  Aberrant 
epigenetic modulation of these pluripotency associated signalling pathways and 
transcription factors drives colorectal tumourigenesis (Berdasco
 
& Esteller, 2010; Munoz 
et al., 2012).    
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Figure81.8. A representation of the cross-talk that occurs between key signalling pathways 
(left) and transcription factors (right) involved in maintaining pluripotency in human ESCs.  
These pathways and transcription factors activate the transcription of genes involved in the 
maintenance of ESC proliferation and self-renewal.  In promoting pluripotency, the 
transcription of genes involved in cell differentiation are suppressed (adapted from Figure 
1 in Medvedev et al., 2008, 1378 p.). 
1.5.1 Extrinsic Signalling Pathways  
WNT signalling maintains pluripotency in both mouse and human ESCs, and in adult SCs 
located in the colonic crypt, through the binding of WNT ligands to the Frizzled/LDL 
receptor-related protein (LRP) co-receptor (Roy & Majumdar, 2012).  Activation of the 
Frizzled/LRP co-receptor leads to the recruitment of AXIN to the plasma membrane, 
which disrupts the destruction complex.  Additionally, Dishevelled is activated via 
phosphorylation which further inhibits GSK-3 activity, a component of the destruction 
complex (Zeng et al., 2008; Roy & Majumdar, 2012).  β-catenin accumulates in the cell 
cytoplasm and is translocated to the nucleus where it associates with T-cell factor 
(TCF)/LEF, and together they activate the transcription of genes involved in maintaining 
pluripotency and cell proliferation (Figure 1.9) (Reya et al., 2003; Shimizu et al., 2008).  
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Figure91.9. The synergistic interaction between BMP and LIF signalling, as well as WNT 
signalling, in maintaining pluripotency in mouse ESCs (adapted from Figure 6 in Hao et 
al., 2006, 89 p.). 
Within the colonic crypt there is a gradient of WNT activity along the axis required for 
compartmentalisation of the various cell types comprising it (Figure 1.10).  WNT activity 
is highest in the SC compartment where it maintains pluripotency and SC proliferation, and 
it is gradually reduced along the axis towards the top of the crypt where the differentiated 
cells are located (Tesori et al., 2013).  The aberrant activation of WNT signalling in adult 
SCs located in the colonic crypt is associated with colorectal tumourigenesis (Roy & 
Majumdar, 2012).  Gain-of-function mutations in the gene encoding β-catenin (CTNNB1), 
or loss-of-function mutations in APC are well characterised in colorectal tumourigenesis 
(Barker & Clevers, 2006; Fodde & Brabletz, 2007; Vermeulen et al., 2010).  The enhanced 
stabilisation of β-catenin results in constitutive WNT activity that designates the colorectal 
CSC population (Vermeulen et al., 2010).  Aberrant epigenetic modulation of the genes 
encoding WNT signalling players also drives colorectal tumourigenesis.  DNA 
hypermethylation of the WNT inhibitors SFRP2, WIF-1, DKK1, DKK2, DKK3, DKK4 and 
SOX17, as well as APC and AXIN, are silenced in colon cancer (Suzuki et al., 2004; 
Taniguch et al., 2005; Ying & Tao, 2009).  Furthermore, aberrant gene silencing by 
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miRNA-145; -135a; -135b; -139 and -145 is also associated with colorectal tumourigenesis 
(Schnekenburger & Diedrich, 2012; Voorham et al., 2013). 
 
 
 
 
 
 
 
 
 
Figure101.10. The colonic crypt showing the lower SC compartment (purple), the transit-
amplifying cells (dark pink) and the differentiated cells (light pink) located in the upper 
third of the crypt.  Indicated on the right are the WNT, BMP and NOTCH signalling 
gradients that are required for compartmentalisation (adapted from Figure 1 in Anderson et 
al., 2011, 321 p.). 
Like WNT, BMP signalling maintains pluripotency in both mouse and human ESCs 
however, with an opposite effect.  In mouse ESCs, Bone morphogenetic protein-4 (BMP4) 
together with Leukaemia inhibitory factor (LIF) maintains pluripotency.  BMP4 binds to 
type I (BMPR1A/B) and type II receptors that phosphorylate SMAD1 and 5 (R-SMAD) 
(Massagué et al., 2005; Retting et al., 2009).  R-SMAD associates with SMAD4 and 
together this complex translocates to the nucleus where it activates a set of inhibitor of 
differentiation (Id) genes to prevent SC differentiation (Figure 1.9) (Medvedev et al., 
2008).  Upon LIF binding to the GP130 receptor, Janus kinase protein (JAK-P) 
phosphorylates Signal transducer and activator of transcription 3 (STAT3), a transcription 
factor that enters the cell nucleus where it activates the transcription of genes required to 
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maintain pluripotency (Hao et al., 2006).  The binding of LIF to GP130 also activates 
MAPK, which is inhibited by BMP4 receptor binding (Figure 1.9).  Therefore, in the 
absence of BMP4 signalling, activated MAPK activates SMAD1 and 5, which inhibit the 
activation of Id genes leading to cell differentiation (Hao et al., 2006; Medvedev et al., 
2008). 
Unlike mouse ESCs, LIF is not associated with human ESCs and the activation of BMP 
signalling leads to cell differentiation as opposed to the maintenance of pluripotency 
(Medvedev et al., 2008).  Rather, fibroblast growth factor (FGF) signalling together with a 
balance of BMP and TGF-β signalling is required to maintain pluripotency in these cells 
(James et al., 2005; Wang et al., 2005; Xu et al., 2005).  Upon FGF binding to its receptor, 
the PI3K pathway is activated which further activates AKT via phosphorylation.  Activated 
AKT is able to maintain pluripotency as it promotes cell proliferation and survival 
(Hammerman et al., 2005; Kim et al., 2005).  BMP signalling promotes differentiation 
upon receptor activation of SMAD1 and 5 whereas, TGF-β signalling maintains 
pluripotency upon receptor activation of SMAD2 and 3 (Chen et al., 1998; Hao et al., 
2006). 
Within the colonic crypt, a gradient of BMP activity is maintained by the expression of 
NOGGIN, an antagonist of BMP signalling.  NOGGIN is expressed in the intestinal SC 
compartment where BMP activity is diminished to allow for cell proliferation and the 
maintenance of pluripotency (Figure 1.10) (Amit et al., 2000; Xu et al., 2005).  
Furthermore, the overexpression of NOGGIN enhances the translocation of cytoplasmic β-
catenin into the nucleus suggesting there is cross-talk between WNT and BMP signalling 
(Rao & Wang, 2010).  
In colorectal cancer, BMP signalling is impaired by the epigenetic silencing of the BMPRII 
receptor.  The silencing of this receptor is mediated by PRC2 wherein its catalytic domain 
EZH2 tri-methylates H3 at lysine 27 (H3K27me3) resulting in the transcriptional 
repression of BMPRII and enhanced tumourigenicity (Parsons et al., 1995; Krausova & 
Korinek., 2012).  Furthermore, DNA methylation of the BMP2 ligand is associated with 
colorectal tumourigenesis (Wen et al., 2006; Kodach et al., 2008; Munoz et al., 2012). 
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NOTCH signalling is important for maintaining pluripotency of adult SCs located in the 
colonic crypt where it also regulates the differentiation of crypt cells (Roy & Majumdar, 
2012).  Its signalling is mediated by the binding of Delta-like (DLL) and Jagged ligands to 
the extracellular domains of the NOTCH-1, -2, -3 and -4 transmembrane receptors 
(Krausova & Korinek, 2012).  The intracellular region of NOTCH is cleaved by proteases 
to produce the NOTCH intracellular domain.  This is translocated to the nucleus where it 
associates with recombination signal binding protein J kappa (RBP-Jκ) to activate the 
transcription of downstream target genes such as Hairy and enhancer of split (HES), Hairy 
ears, Y-linked (HEY) and Hairy/enhancer-of-split related with YRPW motif-like (HEYL) 
that repress genes involved in cell lineage differentiation (Katoh & Katoh, 2007; Roy & 
Majumdar, 2012).  
Within the colonic crypt, a gradient of NOTCH signalling is maintained along the crypt 
axis.  NOTCH signalling is highest in the SC compartment and is gradually reduced along 
the axis towards the top of the crypt where differentiated cells reside (Fig 1.9) (Roy & 
Majumdar, 2012).  The dysregulation of NOTCH activity, as seen by an upregulation of 
NOTCH1 and HES1, has been reported in colon adenocarcinomas (Reedjik et al., 2008) 
however, the epigenetic mechanisms governing this pathway are poorly understood.  
Hedgehog (HH) signalling is important for the maintenance and proliferation of embryonic 
and adult SCs.  HH ligands bind to the 12-transmembrane receptor Patched (PTCH) 
resulting in the de-repression of the 7-transmembrane receptor Smoothened (SMO).  SMO 
then mediates a cascade of downstream events leading to the activation of the 
Glioblastoma (GLI) transcription factors GLI1, GLI2 and GLI3 that further activate the 
transcription of HH target genes involved in maintaining pluripotency (Varjosalo & 
Taipale, 2008).  Furthermore, there is cross-talk between this pathway and the BMP 
pathway in the colonic crypt (Bertrand et al., 2012).  Transit amplifying cells secrete HH 
ligands that associate with PTCH receptors expressed on mesenchymal cells.  This induces 
the production of BMP ligands that mediate BMP signalling (Madison et al., 2005).   
While the role of HH signalling in colorectal carcinogenesis has remained quite 
controversial due to discordant data, Varnat et al. (2009) have nevertheless elucidated a 
functional role for HH-GLI signalling in early and advanced colorectal cancers.  They 
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reported that GLI1, PTCH1 and Sonic Hedgehog (SHH) are expressed in primary and 
metastatic colorectal cancer samples and that GLI1 expression was enriched in the CD133
+
 
putative CSC population of metastatic cancers.  Furthermore, they showed HH-GLI 
signalling is required for CD133
+
 CSC self-renewal and survival in vivo and additionally 
that high HH-GLI is correlated with metastatic behaviour. 
DNA hypermethylation of the PTCH and Hedgehog interacting protein (HHIP) promoters, 
the latter an antagonist of HH, both enhance HH-GLI signalling, and have been implicated 
in the development of various cancers including colorectal cancer (Taniguchi et al., 2007).  
Also, the loss of miR-324-5p that normally functions to suppress GLI1 expression, has also 
been shown to promote tumourigenesis (Ferretti et al., 2008). 
Altogether, these signalling pathways intricately maintain the pluripotency of adult SCs 
located in the colonic crypt and their dysregulation through epigenetic modulation drives 
colorectal carcinogenesis. 
1.5.2 Intrinsic Transcription Factors 
The core transcription factors NANOG, OCT4 and SOX2 are central to maintaining 
pluripotency in embryonic and adult SCs, although other transcription factors such as 
KLF-4 and c-MYC are also involved (Niwa et al., 2000; Avilion et al., 2003; Mitsui et al., 
2003; Rodda et al., 2005).  As they are widely expressed in many cancers, including 
colorectal cancer, this suggests that these “stemness” associated transcription factors play 
an essential role in driving colorectal carcinogenesis (Ben-Porath et al., 2008; Liu et al., 
2013).   
NANOG, often referred to as a “master gene”, was first described by Wang et al. in 2003. 
It is a homeodomain transcription factor that is specifically expressed in embryonic and 
adult SCs where it maintains self-renewal capability (Tai et al., 2005; Liu et al., 2013).  In 
ESCs, the down-regulation of NANOG is associated with cell differentiation whereas, in 
adult and cancer SCs, the up-regulation or down-regulation of NANOG is associated with 
differentiation (Wang et al., 2003; Hyslop et al., 2005; Zaehres et al., 2005; Alvarez et al., 
2010; Kallas et al., 2014).  Alvarez et al. (2010) showed that the overexpression of 
NANOG in human mesenchymal SCs resulted in their differentiation into neural-like cells, 
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as seen by the expression of the neural cell lineage markers βIII-tubulin and glial fibrillary 
acidic protein.  In a study by Kallas et al. (2014), they showed that NANOG protein 
expression was down-regulated in the human ESC line H9 following differentiation 
induced by sodium butyrate, an inhibitor of HDAC activity, whereas in the human 
embryonal carcinoma-derived (hEC) cell line, it remained high.  Based on their findings, it 
was suggested that NANOG is regulated differently in “normal” ESCs compared to hEC 
cells. 
In contrast to NANOG, small changes in OCT4 expression, whether it be up-regulation or 
down-regulation, can induce ESC differentiation therefore, suggesting that its expression is 
tightly regulated (Niwa et al., 2000; Matin et al., 2004; Niwa et al., 2005; Zaehres et al., 
2005; Rodriguez et al., 2007; Kallas et al., 2014).  OCT4, also known as OCT3/4 or 
POU5F1, is a homeodomain transcription factor belonging to the POU family (Tai et al., 
2005).  OCT4 can heterodimerise with SOX2, a member of the SRY-related HMG box 
(SOX) family, and together they regulate the transcription of NANOG and other 
downstream target genes needed to maintain pluripotency (Boyer et al., 2005; Medvedev et 
al., 2008).  Altered expression of SOX2 is also associated with cell differentiation (Chew et 
al., 2005; Masui et al., 2007; Kopp et al., 2008; Adachi et al., 2010; Kallas et al., 2014).  
Similarly to NANOG, Kallas et al. (2014) reported that OCT4 protein expression was 
down-regulated upon H9 cell line differentiation, whereas it remained high in the hEC cell 
line.  This again suggests that OCT4 is also regulated differently in “normal” ESCs 
compared to hEC cells.  Interestingly, they reported that SOX2 protein expression 
remained the same following ESC treatment with sodium butyrate.  This led them to 
conclude that NANOG and OCT4 are regulated at an epigenetic level whereas, other 
mechanisms such as post-translational modifications, regulate SOX2 expression in H9 
human ESCs. 
Since NANOG, OCT4 and SOX2 are widely expressed in colorectal tumours, they may 
play an essential role in maintaining CSC pluripotency to drive colorectal carcinogenesis 
(Shi et al., 2012; Amini et al., 2014).  Shi et al. (2012) evaluated the expression of these 
transcription factors in the colorectal cancer cell lines SW480, SW620 and HT29.  They 
also assessed their expression in putative CSC-enriched tumour spheres.  Although all 
three transcription factors were expressed in all of the cell lines, the majority of their 
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expression was confined to their corresponding CSC-enriched tumour spheres.  A 
subsequent knock-down study of NANOG in the SW620 cell line showed that these cells 
formed tumour spheres less efficiently, they proliferated less efficiently in vitro and had 
reduced tumourigenicity in vivo.  Their findings emphasise the importance of these 
transcription factors, in particular NANOG, in maintaining CSC tumourigenicity in 
colorectal cancer. 
KLF-4 and c-MYC are two additional transcription factors that maintain pluripotency in 
embryonic and adult SCs.  KLF-4 (Kruppel-like factor 4) is a zinc finger transcription 
factor that functions to maintain cell proliferation, differentiation and apoptosis (Shi & Ai, 
2013).  KLF-4 has also been shown to be an upstream regulator of NANOG via its direct 
binding to its promoter (Chan et al., 2009).  Moreover, its involvement in maintaining 
pluripotency in breast (Yu et al., 2011) and colon CSCs (Leng et al., 2013) has been shown 
(Leng et al., 2013).  This is considered in relation to colon CSCs below.   
Leng et al. (2013) investigated whether KLF-4 expression was essential for maintaining 
self-renewal capability and tumourigenicity in DLD1 colorectal CSCs.  Firstly, they 
cultured the DLD1 cells under special culture conditions to enrich for putative CSC 
spheroids and confirmed that these spheroids expressed the CSC associated markers 
CD133, CD166, LGR5, ALDH1, NANOG, OCT4 and SOX2.  They observed that the 
expression levels of these markers were higher in the putative CSC spheroids than in the 
DLD1 parental cell line.  Next, they silenced KLF-4 expression in these spheroids using a 
lentiviral vector bearing KLF-4 short hairpin RNA (shRNA).  Knock-down of KLF-4 
reduced the expression of CD133, CD166, LGR5 and ALDH1.  Importantly, the stem-like 
characteristics of these cells were altered, as they were less invasive and had reduced 
migration capability in vitro.  Furthermore, they were less tumourigenic both in vitro and 
in vivo and had increased pharmacological susceptibility to 5- Fluorouracil.  
c-MYC, a member of the MYC family of transcription factors, maintains pluripotency via 
the transcription of its many downstream target genes.  Its role in maintaining pluripotency 
has been demonstrated by its ability to reprogram mouse embryonic fibroblasts into ES 
cell-like cells, termed induced pluripotent SCs (iPSCs) or in vitro engineered cells, 
together with Oct4, Sox2 and Klf-4 (Takahashi & Yamanaka, 2006).  Its putative role in 
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maintaining pluripotency and tumourigenicity has also been shown by Wang et al. (2008).  
Wang et al. (2008) elucidated the functional role of c-MYC in glioma CD133
+
 cells 
isolated from primary tumours by investigating the effect(s) of c-MYC knock-down in 
these cells.  They reported that its knock-down impaired the ability of these cells to form 
neurospheres in vitro indicating that c-MYC is important for maintaining self-renewal 
capability.  Additionally, c-MYC regulated cell proliferation and survival in CD133
+ 
glioma cells, as its knock-down reduced the number of cells that entered the S-phase of the 
cell cycle, and thus reduced their survival in vitro.  Lastly, c-MYC knock-down impaired 
the ability of CD133
+ 
glioma cells to initiate tumourigenesis in vivo, as these cells failed to 
form tumours in immunodeficient mice.  Altogether, their findings demonstrate the 
importance of c-MYC expression in maintaining CSC pluripotency and tumourigenicity. 
1.5.2.1 Epigenetic Regulation of Pluripotent Transcription Factors 
The epigenetic modulation of pluripotency associated transcription factors in cancer 
remains poorly understood.  In embryonic and CSCs, the promoters of NANOG and OCT4 
have been shown to be methylated upon cell differentiation (Farthing et al., 2008; 
Meissner, 2010; Wang et al., 2013b).  Wang et al. (2013b) explored the methylation status 
of the NANOG promoter in CD133
+high 
putative colorectal CSCs isolated from the HCT116 
cell line and reported that not only was its methylation reduced compared to the parental 
cell line, but that its expression was increased.  Their results demonstrate the role that 
DNA methylation has on modulating NANOG expression in CSCs which may drive 
colorectal tumourigenesis.   
The polycomb repressive complex 2 (PRC2) has also been shown to modulate NANOG 
expression in iPSCs (Villasante et al., 2011).  Villasante et al. (2011) reported that two 
NANOG expressing subpopulations were present in iPSCs, these being NANOG-high and 
NANOG-low.  In the NANOG-high population it was observed that EZH2 expression was 
absent and was associated with low H3K27me3 at the promoter, whereas in the NANOG-
low population, EZH2 expression was high and correlated with high H3K27me3.  
Chromatin immunoprecipitation (ChIP) showed the presence of the histone mark 
H3K4me3 which is associated with gene transcription; and H3K27me3 which is associated 
with gene silencing at the NANOG promoter.  Based on these data, it was thought that the 
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NANOG promoter was bivalent; however, a further study using ChIP revealed that the 
NANOG-high population was associated with the H3K4me3 mark and the NANOG-low 
population was associated with the H3K27me3 mark.  These findings provide good 
evidence for the regulation of NANOG by EZH2 in the maintenance of pluripotency. 
In order to elucidate the mechanisms involved in the epigenetic modulation of pluripotency 
associated transcription factors in cancer, Wang et al. (2013b) evaluated the epigenetic 
status of NANOG, OCT4, SOX2, KLF-4 and c-MYC in a variety of cancer cell lines.  They 
characterised epigenetic signatures based on promoter methylation status and on the status 
of the histone marks H3K4me3 and H3K27me3.  Some of these findings are presented 
below.   
The NANOG and OCT4 promoters, and exon 3 of c-MYC, were hypomethylated in the 
primary hepatocellular carcinoma (HCC) cell line PLC and in the metastatic HCC cell line 
97L when compared to the normal hepatocyte cell line LO2 whereas, they were all found 
to be hypermethylated in the colon carcinoma cell line HCT116.  The SOX2 and KLF-4 
promoters were unmethylated in all of these cell lines.  Altogether, this suggested a 
differential methylation profile of NANOG, OCT4 and SOX2 in HCC versus colorectal 
carcinoma cell lines.  They further correlated the expression of NANOG, OCT4, c-MYC 
and KLF-4 with methylation status and reported that the expression of all these genes was 
high in the 97L cell line but low in the HCT116 cell line, with the exception of KLF-4, 
when compared to their expression in the LO2 and PLC cell lines.  Their results suggested 
that DNA methylation negatively regulates NANOG, OCT4 and c-MYC expression. 
Chromatin mark analyses using ChIP showed H3K4me3 was highly associated with the 
NANOG and OCT4 promoters and exon 3 of c-MYC in 97L cells compared to LO2 and 
HCT116 cells, whereas the histone mark H3K27me3 was low in all of these cells.  With 
regards to the KLF-4 promoter, H3K4me3 was high in the 97L cell line and moderate in 
the HCT116 cell line; whereas H3K27me3 was lower in the HCT116 cell line than in the 
97L cell line, which accounts for the high expression of KLF-4 observed in both these 
cells.  Together their results show that DNA methylation and histone modifications 
modulate pluripotent gene expression. 
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1.6 Implications of the CSC model and Therapeutics 
Current anti-cancer therapies target the bulk of the tumour mass but they fail to eradicate 
the CSC population as these cells express multidrug resistance transporters that provide 
them with the ability to cope with toxic chemotherapeutics (Botchkina, 2013).  Other 
resistant mechanisms used by these cells, include slow cycling, the presence of highly 
efficient DNA repair systems and the expression of anti-apoptotic proteins (Woodward & 
Bristow, 2009; Pajonk et al., 2010).  If the CSC model is correct, these CSCs would be 
able to recapitulate the tumour heterogeneity through self-renewal and differentiation, 
resulting in relapse after therapy (Banerji & Los 2006; Dalerba et al., 2007a; Rashedi et 
al., 2007; Vermeulen et al., 2008; Meacham & Morrison, 2013; Puglisi et al., 2013; 
Easwaran et al., 2014).  Therefore, it is critical to develop new therapies that target and 
eradicate the CSC population.  Although CSC targeted therapies will not eliminate the 
tumour mass, they will prevent tumour growth, metastasis and relapse (Figure 1.11) (Reya 
et al., 2001; Dalerba et al., 2007b; Vermeulen et al., 2008). 
 
 
 
 
 
Figure111.11. A representation of CSC targeted therapy versus conventional therapy.  
Conventional therapy targets the bulk of the tumour (pink) but is unable to eliminate CSCs 
(purple) leading to tumour relapse.  CSC therapy aims to target the CSC population to 
result in tumour regression.  An effective therapeutic would be to combine CSC targeted 
therapy with conventional therapy (adapted from Figure 3 in Dalerba et al., 2007a, 279 p.). 
Based on the roles of extrinsic signalling pathways and intrinsic transcription factors in 
maintaining pluripotency, and that epigenetic mechanisms modulate their expression in 
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embryonic and adult SCs, it is thought that targeting these pathways and transcription 
factors in CSCs could inhibit their activity and induce cell differentiation to ultimately 
sensitise these cells to current anti-cancer therapies (Gudas & Wagner, 2011; Cai & Zhu, 
2012; Munoz et al., 2012; Chen et al., 2013).  Therapeutic strategies include the use of 
small-molecules that either block or promote the activity of pluripotency associated 
signalling pathways; and the use of epigenetic drugs that target the enzymes involved in 
epigenetic modulation, namely histone deacetylases (HDACs) and DNA 
methyltransferases (DNMTs) (Zhang et al., 2012).    
The non-steroidal anti-inflammatory drug Celecoxib has been shown to inhibit β-catenin-
dependent transcription in colorectal cancer cells (Lepourcelet et al., 2004; Tuynman et al., 
2008).  Disruption of β-catenin activity results in the inhibition of cell proliferation and 
induces apoptosis (Anastas & Moon, 2013; Puglisi et al., 2013).  Differentiation therapy 
involving the use of BMP4 to stimulate BMP signalling activity has been shown to induce 
the differentiation of these cells in vitro and increase the sensitivity of CD133
+ 
colorectal 
adenocarcinoma CSCs to the chemotherapeutic drugs 5-Fluorouracil and Oxaliplatin in 
vivo (Lombardo et al., 2011).   
The use of anti-cancer epigenetic drugs, namely HDAC inhibitors and DNMT inhibitors, 
can be utilised in cancer differentiation therapy (Peedicayil, 2006).  HDAC inhibitors are 
classified into four groups, namely the short chain fatty acids (sodium butyrate, Valproic 
acid), hydroxamic acids (Vorinostat, Panobinostat and Trichostatin A), cyclic tetrapeptides 
and benzamides (Yoo & Jones, 2006).  The exact mechanism by which these inhibitors 
mediate their activity remains unknown; although, it is known that Vorinostat inhibits 
histone deacetylation by binding to the enzyme’s catalytic domain.  Therefore, it has been 
suggested that other hydroxamic acids inhibit histone deacetylation in a similar manner 
(Yoo & Jones, 2006).   
DNMT inhibitors are classed as either nucleoside analogues (Zebularine, 5-azacytidine and 
5-azadeoxycytidine) or non-nucleoside analogues, where DNA methylation is inhibited by 
the direct binding of non-nucleoside analogues to the catalytic domain of DNMT (Yoo & 
Jones, 2006).  Antisense oligonucleotides, complementary to mRNA, comprise a third 
class of DNMT inhibitors (Peedicayil, 2006).  Two potentially useful epigenetic 
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therapeutics, Valproic acid (HDAC inhibitor) and Zebularine (DNMT inhibitor) are 
described below, as the in vitro effects of both are assessed in the current study.  
Valproic acid (VPA, 2-propylpentanoic acid) is a well-established short chain fatty acid 
drug used for the treatment of epilepsy and bipolar disorder (Löscher, 2002).  The exact 
mechanism by which this drug mediates its activity is not well understood.  It is however, 
believed to act by increasing gamma-aminobutyric acid levels in the brain, or alternatively, 
it may alter the properties of voltage gated ion channels (McLean & MacDonald, 1986; 
Owens & Memeroff, 2003).  VPA has anti-tumour properties and is able to inhibit the 
growth of various cancer cells, promote cell differentiation, induce apoptosis, and inhibit 
angiogenesis (Blaheta & Cinatl, 2002; Kawagoe et al., 2002; Phillips et al., 2003; 
Michaelis et al., 2004; Tang et al., 2004; Zgouras et al., 2004; Blaheta et al., 2005; 
Kuendgen & Gattermann, 2007).  It can be used for prolonged periods of time and may 
enhance the effect of other cancer therapies (Karagiannis et al., 2006).  The chemical 
structure of VPA is shown in Figure 1.12 (A). 
 
 
 
 
 
 
Figure121.12. The chemical structure of (A) Valproic acid and (B) Zebularine (Bolton et 
al., 2008). 
Zebularine, a drug originally developed as a cytidine deaminase inhibitor (Kim et al., 
1986; Laliberté et al., 1992), is an inhibitor of DNMTs.  It prevents the transfer of methyl 
groups to the cytidines of CpG dinucleotides, resulting in the inhibition of DNMTs, as well 
as the re-activation of tumour suppressor genes previously silenced by DNMTs (Robertson 
& Jones, 2000; Egger et al., 2004).  It is a promising anti-cancer drug, because it is highly 
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stable in acidic and neutral solutions, is low on cytotoxicity both in vivo and in vitro, and 
can be administered orally.  Furthermore, it has been shown to preferentially target cancer 
cells in a variety of cancer cell lines, including T24, SW480 and HT29 (Cheng et al., 
2004).  The chemical structure of Zebularine is shown above in Figure 1.12 (B). 
1.7 Research Aims 
The role of SCs in the onset of haematopoietic cancers is well described.  As there is 
compelling evidence for a role of SCs in the initiation and maintenance of solid tumours, 
and that these cells contribute to the development of therapeutic resistance, the aim of this 
study is to evaluate potential gene regulatory effect(s) of VPA and ZEB on pluripotency 
associated transcription factors in putative colorectal CSCs isolated from advanced colon 
adenocarcinoma cell lines.  The research specific objectives for this study are presented 
below. 
 Evaluate CD133 and EpCAM surface expression in the SW1116, HT29 and DLD1 cell 
lines which represent early-, mid- and late-stage colon adenocarcinomas, using flow 
cytometry.  These markers are of particular interest here as they are both linked to the 
canonical WNT signalling pathway which is dysregulated in colorectal cancer. 
 Isolate a putative colorectal CSC subpopulation from the two advanced colorectal 
adenocarcinoma cell lines HT29 and DLD1, using magnetic cell separation. 
 Characterise the self-renewal capability of HT29 and DLD1 putative CSCs in vitro 
using a sphere formation assay. 
 Culture and treat HT29 and DLD1 putative CSCs with the epigenetic drugs VPA and 
ZEB, to assess potential gene regulatory effects of these drugs on NANOG, OCT4 and 
SOX2 gene expression. 
o Evaluate the cellular expression of each of the pluripotency associated 
transcription factors NANOG, OCT4 and SOX2 following pharmacological 
treatments using confocal microscopy  
o Following on from the above, gene expression profiling will be used to assess 
epigenetic modulation of NANOG, OCT4 and SOX2 at the mRNA level. 
 Propose a mechanism that potentially regulates SOX2 function in HT29 and DLD1 
putative CSCs. 
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CHAPTER 2 
CANCER STEM CELL ISOLATION AND 
CHARACTERISATION 
The characterisation of colorectal cancer stem cells (CSCs) has important clinical 
relevance as they are suggested to be responsible for tumour initiation, metastasis and 
relapse, as proposed by the CSC model (Banerji & Los 2006; Dalerba et al., 2007a; 
Rashedi et al., 2007; Vermeulen et al., 2008; Meacham & Morrison, 2013; Puglisi et al., 
2013; Easwaran et al., 2014).  Moreover, as they are also resistant to current chemo- and 
radiation-therapies, they have become a novel target in cancer therapy (Dalerba et al., 
2007a; O’Brien et al., 2007; Ricci-Vitiani et al., 2007; Vermeulen et al., 2008; Visvader et 
al., 2008; Saigusa et al., 2010; Lin, 2014).   
CSCs are potentially identified based on the expression of a unique panel of cell surface 
markers, which differ from differentiated, non-tumourigenic cells (Horst et al., 2008; 
Yeung et al., 2010; Ren et al., 2013).  A well characterised marker used to identify and 
isolate putative colorectal CSCs is the cluster of differentiation 133 (CD133).  This marker 
holds particular promise as its increased expression has been correlated with enhanced 
tumour aggressiveness and reduced overall patient survival (Al-Hajj et al., 2003; Maeda et 
al., 2008; Zeppernick et al., 2008; Shimada et al., 2011; Patriarca et al., 2012).  However, 
it has yet to be established whether its mere presence identifies colorectal CSCs or whether 
its abundance holds greater value (Botchkina et al., 2009).    
In the current study a dual approach is used to identify putative CSCs from colorectal 
cancer cell lines representative of tumour stages and then to further characterise CSCs 
derived from two advanced colorectal cancer cell lines, using a sphere formation assay.  As 
the use of CD133 as a sole marker to identify putative CSCs is currently controversial, a 
second CSC marker, epithelial cell adhesion marker (EpCAM), will be used in conjunction 
with CD133.  EpCAM is a promising marker of putative colorectal CSCs as it has been 
used to identify CSCs in breast (Al-Hajj et al., 2003) pancreatic (Li et al., 2007) and 
hepatocellular (Yamashita et al., 2009; Chen et al., 2012a) carcinomas.  Furthermore, its 
overexpression has been correlated with reduced overall survival in patients with a variety 
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of cancers including breast (Spizzo et al., 2004), gall bladder (Varga et al., 2004), 
urothelial (Brunner et al., 2008) and colorectal (Patriarca et al., 2012) carcinomas.   
In this study, it is of particular interest to evaluate the potential co-expression of CD133 
and EpCAM in the advanced colorectal adenocarcinoma cell lines HT29 and DLD1, as this 
may increase the probability of identifying putative CSCs.  Moreover, these markers are of 
particular significance here as their expression have been associated with WNT activity in 
SCs (Munz et al., 2009; Mak et al., 2012), WNT being a key signalling pathway 
dysregulated in colorectal cancer.  In this regard, mutations in the transcription factors 
APC and/or β-catenin lead to enhanced WNT activity (Morin et al., 1997).  Since the 
HT29 (Dukes’ stage B) and DLD1 (Dukes’ stage C) cell lines both have mutations in APC 
(Sahlberg et al., 2014), these markers make good candidates to identify, isolate and 
characterise putative CSCs in these cell lines.  Additionally, as a comparison, CD133 and 
EpCAM expression will be assessed in the early Dukes’ stage A colon adenocarcinoma 
cell line, SW1116, since previous studies have correlated the overexpression of these 
markers with poor overall survival in patients with advanced stages of disease (Shimada et 
al., 2011; Patriarca et al., 2012; Ying et al., 2013).  It is of interest here to determine 
whether there is a correlation between the proportion of cells that express these markers 
and tumour stage.  
Next, after assessing surface expression of cells potentially co-expressing CD133 and 
EpCAM, this particular cell subpopulation will be isolated from the HT29 and DLD1 cell 
lines using magnetic cell separation.  Since this study focuses on epigenetic modulation in 
putative CSCs isolated from advanced adenocarcinoma cell lines, CD133
+
/EpCAM
+ 
cells 
will not be isolated from the SW1116 cell line as it represents an early-stage colon 
adenocarcinoma. 
Once isolated, CSCs can be further characterised in relation to their growth properties.   
Such SCs have an inherent capacity to maintain long-term self-renewal and proliferation in 
vitro and/or in vivo.  One such assay, the xenotransplantation assay is used to assess 
“stemness” in vivo.  In this test, CSCs are serially transplanted into immunodeficient mice 
and their “stemness” is demonstrated by their capacity to form clonal tumours that 
resemble the primary tumour from which the cells were isolated (Sampieri & Fodde, 2012; 
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Dalerba et al., 2007a; Vermeulen et al., 2008). However, as such facilities were 
unavailable for this study, the classic in vitro sphere formation assay will be used to 
evaluate the growth properties of the isolated cells.  This assay utilises a three-dimensional 
cell culture system together with a serum-free CSC enrichment medium (Singh et al., 
2004; Ponti et al., 2005) to assess “stemness” in vitro.  In this test, the self-renewal 
capability of single cells is evaluated by their ability to grow as free floating-spheroids in 
non-adherent culture conditions, or as adherent spheres when cultured on a three-
dimensional substrate, for example, Matrigel
TM 
(BD Biosciences).  Furthermore, in 
subsequent work presented here, the expression of a number of essential SC associated 
transcription factors are determined in HT29 and DLD1 putative CSCs using both confocal 
microscopy and quantitative real-time polymerase chain reaction (PCR) (Chapter 3). 
2.1 Materials and Methods 
2.1.1 Cell Lines 
The cell lines SW1116 (donated by Dr J. Magré, INSERM), HT29 (ATCC-American Type 
Culture Collection) and DLD1 (HSRRB-Health Science Research Resources Bank, Japan) 
are human colorectal adenocarcinomas.  The SW1116 cell line was isolated from a 73 year 
old male Caucasian and represents a Dukes’ stage A colon cancer (ATCC).  The HT29 cell 
line, isolated in 1964 from a 44 year old female Caucasian, is a Dukes’ stage B colon 
cancer (Fogh & Trempe, 1975).  The DLD1 cell line, originally isolated from a male adult 
between 1977 and 1979, is representative of a Dukes’ stage C colon cancer (ATCC), which 
has metastasised beyond the intestinal wall of the colon into the lymph nodes (Dukes, 
1932).  
2.1.2 Cell Culture 
An ethics waiver for the culture of commercial cell lines was granted by the Human 
Research Ethics Committee, University of the Witwatersrand, Reference: W-CJ-090317-3 
(Appendix E).   
The SW1116 (passage number 10), HT29 (passage number 30) and DLD1 (passage 
number 13) cell lines were cultured in Dulbecco’s modified Eagles medium: Hams F12 
(DMEM:F12) (Lonza), supplemented with 10% heat inactivated foetal bovine serum 
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(FBS) (Invitrogen and Lonza) and 10000 IU penicillin and streptomycin (Lonza) in 25cm
2
 
flasks (Greiner BioOne).  Each of the cell lines were routinely maintained at 37°C with an 
atmosphere of 5% CO2 and 90% humidity.  The cells were cultured until reaching 70-85% 
confluency, following which they were subcultured; the culture medium was discarded and 
the cells were rinsed with 3ml phosphate buffered saline (PBS) (Sigma Aldrich). Next, the 
PBS was discarded, and 2.5ml of trypsin-ethylenediaminetetraacetic acid (EDTA) (Lonza) 
was added to the flask.  The cells were incubated at 37°C, 5% CO2 and 90% humidity for 
3-5 minutes until they had detached from the culture surface.  To neutralise the trypsin, a 
2.5ml solution of 5% FBS/DMEM:F12, was added to the cell suspension.  This suspension 
was then centrifuged for 3 minutes at 800rpm in 15ml centrifuge tubes (Greiner) and the 
supernatant was discarded.  The cell pellet was resuspended in complete DMEM 
supplemented with 10% FBS and 1% penicillin/streptomycin (Lonza) and aliquoted into 
flasks for further culture and/or experimentation.  
2.1.3 Trypan Blue Exclusion Assay 
The cells from each cell line were counted using the Trypan Blue Exclusion Assay.  To 
40µl of Trypan blue (Molecular Probes), 10µl of resuspended cells were added and pipette 
mixed to make a 1:5 dilution.  Then 10µl of cells were transferred to one of the chambers 
of a fast-read haemocytometer slide (Davies Diagnostics).  Each chamber is marked by a 
grid of ten squares, each square containing 16 smaller squares.  Using a microscope (Zeiss 
Axiovert), the cells were counted in at least two of the larger squares (excluding the cells 
that had stained blue and cells that touched the left and bottom borders of each square).  
The following equation was used to determine the number of cells present in the cell 
suspension:  
(Total number of cells/number of squares counted)(10
4
 x dilution factor) = cells/ml 
Alternatively, 10µl of cell suspension mixed with Trypan Blue (1:1) was transferred to one 
of the chambers of a Bio-Rad dual chamber counting slide, and the cells were counted 
using the Bio-Rad TC10 automated cell counter. 
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2.1.4 Characterisation of CD133 and EpCAM using Flow Cytometry 
Up to 10
7
 SW1116, HT29 and DLD1 cells were re-suspended in 80μl of a PBS solution 
(Sigma Aldrich) containing 2mM EDTA (Sigma Aldrich) and 0.5% bovine serum albumin 
(BSA) (Sigma Aldrich), 20μl fragment crystallizable region (FcR) blocking reagent 
(Miltenyi Biotec), 10μl Anti-CD133/2 (293C3-phycoerythrin (PE), 50μg/ml) from 
Miltenyi Biotec and 20μl anti-EpCAM (fluorescein isothiocyanate (FITC), 3μg/ml) from 
BD Biosciences respectively.  Unstained cells, which served as a gating control, were re-
suspended as above, and were incubated with 20μl FcR blocking reagent only.  SW1116, 
HT29 and DLD1 cells were also stained with either CD133-PE or EpCAM-FITC.  These 
single stained cells served as compensation controls, to ensure that there was no “spill 
over” of FITC into the PE channel.  The cells were washed in 2ml of stain/wash buffer 
(Appendix A.4), and centrifuged for 10 minutes at 300g.  Next, the cells were re-suspended 
in 500μl of stain/wash buffer for analysis on a BD LSRFortessa flow cytometer, together 
with the “DIVA software”.   
The unstained cell lines were analysed in ‘setup mode’ on a forward scatter-area (FSC-A) 
versus forward scatter-height (FSC-H) graph to differentiate doublets from singlets.  The 
singlets were gated for each cell line respectively.  Data was then acquired for both the 
unstained and stained samples respectively, and the data was then evaluated using 
“FlowJo” flow cytometry analysis software (version 9.4.11).  
2.1.5 CSC Isolation using
 
Magnetic Cell Separation 
The MACS cell separator system (Miltenyi Biotech) was used to magnetically isolate 
CD133
+
 cells from cultured HT29 and DLD1 cells.  HT29 and DLD1 cells were 
trypsinised and centrifuged at 300rpm for 10 minutes.  The supernatant was aspirated off 
and the cell pellets were re-suspended in 300µl of stain/wash buffer (Appendix A.4) 
respectively, per 10
8
 cells.  FcR blocking reagent (100µl per 10
8
 cells) was added to the re-
suspended pellets, followed by the addition of 100µl CD133/1 (clone AC133) MicroBeads 
per 10
8
 cells (Miltenyi Biotech).  The cell suspensions were pipette mixed and incubated at 
4°C for 30 minutes.  To each cell suspension, 10µl per 10
7
 cells of conjugated antibody 
CD133/2 (293C3-PE, Miltenyi Biotech) was added, pipette mixed and incubated at 4°C for 
5 minutes.  A CD133/2 control antibody (Miltenyi Biotech) was used together with flow 
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cytometry to evaluate the success of the magnetic cell separation and to determine the 
purity of CD133 cells obtained using the MACS cell separator system.  As CD133 is co-
expressed with EpCAM in the HT29 and DLD1 cell lines (Figure 2.2 B and Figure 2.2 C), 
it follows that magnetically sorted CD133
+
 cells will express EpCAM.  
The cells were washed in 2ml of stain/wash buffer respectively, and were centrifuged at 
300rpm for 10 minutes.  The supernatant was aspirated off and the cells were re-suspended 
in 500µl of stain/wash buffer.  Two MACS MS columns were placed in the magnetic field 
of the MACS separator (Miltenyi Biotech).  The columns were washed with 500µl of 
stain/wash buffer followed by the addition of the HT29 and DLD1 cell suspensions, 
respectively.   
The flow-through (negative fraction) was collected in a flow cytometry tube.  The columns 
were washed three times with 500µl of stain/wash buffer and the flow-through was again 
collected in a second flow cytometry tube.  The columns were removed from the magnetic 
field of the MACS separator, placed over a new flow cytometry tube, whereupon one ml of 
stain/wash buffer was added.  The cells, representing the positive fraction, were then 
flushed into a clean tube.  In order to increase the cell purity, the positive cell fraction was 
applied to a second MACS MS column. 
The cells were analysed on a BD FACSCalibur (Beckton Dickinson), calibrated using the 
FACSComp software (Version 5.2.1), together with BD Calibrite beads (BD Biosciences).  
The data was acquired for each of the unlabelled, labelled but unseparated, negative and 
positive (separated) samples, respectively.  The data was then evaluated using “FlowJo” 
(version 9.4.11).  The forward versus side scatter profiles for the CD133 positive fraction 
of HT29 and DLD1 cells were gated and these gates were used to back-gate the forward 
versus side scatter profiles of the unstained cells (Figure 2.1).  The purification of CD133
+
 
cells obtained using magnetic cell separation was then determined.    
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Figure132.1. Flow cytometry dot plots showing forward scatter height versus side scatter 
height profiles for HT29 (A) and DLD1 (B) cells expressing CD133 following magnetic 
cell separation (left) and unstained cells (right).  The forward versus side scatter profiles 
corresponding to the CD133 positive cell fractions were gated and these gates were used to 
back-gate the forward versus side scatter profiles of the unstained cells.  
2.1.6 Three-Dimensional Cell Culture 
The purified CD133
+
 HT29 and DLD1 cell fractions were seeded into petri-dishes and/or 
flasks pre-coated with 2% agar (Appendix A.1).  As agar prevents cell attachment, the cells 
grow in suspension, forming free-floating spheroids in a defined serum-free cancer stem 
cell enrichment medium supplemented with epidermal growth factor (EGF; 20ng/ml) and 
basic fibroblast growth factor (bFGF; 10ng/ml) (Mather, 2008) (Appendix A.1).  
Alternatively, these cells were seeded into petri-dishes and/or flasks pre-coated with 
growth factor reduced Matrigel
TM
 (BD Biosciences) or Geltrex
TM
 (Gibco) and were 
cultured as adherent spheres.  Matrigel
TM
 and Geltrex
TM
 are soluble forms of basement 
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membrane extracted from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells.  These 
matrices contain laminin, collagen IV, entactin and heparin sulphate proteoglycans that 
mimic the in vivo tumour microenvironment (BD Biosciences; Life Technologies).  The 
thin gel (non-gelling) method was used to coat the petri-dishes and/or flasks and this 
method can be found in Appendix B.1. 
2.1.7 Sphere Formation Assay  
To evaluate the clonogenic potential (self-renewal capacity) of CD133
+
 HT29 and DLD1 
cells, 10
2
 cells were seeded into the wells of a 6 well plate that had been pre-coated with 
Geltrex
TM
 (Gibco) (Appendix B.1).  The cells were seeded at a low density to prevent the 
fusion of nascent spheres.  The cells were cultured for 14 days in a CSC enrichment 
medium (Appendix A.1).  The resulting spheres were counted under a light microscope 
(Zeiss Axiovert 25) and the clonogenic efficiency was calculated as the ratio of the number 
of spheres produced relative to the number of cells plated per well (Rafehi et al., 2011).  
The assay was repeated a further two times (N=3). 
2.1.8 Statistical Analyses 
Statistical analyses were performed using Microsoft Office Excel, 2010. The results are 
presented as median expression and median counts, where appropriate. 
2.2 Results 
Anti-CD133/2 (PE) and anti-EpCAM (FITC) were used to characterise the surface marker 
expression of CD133 and EpCAM in the cell lines, SW1116, HT29 and DLD1, which are 
representative of early-, mid- and late-stage colon adenocarcinomas, respectively.  The 
percentage of cells expressing CD133
-
/EpCAM
-
, CD133
-
/EpCAM
+
, and CD133
+
/EpCAM
+
 
in each cell line are shown in Table C1 in Appendix C.  For unstained cells, 99.50% of the 
SW1116 cells were negative for CD133 and EpCAM, and 100% of the HT29 and DLD1 
cells were negative for these markers (Figure 2.1).  For cells stained with both CD133 and 
EpCAM, it was found that EpCAM was co-expressed with CD133.  Note that a 
CD133
+
/EpCAM
-
 cell population was not identified within any one of these cell lines. 
Within the SW1116 cell line, three distinct isotypic cell populations were identified 
including, CD133
-
/EpCAM
-
, CD133
-
/EpCAM
+
, and CD133
+
/EpCAM
+
, as shown in Figure 
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2.2 A.  In contrast, only two distinct populations were identified in each of the HT29 and 
DLD1 cell lines, these being, CD133
-
/EpCAM
+
 and CD133
+
/EpCAM
+
, as shown in Figure 
2.2 B and Figure 2.2 C. 
 
 
  
 
 
 
 
 
 
 
 
 
Figure142.2. Flow cytometry detection of CD133 (PE) and EpCAM (FITC) in SW1116 
(A), HT29 (B) and DLD1 (C) cell lines.  Left to right these figures show unstained cells 
followed by triplicate cell staining of each cell line with CD133-PE and EpCAM-FITC 
antibodies.  The unstained SW1116 cells show some degree of auto-fluorescence as 0.42% 
of these cells fluoresce in the PE and FITC channels (upper right quadrant).  The gated 
cells co-express CD133 and EpCAM, whereas the un-gated cells do not express CD133, 
but may express EpCAM. 
In the SW1116 cell line, 9.03% of these cells are CD133
-
/EpCAM
-
, 88.70% of these cells 
are CD133
-
/EpCAM
+ 
and 2.33% of these cells are CD133
+
/EpCAM
+ 
(Figure 2.3 A-C).  In 
the HT29 cell line, 0.58% of these cells are CD133
-
/EpCAM
-
, 94.10% of these cells are 
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CD133
-
/EpCAM
+ 
and 5.11% of these cells are CD133
+
/EpCAM
+ 
(Figure 2.3 A-C).  In the 
later stage DLD1 cell line, 0.19% of these cells are CD133
-
/EpCAM
-
, 89.50% of these 
cells are CD133
-
/EpCAM
+ 
and 10.30% of these cells are CD133
+
/EpCAM
+ 
(Figure 2.3 A-
C).  These results indicate that there is an increase in the proportion of CD133
+
 expressing 
cells with advancement of tumour stage. 
 
 
 
 
 
 
 
 
Figure152.3. Flow cytometry analyses of CD133
-
/EpCAM
-
 (A), CD133
-
/EpCAM
+
 (B) and 
CD133
+
/EpCAM
+
 (C) expression in the SW1116, HT29 and DLD1 cell lines.  The 
columns represent the median expression of each cellular subset and the lines show the 
maximum and minimum ranges of the data. 
As the focus of this study centres on epigenetic modulation of CD133
+
/EpCAM
+ 
cells 
isolated from advanced cell lines, MACS magnetic cell separation was used to isolate 
CD133
+
 cells from the HT29 and DLD1 cell lines, but not from the early-stage SW1116 
cell line.  Furthermore, as CD133 is co-expressed with EpCAM (Figure 2.2), magnetically 
sorted CD133
+
 cells will express EpCAM.  A 98.60% and 98.00% purification of 
CD133
+
/EpCAM
+
 HT29 and DLD1 cells were obtained respectively, as confirmed by flow 
cytometry (Figure 2.4). 
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Figure162.4. Flow cytometry analyses showing the efficiency of CD133 magnetic cell 
separation in the HT29 (A) and DLD1 (B) cell lines.  Left to right these figures show 
gated, unstained cells followed by the percentage of cells expressing CD133, prior to and 
following separation. 
Next, the CD133
+
/EpCAM
+
 cells were cultured as three-dimensional free-floating 
spheroids and/or as adherent spheres in a defined CSC enrichment medium supplemented 
with bFGF and EGF.  CD133
+
/EpCAM
+
 HT29 and DLD1 cells produced free-floating 
spheroids that ranged in size from less than 2μm to more than 5μm in diameter when 
cultured over a period of two weeks (Figure 2.5).  Three-dimensional cultures are favoured 
over two-dimensional monolayer cultures as they better reflect the physiology and 
microenvironment of an in vivo tumour (Pampaloni et al., 2007; Friedrich et al., 2009; 
Vinci et al., 2012).  Furthermore, these cells doubled approximately every 48-72 hours 
whereas their corresponding parental cell lines doubled approximately every 24 hours.  
These findings indicate that CD133
+
/EpCAM
+ 
HT29 and DLD1 cells cycle much slower 
than their parental cell lines.  This phenomenon of longer cycling times could possibly be 
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used in addition to both in vitro sphere formation assays and in vivo tumourigenic assays, 
to further characterise putative CSCs. 
 
 
 
 
 
 
Figure172.5. Brightfield images of HT29 (left) and DLD1 (right) free-floating putative 
CSC spheroids (Zeiss Axiovert 25, Original magnification 5X).   
Subsequently, a sphere formation assay was carried out to determine the self-renewal 
capacity of these cells.  This assay essentially recapitulates the in vivo xenotransplantation 
assay, in vitro.  The number of spheres produced were counted (Table C2 in Appendix C) 
and the clonogenic efficiency was calculated as the ratio of the number of spheres 
produced to the number of cells plated per well.  The clonogenic efficiency of both the 
CD133
+
/EpCAM
+
 HT29 and DLD1 cells was 21%.  Therefore, approximately 1 in 5 of 
each of these cells produced spheres.  Figure 2.6 shows the number of spheres produced 
per 10
2
 cells plated per well.   
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Figure182.6. Sphere-forming capacity of CD133
+
/EpCAM
+
 HT29 and DLD1 cells.  Equal 
numbers of CD133
+
/EpCAM
+
 HT29 and DLD1 cells (10
2 
cells/well) each produced 
twenty-one spheres.  The columns represent the median results, and the lines show the 
upper and lower interquartile ranges.  
2.3 Discussion 
In this aspect of the study, it was determined whether CD133 and EpCAM were co-
expressed in three established colorectal adenocarcinoma cell lines that represent the three 
progressive stages of colorectal cancer; it was queried whether an increase in their 
expression could be correlated with tumour stage, and whether they could be used to 
isolate and characterise putative CSCs from advanced colorectal adenocarcinomas.  These 
markers were of interest here as their increased expression has been correlated with 
enhanced WNT activity, a driver of colorectal tumourigenesis. 
Flow cytometry characterisation of CD133 and EpCAM surface expression revealed the 
presence of three distinct populations in the SW1116 cell line (CD133
-
/EpCAM
-
, CD133
-
/ 
EpCAM
+
 and CD133
+
/EpCAM
+
), and two in the HT29 and DLD1 cell lines (CD133
-
/ 
EpCAM
+
 and CD133
+
/EpCAM
+
) (Figure 2.2).  The expression of EpCAM was high in all 
of these cell lines and ranged from 88.70-94.10% (Figure 2.3 B).  However, and in contrast 
to EpCAM expression, CD133 expression was found to vary from 2.33% in the SW1116 
 Sphere Formation Assay 
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cell line to 5.11% and 10.30% in the HT29 and DLD1 cell lines, respectively (Figure 2.3 
C).  These data clearly indicate that there is a correlation between the number of cells 
expressing CD133 and tumour stage.  More specifically, there was a two-fold increase in 
the number of HT29 cells expressing CD133, when compared to the number of SW1116 
cells expressing this marker.  Similarly, there was a two-fold increase in the number of 
DLD1 cells expressing CD133 compared to the HT29 cell line and a four-fold increase, 
relative to the SW1116 cell line.  CD133 was also shown to be co-expressed with EpCAM.  
It has similarly been reported by Ricci-Vitiani et al. (2007) and Horst et al. (2008) that 
CD133
+
 colorectal cancer cells also express EpCAM.  
While the data reported here differs to other studies, it must however be emphasised that 
published data relating to CSCs is quite varied.  This relates to the use of various cell lines, 
differing culture conditions, prolonged cell culture, cells sourced from patient tumours, 
different antibody clones and binding epitopes used to detect the same antigens (Dittfeld et 
al., 2009; Hermansen et al., 2011; Sahlberg et al., 2014), combined with very different 
platforms for analysis.  Some examples relating to colon CSCs are discussed below.  
Ieta et al. (2008) using flow cytometry, evaluated the expression of CD133 in twelve 
colorectal cancer cell lines, including HT29 and DLD1; and reported that while 47.50% of 
the HT29 cells expressed CD133 only 0.40% of the DLD1 cells expressed this marker.  In 
contrast, Elsaba et al. (2010) found that the HT29 cell line had in excess of 95% CD133 
expression, whereas, the DLD1 cell line lacked CD133 expression.  More recently, 
Sahlberg et al. (2014) reported that 63% of the HT29 cells and 14% of the DLD1 cells 
expressed CD133, respectively.  It should be noted that Ieta et al. (2008) used an anti-
CD133 antibody (clone not mentioned), Elsaba et al. (2010) used an anti-CD133/1 
antibody and Sahlberg et al. (2014) used an anti-CD133/2 antibody which may contribute 
to the inconsistencies found amongst their data. 
In contrast to the use of established cell lines to evaluate CD133 expression, Ricci-Vitiani 
et al. (2007) investigated the expression of CD133 in novel cell lines derived from many 
colonic tumours, ranging in Dukes’ stages (A-D).  Although they reported that 2.5 ± 1.4% 
of cells expressed CD133 in the majority of the colonic tumours, there was however, no 
evident trend associating CD133 expression with tumour stage (Table C3 in Appendix C).  
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In Table C3, the expression of CD133 varies from 0.7-2.4% in Dukes’ stage A tumours, 
from 0.7-6.1% in Dukes’ stage B tumours, from 1.4-2.7% in Dukes’ stage C tumours, and 
in one Dukes’ stage D tumour, the expression of CD133 was 2.5%.  Similarly, O’Brien et 
al. (2007) investigated CD133 expression in 17 colonic tumours (six were primary 
tumours).  Of these 17 colonic tumours, eleven were stage IV, three were stage IIIC, one 
was stage IIB and two were stage I.  Overall, CD133 expression ranged from 1.8-24.5% 
(Table C4 in Appendix C).  The expression of CD133 in stage I tumours ranged from 9.3-
12.0%, in a stage IB tumour the expression of CD133 was 14.0%, in stage IIIC tumours the 
expression ranged from 7.5-15.9% and in stage IV tumours the expression ranged from 
18.0-24.5%.  Furthermore, O’Brien and colleagues (2007) investigated the expression of 
CD133 in the normal colonic tissues of six patients.  CD133 was expressed in these normal 
tissues, however, CD133 expression was greater in the corresponding tumour tissues 
(Table C4).  Overall, the findings reported by Ricci-Vitiani et al. (2007) and O’Brien et al., 
(2007) suggest that there is no evident trend associating CD133 expression with tumour 
stage. 
It is evident from the above that proportions of CSCs vary greatly even within samples 
derived from patients.  Furthermore, it is difficult to compare the data obtained from 
established cell lines with clinical specimens, as established cell lines lack a tumour 
microenvironment that modulates surface marker expression (Platet et al., 2007; Dittfeld et 
al., 2009; Rao et al., 2012; Visvader & Lindeman, 2012; Grosse-Gehling et al., 2013; Hsu 
et al., 2013).  In vitro approaches at best attempt to mimic the in vivo environment with 
defined growth factors, and extracellular matrices to maintain stem growth. 
Despite these differences, CD133 and EpCAM are associated with poor prognosis in 
colorectal cancer patients.  Horst et al. (2008) evaluated CD133 expression in patient-
derived colorectal tumours using immunohistochemistry and reported that a high 
expression of CD133 was associated with worse overall survival.  Similarly, in a meta-
analysis study by Chen et al. (2013), they too reported that a high expression of CD133 
was associated with a worse prognosis.  High EpCAM expression has also been shown to 
be associated with advanced tumour stage and with a worse overall survival (Patriarca et 
al., 2012).  However, and contrary to these findings, Lugli et al. (2010) reported that low 
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levels of membranous EpCAM, as opposed to high levels of EpCAM, is prognostic. 
Therefore, the use of EpCAM as a prognostic marker may need further validation. 
Having confirmed the surface co-expression of CD133 and EpCAM in the SW1116, HT29 
and DLD1 cell lines, magnetic cell separation was used to isolate a CD133
+
 cell population 
from the advanced colorectal adenocarcinoma cell lines HT29 and DLD1.  MACS 
magnetic cell separation is a technology used to isolate frequent or rare occurring cell 
populations.  It uses paramagnetic microbeads, as small as 50nm in size, which have been 
conjugated with an antibody specific to the researcher’s needs (Miltenyi Biotec).  The 
rationale for subsequently isolating putative CSCs based on CD133 expression emanates 
from two studies by Ricci-Vitiani et al. (2007) and O’Brien et al. (2007).  Ricci-Vitiani et 
al. (2007) evaluated the tumourigenic potential of CD133
+
 colon cancer cells isolated from 
primary tumours and found that these cells could initiate a tumour when they were 
transplanted into SCID mice.  However, this was not true for the CD133
-
 colon cancer 
cells, as the transplantation of these cells into SCID mice failed to elicit tumour formation.  
Similarly, O’Brien et al. (2007) showed that colorectal cancer initiating cells were CD133+ 
whereas, CD133
-
 cells were unable to initiate tumourigenesis when transplanted into 
immunodeficient mice.  
Prior to magnetic cell separation, it was found that 36.50% and 68.60% of the HT29 and 
DLD1 cells expressed CD133, respectively (Figure 2.4).  These values differ considerably 
to those previously reported here, that is 36.50% versus 5.11% in the HT29 cell line, and 
68.60% versus 10.30% in the DLD1 cell line.  These discrepancies most likely result from 
the use of different flow cytometry gating strategies.  Furthermore, these findings highlight 
the importance of standardising methods as the use of different methods can lead to varied 
data, making it difficult to compare data amongst studies.   
The gating strategy used for analysing CD133 and EpCAM surface expression in the 
SW1116, HT29 and DLD1 cell lines involved gating on a singlet population.  This is the 
preferred strategy (Figure 2.2) whereas, the gating strategy used for analysing the 
effectiveness of magnetic cell separation involved back-gating on the forward versus side 
scatter profile of the CD133
+ 
cell fractions (Figure 2.1).  The unstained HT29 and DLD1 
cells that were gated using the back-gating strategy, have a low forward scatter versus a 
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low side scatter profile.  As CSCs are known to be smaller in size and less complex 
compared to the remainder of the population, it is likely that putative CSCs reside in a 
population of cells with a low forward and side scatter (De Paiva et al., 2006; Allen et al., 
2009; Allahverdiyev et al., 2012).  Ideally these gating strategies should have been the 
same however, the parameters required to analyse a singlet population post-data 
acquisition were not set when the magnetic sorting data was captured.  The inability to 
change the parameters post-data acquisition is one of the disadvantages of using an 
analogue instrument such as the BD FACS Calibur, whereas, this could have been done 
had the data been captured on a digital instrument such as the BD Fortessa.  Although not 
ideal, the gating strategy used to analyse the pre- and post-magnetic cell separation data 
was not a limiting factor in this study as flow cytometry was merely used to determine the 
efficiency of magnetic cell separation.  A 98.60% and a 98.00% pure population of 
CD133
+
 cells were obtained from the HT29 and DLD1 cell lines, respectively.  Therefore, 
magnetic cell separation was shown to be a valuable tool that can successfully be used to 
isolate and enrich for CD133
+
 cells.  
Since not all CD133
+
 cells are putative CSCs, a sphere formation assay was used to 
determine the sphere-forming capacity of these CD133
+
/EpCAM
+
 HT29 and DLD1 cells in 
vitro.  This assay evaluates the self-renewal capability of these cells.  In the present study, 
approximately 1 in 5 (21%) CD133
+
/EpCAM
+
 HT29 and DLD1 cells produced spheres 
when cultured in a defined CSC medium that serves to maintain “stemness”.  A similar 
percentage of such cells could be predicted to initiate tumours upon transplantation into 
immunodeficient mice.  A xenotransplantation assay should be used to compare the in vivo 
properties of these cells with their in vitro growth patterns, however, as previously 
mentioned (page 41), such facilities were unavailable for this study.   In contrast, O’Brien 
et al. (2007) reported a far lower value, wherein only 1 in 262 CD133
+
 cells were capable 
of initiating colorectal tumourigenesis when transplanted into immunodeficient mice.  The 
relatively high percentage of spheres obtained here in the present study, may well reflect 
the use of the additional CSC enrichment step using magnetic cell separation.  The use of 
additional markers may well be important to better define putative CSC populations and 
some of these are discussed below. 
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Other markers used to identify putative CSC include amongst others CD44, CD166 and 
CD24 (Dalerba et al., 2007b; Chen et al., 2011; Wang et al., 2012; Sahlberg et al., 2014).  
Although, the use of these markers may further enrich for colorectal CSCs, they may not 
be entirely reliable and their expression may not always be restricted to putative CSCs 
(Medema, 2013).  For example, Chen et al. (2011) and Wang et al. (2012) showed that 
CD44 could be used to further enrich for putative CSCs that express CD133.  However, 
since multiple CD44 splice variants exist whose functional roles remain poorly understood, 
this challenges its use as a marker of putative CSCs (Naor et al., 1997; Medema, 2013; 
Sahlberg et al., 2014).  Similarly, Dalerba et al. (2007b) showed that CD44, when used in 
combination with EpCAM
high
, marks colorectal CSCs and that CD166 could further enrich 
for CD44
+ 
putative CSCs.  However, and in contrast to these studies, Muraro et al. (2012) 
showed that neither of these markers could be used to identify and characterise putative 
CSCs in any of the ten colorectal cancer cell lines used in their study.  The differences in 
these findings may again be attributed to the lack of a tumour microenvironment when 
using established cell lines, which has been shown to modulate marker expression and 
tumourigenicity in vivo (Rao et al., 2012; Visvader & Lindeman, 2012), as well as due to 
the use of different antibodies and techniques (Grosse-Gehling et al., 2013; Sahlberg et al., 
2014).  Nonetheless, these differences highlight the importance of identifying novel and 
universal markers that can be used to identify and characterise colorectal CSCs, as well as 
the importance to standardise the use of antibodies and techniques. 
Although it was shown here that approximately 1 in 5 CD133
+
/EpCAM
+
 HT29 and DLD1 
cells were capable of producing spheres in vitro, other studies have shown that CD133
-
 
cells are also capable of forming spheres in vitro (Botchkina et al., 2009; Chen et al., 
2012a; Hsu et al., 2013) and initiating tumourigenesis in vivo (Dalerba et al., 2007b; 
Shmelkov et al., 2008; Chu et al., 2009; Kawamoto et al., 2010).  Chen et al. (2012) 
identified and isolated four cellular subsets characterised as CD133
+
/EpCAM
+
, 
CD133
+
/EpCAM
-
, CD133
-
/EpCAM
+
 and CD133
-
/EpCAM
-
 from the hepatocellular 
carcinoma cell line Huh7.  Although, all the cellular subsets showed some degree of 
“stemness”, the subpopulation characterised as CD133+/EpCAM+ produced more colonies 
that were larger in size compared to the other cellular subsets.  Also, they possessed more 
biological features of CSCs including enhanced differentiation potential and enhanced 
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resistance to the chemotherapeutic agents, 5-Fluorouracil and Doxorubicin in vitro, and 
enhanced tumourigenicity in vivo. 
Shmelkov et al. (2008) and Kawamoto et al. (2010) showed both CD133
+
 and CD133
-
colorectal cancer cells could elicit tumour formation in immunocompromised mice.  
Shmelkov et al. (2008) isolated CD133
+ 
and CD133
-
 cells from a metastatic tumour 
whereas, in contrast to the studies by O’Brien et al. (2007) and Ricci-Vitiani et al. (2007), 
they isolated CD133
+
 and CD133
- 
cells from primary tumours.  Since epithelial cells 
undergo EMT during metastasis, these cells may acquire SC characteristics and this might 
explain why the CD133
- 
cells showed tumourigenicity in vivo (Tsai & Yang, 2013).  
Another explanation is based on the findings by Kemper et al. (2010) who reported that 
CD133 expression is not confined to the putative CSC population, but rather the AC133 
epitope is masked due to differential folding of the CD133 protein and therefore, CD133 
would not be detected in differentiated cells when using AC133 antibodies.  In the present 
study, the antibodies CD133/1 (linked to MACS magnetic beads) and CD133/2 
(conjugated with PE) were used.  Since both these antibodies recognise the AC133 epitope, 
their use was not a limiting factor with regards to putative CSC identification, isolation and 
characterisation in the HT29 and DLD1 cell lines as both of these cell lines were shown to 
express AC133.  In addition, their CD133
+ 
cellular fractions were shown to have 
clonogenic potential in vitro. 
Hsu et al. (2013) also showed that CD133
+
 and CD133
- 
cells isolated from the metastatic 
colorectal cancer cell line SW620 had clonogenic capability in vitro and tumourigenic 
potential in vivo.  Both the cellular subsets showed similar characteristics with regards to 
their morphology, proliferative potential and resistance to the anti-tumour drugs Taxol, 
Cisplatin, Actinomycin D and Camptothecin when cultured under standard conditions.  
However, the CD133
-
 cells showed enhanced growth potential when exposed to 3D 
Matrigel culture conditions and enhanced tumourigenicity when injected into 
immunocompromised mice suggesting that the tumour microenvironment may modulate 
metastatic progression.  Therefore, they exposed the CD133
+ 
and
 
CD133
- 
cells to hypoxic 
conditions, cell adhesion free conditions and to ECM, the three environmental stressors 
faced by metastasising cells.  Exposure to these conditions was found to promote cell-type 
switching, a phenomenon wherein CD133
+ 
cells switch to CD133
- 
cells and vice versa.  
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Exposure to hypoxic and cell adhesion free conditions enhanced the switching of CD133
-
 
cells to CD133
+ 
cells whereas, exposure to ECM enhanced the switching of CD133
+ 
cells 
to CD133
-
 cells.  Based on their findings, they proposed a model on metastasis progression 
that might explain why CD133
-
 cells, and not just CD133
+
 cells, show tumourigenic 
potential in vitro and in vivo.  In this model, both CD133
+
 and CD133
- 
cells are released 
into the bloodstream and migrate to the metastatic site where they are faced with 
environmental stressors.  Exposure to ECM promotes the switching of CD133
+ 
cells to 
CD133
-
 cells thereby enhancing their proliferation ability.  Once colonisation has been 
established these cells are exposed to hypoxic and adhesion free conditions, which 
promotes the switching of CD133
- 
cells to CD133
+
 cells to enhance their “stemness” and to 
initiate tumour growth. 
Altogether, the findings reported in the present study, as well as those of other studies, 
indicate that not all CD133
+ 
cells are necessarily putative CSCs.  In this regard, the stable 
retention of SC properties are highly likely to be influenced by “factors”, including growth 
factors and ECM molecules, within the in vivo and/or in vitro culture environments.  
2.4 Conclusion 
In this chapter, the SW1116, HT29 and DLD1 cell lines were shown to co-express CD133 
and EpCAM.  The percentage of cells expressing EpCAM was high in each of these cell 
lines whereas, the percentage of cells expressing CD133 increased with tumour stage.  
Furthermore, using magnetic cell separation, a pure population of CD133
+
 cells were 
isolated from the advanced colorectal adenocarcinoma cell lines, HT29 and DLD1.  In 
evaluating their in vitro growth properties, some 21% of these cells showed clonogenic 
potential.  The use of other markers, in addition to CD133 and EpCAM, would be useful 
for further enrichment of putative CSCs in the HT29 and DLD1 cell lines.  
The following phase of this study employs CD133
+
/EpCAM
+
 cells for subsequent 
epigenetic studies that focus on epigenetic modulation of the pluripotent-associated 
transcription factors NANOG, OCT4 and SOX2 in these cells. 
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CHAPTER 3  
THE EFFECT(S) OF EPIGENETIC MODULATION 
ON PLURIPOTENT MARKERS 
Colorectal cancer is known to arise from an accumulation of mutations in both oncogenes 
and tumour-suppressor genes, as proposed by Vogelstein et al. (1988), as well as due to 
epigenetic modifications (Issa et al., 2004; Barker & Clevers, 2007; Vermeulen et al., 
2008; Markowitz & Bertognolli, 2009; Goel & Boland, 2012; Schnekenburger & 
Diederich, 2012).  Epigenetic modifications include alterations in patterns of DNA 
methylation, histone modifications and the influence of non-coding RNAs on post-
translational protein regulation, all of these being important in colorectal cancer initiation 
and progression (Migheli et al., 2012).  Of the three modifications, DNA methylation is the 
best understood and it involves the addition of methyl groups to CpG islands often located 
in the promoter regions of genes, thereby resulting in gene silencing (Graff et al., 1997; 
Migheli et al., 2012).  In colorectal cancer, several genes are known to be methylated that 
affect cellular processes, including amongst others DNA repair, apoptosis, WNT 
signalling, cell cycle arrest, invasion and metastasis (Migheli et al., 2012; Schnekenburger 
& Diederich, 2012).   
Histone modifications, although less understood than DNA methylation, involve the 
addition and removal of acetyl and methyl groups from histone tails that protrude from 
nucleosomes, and these may either enhance or repress gene transcription (van Engeland et 
al., 2011; Goel & Boland, 2012).  In addition to histone acetylation and methylation, other 
histone modifications include phosphorylation, ubiquitylation and sumoylation although, 
acetylation and methylation are best characterised in colorectal cancers (van Engeland et 
al., 2011; Goel & Boland, 2012; Nakazawa et al., 2012; Schnekenburger & Diederich, 
2012). Non-coding miRNAs further regulate gene expression by annealing to 
complementary mRNA resulting in mRNA degradation and gene silencing (Rane et al., 
2007; Fabian et al., 2010).  Cellular processes affected by miRNA regulation in colorectal 
cancer include WNT signalling, cell migration and invasion, epithelial differentiation and 
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cell cycle regulation (Lujambio et al., 2007; Shi et al., 2007; Burk et al., 2008; Huang et 
al., 2008; Schnekenburger & Diederich, 2012).    
Since epigenetic defects are potentially reversible, and CSCs are thought to trigger tumour 
initiation, progression and metastasis, it is of interest here to evaluate the cellular 
expression of each of the SC associated pluripotent factors NANOG, OCT4 and SOX2 
following epigenetic treatments in putative CSCs derived from the HT29 and DLD1 cell 
lines.  These key pluripotency associated transcription factors are widely expressed in a 
variety of cancers, including colorectal cancer, suggesting that they might also play an 
essential role in maintaining the “stemness”, and thus, the continued proliferation of 
colorectal CSCs (Ben-Porath et al., 2008; Liu et al., 2013).  Therefore, each of these 
transcription factors are potential targets for the treatment of colorectal cancer in patients 
with advanced stages of disease.  The expression of NANOG, OCT4 and SOX2 are tightly 
modulated by epigenetic mechanisms to allow them to maintain pluripotency in embryonic 
and adult SCs, however, these mechanisms are poorly understood (Farthing et al., 2008; 
Meissner, 2010; Villasante et al., 2011; Wang et al., 2013b).  Additionally, they further 
modulate their own expression via an auto-regulatory feed-back network (Figure 3.1 A) 
and regulate the transcription of NANOG and downstream target genes via a feed-forward 
loop (Figure 3.1 B; Boyer et al., 2005).  
 
 
 
 
 
 
Figure193.1. Transcriptional regulation of NANOG, OCT4 and SOX2 via an auto-regulatory 
feed-back loop (A); and transcriptional regulation of NANOG and ESC genes via a feed-
forward loop (B).  The promoters of genes are indicated as blue blocks and regulators are 
indicated as green ovals (adapted from Figure 4 in Boyer et al., 2005, 952 p.). 
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In this chapter, the potential regulatory effects of Valproic acid (VPA) and Zebularine 
(ZEB) on NANOG, OCT4 and SOX2 expression in HT29 and DLD1 putative CSCs are 
investigated.  To date, no studies have explored the effects of these two drugs on the 
expression of these genes in putative CSCs derived from colorectal adenocarcinomas.  In 
the first section of this chapter, confocal microscopy is utilised to qualitatively evaluate the 
expression of each of these pluripotency factors following epigenetic treatments in vitro.  
In the second section, and following on from the above, gene expression profiling (qPCR) 
will be used to quantitatively assess epigenetic modulation of NANOG, OCT4 and SOX2. 
VPA, an inhibitor of class I and IIa histone deacetylase (HDAC) activity, relaxes the 
association of core histones with DNA to allow transcription and hence, gene expression.  
Furthermore, its biochemical actions have been shown to inhibit cancer cell proliferation, 
promote differentiation, induce apoptosis, and inhibit angiogenesis in a number of cancer 
cell lines, including breast and colon adenocarcinomas (Göttlicher et al., 2001; Phiel et al., 
2001; Blaheta & Cinatl, 2002; Kawagoe et al., 2002; Phillips et al., 2003; Gurvich et al., 
2004; Michaelis et al., 2004; Tang et al., 2004; Thelen et al., 2004; Zgouras et al., 2004; 
Blaheta et al., 2005; Friedmann et al., 2006; Kuendgen & Gattermann, 2007).   
ZEB, a nucleoside analogue of cytidine, inhibits DNA methyltransferase (DNMT) activity 
by inhibiting the transfer of methyl groups to the cytidines of CpG dinucleotides, serving 
to prevent the maintenance of DNA methylation (Yoo & Jones, 2006).  This allows 
transcription factors to bind to the promoters of their target genes resulting in gene 
expression.  Compared to similar DNA methylation inhibitors, 5-aza-2’deoxycytidine and 
5-azacytidine, ZEB has low cytotoxicity both  in vitro and in vivo, is highly stable in acidic 
and neutral solutions; and can be administered orally (Barchi et al., 1992; Cheng et al., 
2003).  
Based on the inhibitory activity that VPA and ZEB have on HDACs and DNMTs, it is 
proposed here that these epigenetic drugs will promote the up-regulation of NANOG, 
OCT4 and SOX2 expression in HT29 and DLD1 putative CSCs.  Since their up-regulation 
in embryonic and adult SCs has been shown to promote cell differentiation (Niwa et al., 
2000; Rodriguez et al., 2007; Kopp et al., 2008; Alvarez et al., 2010),  epigenetic 
modulation of these transcription factors in CSCs may make these cells more susceptible to 
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current anti-cancer therapies.  Ultimately, this could result in tumour regression and may 
prevent tumour relapse. 
(i) Confocal Microscopy 
3.1 Materials and Methods 
3.1.1 CD133 and EpCAM  
Prior to drug treatments, confocal microscopy was used to confirm the expression of 
CD133 and EpCAM in HT29 and DLD1 putative CSCs, isolated using magnetic cell 
separation (Chapter 2.1.5).  HT29 and DLD1 putative CSCs were seeded onto sterile glass 
coverslips, placed in 30mm Petri dishes, and cultured in a serum free CSC enrichment 
medium at 37˚C in 5% CO2 until they reached 60-70% confluency.  Next, the cells were 
rinsed with PBS and fixed for 15 minutes in 3% formaldehyde diluted in PBS, followed by 
three PBS washes (refer to Appendix A.2).  The cells were then permeabilised for 5 
minutes in a PBS solution containing 0.5% bovine serum albumin (BSA) and 0.25% Triton 
X-100 (refer to Appendix A.2), followed by three PBS washes.  The coverslips were 
incubated overnight at 4°C, in a moist sealed container with 1:100 of rabbit polyclonal 
anti-CD133 (H-284, Santa Cruz Biotechnology) and goat polyclonal anti-EpCAM (A-20, 
Santa Cruz Biotechnology).  The coverslips were washed three times with a 0.5% 
PBS/BSA blocking solution (refer to Appendix A.2); and excess liquid was blotted on 
tissue paper.  The coverslips were then incubated with 1:200 of Alexa Fluor 594, donkey 
anti-rabbit IgG (H+L) (Invitrogen), to detect CD133; and Alexa Fluor 568 donkey anti-
goat IgG (Invitrogen), to detect EpCAM.  Incubations were carried out in a moist sealed 
container in the dark at room temperature for one hour.  The coverslips were washed three 
times in 0.5% PBS/BSA and blotted.  This was followed by one hour incubation in the 
dark, in a moist sealed container with 1:20 Phalloidin (Alexa Fluor 488-green) (Lonza).  
Again the coverslips were washed three times in 0.5% PBS/BSA and blotted, and then 
incubated with 1:10000 of 4', 6-diamidino-2-phenylindole (DAPI) (Cambrex) in PBS for 5 
minutes in the dark at room temperature, in a moist sealed container.  The coverslips were 
washed a further three times in 0.5% PBS/BSA, followed by a PBS wash.  The coverslips 
were blotted and mounted onto slides using Gel Mount Aqueous Mounting Media (Sigma-
Aldrich) and allowed to set.  The slides were viewed on the Zeiss LSM-780 confocal 
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microscope.  Negative controls were carried out, wherein either primary or secondary 
antibodies were omitted, respectively.  In such cases, cells were incubated with PBS/BSA 
for equivalent time periods to the experimental conditions.   
3.1.2 Drug Treatments 
Having confirmed the expression of CD133 and EpCAM in HT29 and DLD1 putative 
CSCs, these cells were seeded onto sterile coverslips and were serum starved for 12 hours 
to synchronise the cell cycle.  The cells were treated for 24 hours, in triplicate, with the 
epigenetic drugs VPA (Sigma) and ZEB (Santa Cruz Biotechnology) respectively, to 
assess their possible effects on NANOG, OCT4 and SOX2 expression.  A range of drug 
concentrations were tested, including 1mM, 2.5mM and 5mM VPA; and 100µM, 250µM 
and 500µM ZEB, respectively.  Controls included untreated cells, and cells treated with 
dimethyl sulphoxide (DMSO) (Sigma) (ZEB carrier).  The range of drug concentrations 
were carefully selected  based on the following literature: Gӧttlicher et al. (2001), Phiel et 
al. (2001), Cheng et al. (2004), Gurvich et al. (2004), Scott et al. (2007), Billam et al. 
(2010), Venkataramani et al. (2010), Marquardt et al. (2011), and Witt et al. (2013).  Next, 
the coverslips with attached cells were processed for indirect immunofluorescence staining 
as previously described in Section 3.1.1.  The coverslips were incubated overnight at 4°C, 
in a moist sealed container with 1:100 of goat polyclonal anti-NANOG (W-18, Santa Cruz 
Biotechnology), 1:100 of goat polyclonal anti-OCT3/4 (N-19, Santa Cruz Biotechnology) 
and mouse monoclonal anti-SOX2 (Abcam).  The coverslips were washed three times with 
a 0.5% PBS/BSA blocking solution (refer to Appendix A.2); and excess liquid was blotted 
on tissue paper.  The coverslips were then incubated with 1:200 of Alexa Fluor 568, 
donkey anti-goat IgG (Invitrogen) to detect NANOG and OCT4; and Alexa Fluor 488 
donkey anti-mouse IgG (Invitrogen) to detect SOX2.  Incubations were carried out in a 
moist sealed container in the dark at room temperature for one hour.  The coverslips were 
washed three times in 0.5% PBS/BSA and blotted, and then incubated with 1:10000 of 
DAPI (Cambrex) in PBS for 5 minutes in the dark at room temperature, in a moist sealed 
container.  The coverslips were washed and mounted onto slides as previously described in 
Section 3.1.1.  The slides were viewed on the Zeiss LSM-780 confocal microscope.  
Negative staining controls were performed by omitting either the primary or secondary 
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antibodies in each case and replacing these with an equivalent amount of PBS/BSA 
solution.  
3.1.3 Scoring of Pluripotent Marker Expression 
The drug treated HT29 and DLD1 putative CSC confocal images were analysed and scored 
according to zero, low, intermediate and high pluripotent marker expression in the nucleus.  
The scoring system used in this study is based on the system used by Yu et al. (2010).  Six 
to eight cells per field of view were assessed.  A score of zero was assigned to cells with no 
marker expression, one was assigned to cells with low marker expression, two was 
assigned to cells with intermediate marker expression and three was assigned to cells with 
high marker expression.  The median fluorescence scores were plotted onto bar graphs.  
Cytoplasmic expression of NANOG, OCT4 and SOX2 was of less interest here as the 
exclusion of these transcription factors from the nucleus prevents them from binding to the 
promoters of their target genes (Baltus et al., 2009).  
3.1.4 Statistical Analyses 
The Kruskal-Wallis and Mann-Whitney tests were used to assess whether there were any 
significant changes in pluripotent marker expression, with respect to drug treatment.  The 
Kruskal-Wallis test examines variance in more than two independent samples and being 
non-parametric does not assume a normal distribution, whereas the Mann-Whitney test 
examines variance between two independent samples (Swinscow & Campbell, 2001).  In 
analysing the confocal microscopy scored data, where the Kruskal-Wallis test indicated 
significant changes in nuclear expression, a Mann-Whitney post hoc analysis was 
subsequently performed.  A two sample Mann-Whitney test was also used to determine 
whether there were significant differences between the untreated/no treatment (NT) and 
DMSO treatment groups.  These statistical analyses were carried out using the “PAST” 
software, version 2.17c (Hammer et al., 2001).  Statistical significance was considered at a 
p-value ≤ 0.05. 
The sign test was also considered to examine the data for trends.  This test is less powerful 
than the Kruskal-Wallis and Mann-Whitney tests as it only considers the medians of 
variables whereas, the Kruskal-Wallis and Mann-Whitney tests consider the spread of 
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unmatched and unpaired variables, respectively (Hart, 2001; Pappas & DePuy, 2004).  
However, the smallest p-value that can be obtained when using the sign test on a sample 
size of three is 0.25 (one-sided) or 0.50 (two-sided), assuming that two “positives” (or 
“negatives”) occur consecutively.  Consequently, it is recommended that a minimal sample 
size of seven should be used when evaluating data using the sign test (Hammer et al., 
2001).   
3.2 Results and Discussion 
Immunofluorescence staining confirmed the expression of CD133 and EpCAM in HT29 
and DLD1 derived putative CSCs following their isolation.  In this aspect of the study, 
confocal microscopy shows that CD133 and EpCAM are localised on the cell membrane 
and in the cytoplasm in both HT29 and DLD1 putative CSCs (Figures 3.2-3.3).  The 
primary and secondary antibody staining controls are shown in Figure D.1 in Appendix D 
and indicate a complete lack of non-specific antibody binding or fluorescence.  
 
 
 
 
 
 
 
Figure203.2. Immunofluorescence images showing CD133 expression in HT29 and DLD1 
putative CSCs.  Cells were stained with Phalloidin-Alexa Fluor 488 conjugate (F-actin) 
indicated in green, DAPI (nuclei) indicated in blue and CD133 detected with Alexa Fluor 
594, donkey anti-rabbit IgG (H+L) indicated in red, as shown by the arrows.  (Original 
magnification 63X). 
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Figure213.3. Immunofluorescence images showing EpCAM expression in HT29 and DLD1 
putative CSCs.  Cells were stained with Phalloidin-Alexa Fluor 488 conjugate (F-actin) 
indicated in green, DAPI (nuclei) indicated in blue and EpCAM detected with Alexa Fluor 
568 donkey anti-goat IgG indicated in red, as shown by the arrows. (Original 
magnification 63X). 
Similar to the findings reported here, some studies have described that CD133 is expressed 
exclusively on the membrane (Kojima et al., 2008; Li et al., 2009; Wang et al., 2009; 
Garcia et al., 2011), whilst others have reported that it is expressed on the cell membrane 
and in the cytoplasm of colorectal cancer cells (Takahashi et al., 2010; Xi & Zhao, 2011; 
Coco et al., 2012; Li et al., 2012b; Reggiani et al., 2012).  Although it is cell surface 
expression of CD133 that is prognostic, the shift in its expression from the cytoplasm to 
the surface on the cell membrane is believed to be a characteristic of cell invasiveness 
(Takahashi et al., 2010; Chen et al., 2013).  Therefore, the cytoplasmic expression of 
CD133 in HT29 and DLD1 putative CSCs may indicate the invasive nature of these cells.  
Similarly, cytoplasmic expression of EpCAM has been described in colorectal carcinoma 
cells (Gosens et al., 2007; Yanamoto et al., 2007).  These findings support the observations 
that CD133 and EpCAM are expressed on the cell membrane and in the cytoplasm in 
HT29 and DLD1 putative CSCs. 
Having confirmed CD133 and EpCAM expression in HT29 and DLD1 putative CSCs, 
these cells were treated with varying concentrations of VPA and ZEB to evaluate the 
epigenetic modulatory effects that these drugs have on NANOG, OCT4 and SOX2 
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expression in these cells.  Cell proliferation and morphology were not affected by these 
epigenetic drugs.  The confocal images of drug treated HT29 and DLD1 putative CSCs are 
shown in Figures D2-D13 in Appendix D (N=1).  The primary and secondary antibody 
negative staining controls indicate a complete lack of non-specific fluorescence (refer to 
Figure D14 in Appendix D).     
Confocal microscopy shows that these proteins are localised in the nucleus and cytoplasm 
in HT29 and DLD1 putative CSCs.  Figure 3.4 shows an example of nuclear and 
cytoplasmic expression of these transcription factors in untreated HT29 putative CSCs.  
Although these proteins were shown to localise in the cell nucleus and cytoplasm, it is 
nuclear expression that is of particular interest here as the exclusion of these transcription 
factors from the nucleus prevents them from maintaining pluripotency as they are no 
longer able to bind to the promoters of their downstream target genes.  
 
 
Figure223.4. Immunofluorescence images showing nuclear (N) and cytoplasmic (C) 
expression of NANOG, OCT4 and SOX2 in untreated HT29 putative CSCs.  Cells were 
stained with DAPI (nuclei) indicated in blue, NANOG detected with Alexa Fluor 568 
donkey anti-goat IgG indicated in red, OCT4 detected with Alexa Fluor 568 donkey anti-
goat IgG indicated in red and SOX2 detected with Alexa Fluor 488 donkey anti-mouse IgG 
indicated in green. (Original magnification 63X). 
Similar to the findings reported here, Guo et al. (2011) reported that NANOG and OCT4 
localised in the cell nucleus and cytoplasm in human glioma cells whereas, SOX2 localised 
exclusively in the nucleus.  Despite the difference in SOX2 localisation, SOX2 has been 
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reported in other studies to shuttle from the nucleus into the cytoplasm in SCs, and in 
colorectal cancer cells (Lin et al., 2010).  In a study by Ishiguro et al. (2012), they reported 
that NANOG predominantly localised in the cytoplasm in HT29 and SW620 colorectal 
cancer cells whereas in Tera-2 cells, it predominantly localised in the nucleus.  Alternative 
splicing of NANOG and OCT4 mRNA transcripts, and post-translational modifications of 
NANOG and OCT4 proteins, could explain their nuclear and cytoplasmic localities (Lee et 
al., 2006; Guo et al., 2011).  For example, the alternatively spliced and translated protein 
OCT4A is localised in the cell nucleus of pluripotent cells where it maintains pluripotency 
whereas, the alternatively spliced and translated protein OCT4B is localised in the 
cytoplasm of tumour and pluripotent cells (Cauffman et al., 2005; Lee et al., 2006).  The 
functional role of OCT4B remains unknown; however, it may play a role in regulating the 
cell-cycle, and in regulating cell proliferation and survival (Cortes-Dericks et al., 2013).  
Cortes-Dericks et al. (2013) showed that the knock-down of OCT4B in the lung 
adenocarcinoma cell line A549 increased the sensitivity of these cells to the 
chemotherapeutic drug Cisplatin by promoting cell-cycle progression, cell proliferation 
and apoptosis.  Altogether, these findings support the observations that NANOG, OCT4 
and SOX2 are expressed in the nucleus and cytoplasm in HT29 and DLD1 putative CSCs, 
which as stated above may indicate that NANOG and OCT4 are alternatively transcribed 
and translated in these cells.  Furthermore, the differential localisation of these 
pluripotency associated transcription factors in HT29 and DLD1 putative CSCs suggests 
that apart from their functional role in maintaining pluripotency, they might also 
participate in regulating other cellular functions. 
Next, the nuclear expression of NANOG, OCT4 and SOX2 in HT29 and DLD1 putative 
CSCs were scored according to zero, low, intermediate and high expression (N=3).  The 
data was then analysed using the Kruskal-Wallis and Mann-Whitney tests to determine 
whether VPA and ZEB significantly modulate the expression of these markers at a protein 
level. The medians of the scored expression data are shown in Tables C5-C6 in Appendix 
C and the results of the statistical analyses are shown in Tables C7-C8 in Appendix C.  The 
median expression of nuclear NANOG, OCT4 and SOX2 in drug treated HT29 and DLD1 
putative CSCs is graphically represented using bar graphs, and these are shown in Figures 
3.5-3.10.  The effects of VPA and ZEB on the nuclear expression of these transcription 
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factors was analysed relative to untreated and DMSO treated cells, respectively.  Statistical 
significance where p≤0.05 is also presented in these figures. 
 
 
 
 
 
 
 
 
Figure233.5. Confocal microscopy analyses of nuclear NANOG in HT29 putative CSCs 
treated with VPA and ZEB.  The columns represent the median fluorescence and the lines 
show the maximum and minimum ranges of the data (*p≤0.05; N=3). 
 
 
 
 
 
 
 
Figure243.6. Confocal microscopy analyses of nuclear OCT4 in HT29 putative CSCs 
treated with VPA and ZEB.  The columns represent the median fluorescence and the lines 
show the maximum and minimum ranges (*p≤0.05; N=3). 
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Figure253.7. Confocal microscopy analyses of nuclear SOX2 in HT29 putative CSCs 
treated with VPA and ZEB.  The columns represent the median fluorescence and the lines 
show the maximum and minimum ranges (*p≤0.05; N=3). 
 
 
 
 
 
 
 
 
 
Figure263.8. Confocal microscopy analyses of nuclear NANOG in DLD1 putative CSCs 
treated with VPA and ZEB.  The columns represent the median fluorescence and the lines 
show the maximum and minimum ranges (*p≤0.05; N=3). 
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Figure273.9. Confocal microscopy analyses of nuclear OCT4 in DLD1 putative CSCs 
treated with VPA and ZEB.  The columns represent the median fluorescence and the lines 
show the maximum and minimum ranges (*p≤0.05; N=3). 
 
 
 
 
 
 
 
 
 
Figure283.10. Confocal microscopy analyses of nuclear SOX2 in DLD1 putative CSCs 
treated with VPA and ZEB.  The columns represent the median fluorescence and the lines 
show the maximum and minimum ranges (*p≤0.05; N=3). 
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In HT29 putative CSCs, 2.5mM and 5mM VPA up-regulate nuclear NANOG and OCT4, 
respectively (Figures 3.5 and 3.6).  When these cells are treated with ZEB, concentrations 
of 250µM and 500µM up-regulate nuclear NANOG equally whereas, ZEB at 500µM up-
regulates OCT4 in these cells (Figures 3.5 and 3.6).  Neither VPA nor ZEB modulate 
SOX2 expression in these cells, as its expression remained unchanged (Figure 3.7). 
In DLD1 putative CSCs, neither VPA nor ZEB modulate NANOG, OCT4 and SOX2 
expression (Figures 3.8-3.10) as sample size may have been a limiting factor.  Due to 
financial and time constraints experiments were carried out in triplicate, which is common 
amongst molecular and cellular biologists (Vaux, 2012).  However, treatment of these cells 
with DMSO, a ZEB carrier, down-regulates OCT4 relative to untreated cells (Figure 3.9).  
Although DMSO was used as a drug carrier, it is also a differentiation inducing agent that 
has been shown to induce the differentiation of embryonic SCs (Torres et al., 2012; Chetty 
et al., 2013).  Torres et al. (2012) reported that the treatment of E14Tg2a embryonic SCs 
with DMSO induced their differentiation.  Moreover, they reported that DMSO reduced 
the expression of NANOG and OCT4 by 0.18±0.07- and 0.70±0.02-fold, respectively.  
Although DMSO did not reduce the expression of NANOG in HT29 and DLD1 putative 
CSCs, it was shown in the present study to reduce the expression of OCT4 in DLD1 CSCs. 
Taken together, specific concentrations of VPA and ZEB were shown to modulate nuclear 
NANOG and OCT4 expression in HT29 putative CSCs.  Whether these drugs modulate 
NANOG and OCT4 expression in DLD1 putative CSCs remains inconclusive as a larger 
sample size is required to verify results.  Moreover, SOX2 protein expression remained 
unchanged in both HT29 and DLD1 putative CSCs following their treatment with VPA 
and ZEB.  This finding is worthy of note as SOX2 and OCT4 cooperatively regulate 
NANOG transcription.  Consequently, it is thought that VPA and ZEB would up-regulate 
SOX2 protein expression, especially in HT29 putative CSCs, as these drugs were shown to 
up-regulate NANOG and OCT4 expression in these cells.  Similar to the finding reported 
here, Kallas et al. (2014) reported that SOX2 protein expression remained unchanged in 
the human ESC line H9 following its differentiation induced by sodium butyrate, whereas 
NANOG and OCT4 were down-regulated upon differentiation.  Based on their findings, 
they concluded that NANOG and OCT4 are regulated at an epigenetic level whereas, other 
mechanisms such as post-translational modifications, regulate SOX2 expression in H9 
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ESCs.  Although it is yet to be determined whether specific concentrations of VPA and 
ZEB induce the differentiation of HT29 and DLD1 putative CSCs, the findings reported 
here suggest that additional mechanism(s), other than epigenetic mechanisms, might 
modulate SOX2 expression in these cells.   
In Part 2 of this chapter, gene expression profiling (qPCR) is used to assess the epigenetic 
modulatory effects that VPA and ZEB have on NANOG, OCT4 and SOX2 expression in 
HT29 and DLD1 putative CSCs.  Surprisingly, SOX2 mRNA transcripts were 
undetectable, or even absent, in HT29 and DLD1 putative CSCs.  This finding might 
provide an explanation as to why SOX2 protein expression remained unchanged in HT29 
and DLD1 putative CSCs following epigenetic drug treatments.   
(ii) Gene Expression Profiling (qPCR) 
3.3 Materials and Methods 
3.3.1 Primer design 
Gene specific DNA primers to NANOG, OCT4 and SOX2 were designed using various 
bioinformatic tools.  The bioinformatic programs used for the design of these primers 
included: UCSC Genome Bioinformatics (UCSC), Ensembl Genome Browser (Ensembl) 
and Primer Blast NCBI (NCBI).  Ensembl was used to obtain candidate gene sequences.  
UCSC Genome Bioinformatics (Blat) and Primer Blast NCBI were used to ensure that the 
DNA primers bound specifically to the candidate genes, and in using in silico PCR to 
ensure an optimal product size of 120-170 base pairs.  The primers were specifically 
designed to span the exons of the candidate genes.  All of these primers ranged from 20-30 
base pairs in length and contained a GC content of 40-60%.  Furthermore, they were 
designed to have melting temperatures (TM) that ranged between 55°C and 65°C 
[calculated using the formula: TM = 4(G+C) + 2(A+T)].  The primers were synthesised 
either by the Department of Molecular and Cell Biology, University of Cape Town or by 
Integrated DNA Technologies (Iowa).  However, as the designed primers failed to amplify 
their target regions, possibly due to the existence of pseudogenes (Suo et al., 2005; Zhang 
et al., 2006), published primers were used.  The published primer sequences are shown in 
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Table 3.1.  The coding sequences, accession numbers and mapped primers to these genes 
are included in Figures D15-D17 (Appendix D). 
TableB3.1: Primer pair sequences for NANOG, OCT4 and SOX2. 
 
3.3.2 Drug Treatments 
HT29 and DLD1 putative CSCs were cultured in a CSC enrichment medium (Chapter 
2.1.6).  The culture medium was aspirated off once the cells had reached 60% confluency, 
and were then serum starved for 12 hours in DMEM:F12 supplemented with 10000 IU 
penicillin and streptomycin.  Following this, the serum-free medium was aspirated off and 
the cells were pharmacologically treated in triplicate with VPA and ZEB (see Section 
3.1.2) for 24 hours.  The cells were harvested, centrifuged at 800rpm for 5 minutes and 
their pellets re-suspended in 600µl RLT lysis buffer (Qiagen).  The cell lysates were stored 
at -70˚C for up to six months.   
3.3.3 RNA Extraction 
For the extraction and purification of total RNA, the Qiagen RNA extraction kit was used 
and the protocol modified to accommodate for the use of both on-column DNase treatment 
(Qiagen) and off-column DNase treatment (New England Biolabs) (refer to Appendix B.2 
for protocol). 
The concentration as well as the purity of RNA (260/280 ratio) was measured on a 
NanoDrop-1000 spectrophotometer (Nanodrop Technologies) and the samples 
standardised to a concentration of 50ng/µl.  
Primer Pair Sequence (forward and reverse, respectively) 
NANOG (Freberg et al., 2007) 5’- CAA AGG CAA ACA ACC CAC TT -3’ 
5’- TCT GCT GGA GGC TGA GGT AT -3’ 
OCT4 (Freberg et al., 2007) 5’- ACA TCA AAG CTC TGC AGA AAG AAC -3’ 
5’- CTG AAT ACC TTC CCA AAT AGA ACC C -3’ 
SOX2 (Chen et al., 2012b) 5’- AAA ACA GCC CGG ACC GCG TC -3’ 
5’- CTC GTC GAT GAA CGG CCG CT -3’ 
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3.3.3.1 Assessment of RNA Integrity 
The Agilent RNA 6000 Pico Kit (Agilent Technologies) was used to determine RNA 
integrity numbers (RINs).  This technique is superior to gel electrophoresis, as it is 
standardised. A software algorithm is applied to RNA following microfluidic 
electrophoresis, to estimate total RNA integrity, this being classified from a range of one to 
ten (Schroeder et al., 2006).  A RIN of one is representative of completely degraded RNA 
and a RIN of ten is representative of completely intact RNA (Schroeder et al., 2006).  
RNA samples were diluted to 5000pg/µl, in RNase-free water.  The RNA ladder and gel-
dye mix was prepared according to the manufacturer’s protocol, and were loaded into the 
wells of a RNA chip, together with the RNA conditioning solution and the RNA marker.  
Next, the RNA samples were loaded into the wells of the RNA chip, and the chip was 
vortexed for 1 minute at 2400rpm in an IKA vortex.  The RNA chip was run on the Agilent 
2100 Bioanalyzer and RINs were acquired.  The output data is viewed as an 
electropherogram (Schroeder et al., 2006).  Figure 3.11 shows an example of an 
electropherogram for the RNA sample DLD1 NT1 with a RIN of 8.60.  In this study, RINs 
ranged between 6.30 and 9.60 indicating that all the samples were intact and were of 
similar integrity (Table C9 in Appendix C).  
 
 
  
 
 
 
 
 
Figure293.11. An electropherogram of RNA isolated from untreated (NT1) DLD1 putative 
CSCs showing the 18S (left) and 28S (right) rRNA peaks, respectively. 
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3.3.4 Reverse Transcription 
The TaqMan Reverse Transcription reagents kit (Applied Biosystems) was used to reverse 
transcribe total RNA to complementary deoxyribonucleic acid (cDNA), using random 
hexamers, according to the manufacturer’s protocol (Table C10 in Appendix C).  Two 
reverse transcription reactions were prepared for each sample; one containing and one 
excluding, reverse transcriptase (the latter referred to as the negative/minus RT).  The latter 
was performed as a control to rule out genomic DNA contamination.  The reverse 
transcription thermal cycling parameters used are shown in Table C11 (Appendix C), and 
include an initial incubation at 25°C for 10 minutes, followed by one cycle of reverse 
transcription at 48°C for 30 minutes and Taq inactivation at 95°C for 5 minutes. 
3.3.5 Quantitative Real-Time PCR (qPCR) Optimisation 
qPCR reactions were prepared on ice, in duplicate, using 50ng cDNA from the untreated 
HT29 and DLD1 putative CSCs, with primers to β-Actin (ACTB) (a reference gene used as 
a positive control), NANOG, OCT4 and SOX2.  The qPCR reactions were prepared with a 
SYBR Green master mix in a total volume of 10µl, according to the manufacturer’s 
protocol (Applied Biosystems) (Table C12 in Appendix C).  The reactions were run on the 
7500 real-time PCR system (Applied Biosystems) with the following thermal cycling 
parameters: an initial incubation step at 50°C for 2 minutes, a hot start step at 95°C for 10 
minutes, followed by 40 cycles of denaturation at 95°C for 15 seconds and 40 cycles of 
primer annealing/extension at 55/60/65°C for 1 minute.  This was followed by a 
dissociation/melt curve analysis of the PCR products.  Annealing/extension temperatures 
for primer pairs ACTB, NANOG and OCT4 were optimised to 60°C.  Primers pairs to 
SOX2 could not be optimised as SOX2 expression was undetectable in untreated HT29 and 
DLD1 putative CSCs.  Based on this latter finding, SOX2 is further investigated in HT29 
and DLD1 putative CSCs, and in their parental cell lines, in Chapter 4. 
3.3.6 Selection of Reference Genes using geNORM 
geNORM is an algorithm that determines the most stably expressed reference/house-
keeping genes tested under certain experimental conditions, to ensure an accurate measure 
of candidate gene expression (Vandesompele et al., 2002).  Reference genes although 
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constitutively expressed, may differ in expression in various tissues and under different 
experimental conditions (Spanakis, 1993; Thellin et al., 1999; Bustin, 2000; Suzuki et al., 
2000; Warrington et al., 2000).  Therefore, it is important to determine and validate the 
expression of a number of reference genes to ensure reliable normalisation of candidate 
gene expression.   
Ten reference genes were selected based on literature review and availability; these 
included: ACTB, GUS, β2M, GAPDH, HPRT, TBP, UBC, YWHAZ and TR (Integrated 
DNA Technologies).  Primers to these reference genes were obtained from the Department 
of Internal Medicine, University of the Witwatersrand, and their sequences are shown 
Table C13 (Appendix C).   
qPCR reactions were prepared, in duplicate, using 50ng cDNA from HT29 and DLD1 
CSCs that had been treated in the following ways: untreated, 5mM VPA, 500µM ZEB and 
DMSO, respectively.  qPCR reactions were prepared in a total volume of 10µl as 
previously described (Section 3.3.5).  The plates were run on the 7500 real-time PCR 
system (Applied Biosystems) with the aforementioned thermal cycling parameters 
(annealing/extension at 60˚C).  The data were exported and analysed using geNORM 
(qBasePlus).  The reference genes were ranked according to their expression stability.  A 
minimum of three reference genes were required for reliable normalisation, these being β-
Actin (ACTB), Hypoxanthine phosphoribosyltransferase 1 (HPRT) and Tyrosine 3-
monooxygenase/tryptophan 5- monooxygenase activation protein, zeta polypeptide 
(YWHAZ).  The coding sequences, accession numbers and mapped primers to these 
reference genes are included in Figures D18-D20 (Appendix D). 
 3.3.7 qPCR of NANOG and OCT4 
Following geNORM analysis, qPCR reactions were prepared in duplicate as above 
(Section 3.3.5) using 50ng cDNA from all of the treatment groups with primers to: ACTB, 
HPRT, YWHAZ (reference genes), and with primers to NANOG and OCT4 (genes of 
interest).  Controls included a minus RT control (genomic deoxyribonucleic acid (gDNA) 
contamination), a H2O control (PCR product contamination) and an inter-plate calibrator 
(IPC) control.  The IPC control consisted of a mix of cDNA from the HT29 and DLD1 
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treated putative CSCs to correct for inter-run variation when samples were distributed 
across plates. 
The following equation was obtained from the TATAA Interplate Calibrator SYBR 
protocol (TATAA Biocenter) and was used to manually adjust quantification cycle (Cq) 
values to correct for inter-plate variation:  
Cqi
corrected
 = Cqi
uncorrected
 - Cqi
IPC 
+ 
 1
no.plates
 ∑ 𝐶𝑞𝑛𝑜.𝑝𝑙𝑎𝑡𝑒𝑠𝑖=1 i
IPC 
Having adjusted the Cq values, the data was analysed using qBasePlus (Biogazelle).  
qBasePlus uses the following equation as a quantification model:  
 
This model allows for the use of several reference genes and is compliant with the 
minimum information for publication of quantitative real-time PCR experiments (MIQE) 
guidelines (Bustin et al., 2009) and therefore it was the preferred method.  The log10 
2-ΔΔCq 
data, which is gene expression data that has been calibrated and normalised using the         
2
-ΔΔCq method (Livak & Schmittgen, 2011), are shown in Tables C14 and C16 in 
Appendix C. 
3.3.8 Statistical Analyses 
The Kruskal-Wallis and Mann-Whitney tests were used to assess statistical significance in 
pluripotent marker expression, with respect to drug treatment (see Section 3.1.4 for a 
description of these statistical tests).  Statistical significance was considered at a p-value ≤ 
0.05.  The sign test was also considered to examine the data for trends; however, as 
previously mentioned (page 65), a minimal sample size of seven is required to evaluate 
data using this test. 
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3.4 Results and Discussion 
In this aspect of the study, qPCR was used to quantify any changes that VPA and ZEB 
have on NANOG, OCT4 and SOX2 gene expression in HT29 and DLD1 putative CSCs.  
As SOX2 expression was absent, or at least undetectable, in HT29 and DLD1 putative 
CSCs, only NANOG and OCT4 gene expression was quantified.  The raw data obtained 
from the qPCR assay showed NANOG and OCT4 expression.  The Cq values of the raw 
data were manually adjusted to correct for inter-plate variation, and the data was analysed 
using qBasePlus.  The gene expression data (log10 
2-ΔΔCq)
 
from qBasePlus is quantitative 
data that has been calibrated and normalised relative to the reference genes ACTB, HPRT 
and YWHAZ, and to the global mean expression of NANOG and OCT4 (Hellemans et al., 
2007).  The gene expression data are shown in Tables C14 and C16 (Appendix C).  The 
median expression of NANOG and OCT4 prior to and following drug treatments were 
plotted onto bar graphs (Figures 3.12 and 3.13) and the effects of VPA and ZEB on their 
expression were statistically analysed relative to untreated and DMSO treated cells, 
respectively.  The results of the statistical analyses are shown in Table C18 (Appendix C). 
 
Figure303.12. Relative gene expression of NANOG and OCT4 in VPA and ZEB treated 
HT29 putative CSCs.  The columns represent the sample median and the vertical lines 
show the maximum and minimum ranges (*p≤0.05; N=3). 
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Figure313.13. Relative gene expression of NANOG and OCT4 in VPA and ZEB treated 
DLD1 putative CSCs.  The columns represent the sample median and the vertical lines 
show the maximum and minimum ranges (*p≤0.05; N=3). 
Statistical analyses show that VPA and ZEB do not modulate NANOG and OCT4 gene 
expression in both HT29 and DLD1 putative CSCs.  Statistical significance may have been 
obscured due to the large range in gene expression, as seen in Figures 3.12-3.13.  Despite 
best efforts to control for inter-plate variation, experimental error is always a concern.  
This is apparent in the data from the third run of the replicates, as the gene expression 
values are consistently higher than those from the first and second runs.  The RNA used for 
the first and second runs was extracted from HT29 and DLD1 putative CSCs that were 
drug treated simultaneously, whereas the RNA used for third run was extracted from CSCs 
that were drug treated approximately three months later.  Although the cells were cultured 
under the same conditions, these cultures may change over time; which may account for 
some of the variation and potential experimental error observed in the third run. 
Overall, the modulatory effects that VPA and ZEB have on NANOG and OCT4 gene 
expression could not be determined in this aspect of the study, with sample size being a 
limiting factor.  Even though these results are currently inconclusive, these drugs were 
shown to up-regulate nuclear NANOG and OCT4 protein expression in HT29 putative 
CSCs.  Previous studies have shown that altering the expression of these pluripotent 
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associated transcription factors above and below endogenous levels in embryonic and adult 
SCs stimulates cell differentiation (Niwa et al., 2000; Wang et al., 2003; Matin et al., 
2004; Hyslop et al., 2005; Niwa et al., 2005; Zaehres et al., 2005; Rodriguez et al., 2007; 
Alvarez et al., 2010; Kallas et al., 2014).  Therefore, it would be of future interest to 
determine whether the up-regulation of NANOG and OCT4 in HT29 putative CSCs is 
associated with cell differentiation, as this may sensitise these cells to current anti-cancer 
therapies.  Differentiation therapy holds promise as the use of the differentiation inducing 
agent Retinoic acid has been shown to have high cure rates in patients with acute 
promyelocytic leukaemia (Huang et al., 1988).  Moreover, differentiation therapy 
involving the use of BMP4 molecules has been shown to stimulate the differentiation of 
putative colorectal adenocarcinoma CSCs in vitro and enhance their sensitivity to the 
chemotherapeutic agents, 5-Fluorouracil and Oxaliplatin in vivo (Lombardo et al., 2011). 
Therefore, stimulating putative CSC differentiation with epigenetic drugs that target the 
mechanisms involved in maintaining pluripotency may enhance their sensitivity to current 
chemo- and radiation-therapies. Ultimately, this approach could lead to tumour regression 
and prevent tumour relapse. 
3.5 Conclusion 
In this chapter, the effects of VPA and ZEB on the expression of the SC associated 
pluripotent transcription factors NANOG, OCT4 and SOX2 were investigated in HT29 and 
DLD1 putative CSCs.  Confocal microscopy showed that CD133 and EpCAM were 
expressed on the cell membrane and in the cytoplasm; and that NANOG, OCT4 and SOX2 
were expressed in the nucleus and cytoplasm in HT29 and DLD1 putative CSCs.  Specific 
concentrations of VPA and ZEB were shown to up-regulate the expression of nuclear 
NANOG and OCT4 in HT29 putative CSCs whereas, neither drug modulated the 
expression of these transcription factors in DLD1 putative CSCs.  Moreover, SOX2 
expression was not affected by either of these drugs in both HT29 and DLD1 putative 
CSCs. Next, gene expression profiling was used to quantitatively assess the 
pharmacological effects of VPA and ZEB on NANOG, OCT4 and SOX2 gene expression.  
Interestingly, SOX2 expression was either undetectable or possibly absent, in HT29 and 
DLD1 putative CSCs.  The results obtained from the gene expression profiling assay of 
NANOG and OCT4 were inconclusive possibly due to the amount of variability in gene 
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expression.  Bearing in mind that statistical power is affected by sample size, expanding 
the sample size of this study would improve statistical robustness. 
In Chapter 4 of this study, SOX2 is further considered in HT29 and DLD1 putative CSCs 
and in their parental cell lines. Moreover, a mechanism that potentially regulates SOX2 
function in HT29 and DLD1 putative CSCs is proposed.  
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CHAPTER 4 
POST-TRANSLATIONAL MODIFICATIONS ALTER 
SOX2 FUNCTION 
SOX2 is a member of the SRY-related HMG box (SOX) family.  It is an intron-less gene 
located within the SOX2 overlapping transcript gene sequence (Pruitt et al., 2013).  There 
are two SOX2 splice variants, these being SOX2-001 and SOX2-201, each has a transcript 
length of 2500bp and 1318bp, respectively (Flicek et al., 2014).  The protein coding 
sequence of these two variants codes for the same 317 amino acid long protein (Flicek et 
al., 2014).  The accession numbers for these transcripts and proteins are shown in Table 
C19 (Appendix C). 
SOX2 primarily functions to maintain pluripotency in embryonic and adult SCs (Masui et 
al., 2007).   The putative role of SOX2 in cellular pluripotency involves the dimerisation of 
SOX2 and OCT4 to regulate the transcription of NANOG, and other key pluripotent factors 
(Boyer et al., 2005; Medvedev et al., 2008).  Since SOX2 imbues cells with pluripotent 
qualities by controlling the expression of a variety of “stemness” factors, its expression is 
tightly controlled via positive and negative feed-back loops, and by numerous feed-forward 
loops that respond to SOX2 regulated gene products (Boyer et al., 2005; Ormsbee et al., 
2013).  However, the exact mechanism by which SOX2 is regulated in pluripotent cells is 
not well understood (Boyer et al., 2005; Ormsbee et al., 2013).   
To elucidate a mechanism that modulates SOX2 gene expression in human embryonic SCs, 
Ormsbee et al. (2013) hypothesised that an increase in endogenous SOX2 inhibits SOX2 
transcription via a negative feed-back loop.  They tested this hypothesis using genetically 
engineered embryonic SCs that inducibly express OCT4, SOX2, KLF-4 and c-MYC (i-
OSKM-ESC) when treated with Doxycycline.  They reported that elevating the expression 
of these transcription factors resulted in the phosphorylation of AKT, a player in the PI3K 
signalling pathway, which activates a negative feed-back loop that specifically modulates 
SOX2 expression in these cells.  In a study by Kuzmichev et al. (2012), they showed that 
SOX2 regulates Sox21 transcription to repress Cdx2 in mouse colorectal cancer cells.  As 
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Cdx2 is a repressor of Sox2 transcription, its repression by Sox21 allows these cells to 
maintain pluripotency (Kuzmichev et al., 2012).  Together, these studies illustrate that the 
mechanisms involved in modulating SOX2 expression are complex.   
CSCs are thought to trigger tumour initiation, progression and metastasis.  Since SOX2 
functions to maintain SC identity in embryonic and adult SCs, its dysregulation in CSCs is 
likely to play an important role in tumourigenesis.  In this regard, SOX2 dysregulation has 
been reported in cancers of the breast (Ben-Porath et al., 2008), gastrointestinal tract 
(Otsubo et al., 2008), lung (Bass et al., 2009; Maier et al., 2011), oesophagus (Bass et al., 
2009; Maier et al., 2011) and colon (Neumann et al., 2011).  A SOX2 knock-down study 
by Han et al. (2012) showed reduced WNT signalling in the colorectal cell line SW620, 
resulting in mesenchymal-epithelial transition (MET).  As a consequence, these cells lost 
their ability to metastasise in vitro and invade surrounding tissue in vivo (Han et al., 2011).  
In another SOX2 knock-down study by Alonso et al. (2011), brain tumour SCs cultured as 
neurospheres lost their ability to self-renew.  These studies demonstrate the importance of 
SOX2 in maintaining self-renewal and pluripotency, and that its aberrant expression may 
possibly drive cancer pathogenesis. 
In the present study, SOX2 mRNA transcripts were surprisingly undetectable by qPCR 
assay in both HT29 and DLD1 putative CSCs.  Even so, the transcription factor was 
clearly localised subcellularly in these cells, as previously shown by confocal microscopy.  
The lack of mRNA transcripts in the presence of expressed proteins possibly suggests 
unusual post-translational processing of SOX2.  In an attempt to determine whether this 
phenomenon is restricted to putative CSCs, the SOX2 gene and its expression is further 
explored in HT29 and DLD1 putative CSCs, and in their parental cell lines.  The results 
obtained in this aspect of the study are interpreted by a conceptual model.   
4.1 Materials and Methods 
As SOX2 failed to amplify at the mRNA level in both HT29 and DLD1 putative CSCs, 
PCR amplification was carried out using genomic DNA (gDNA) to confirm the presence 
of this gene in HT29 and DLD1 putative CSCs, and in their parental cell lines.  gDNA was 
extracted using the QIAamp DNA Mini Kit (Qiagen), according to the manufacturer’s 
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protocol (Appendix B.5).  The concentration, as well as the purity, of gDNA was measured 
on a NanoDrop-1000 spectrophotometer (Nanodrop Technologies). 
Next, PCR reactions with primers that span the SOX2 coding sequence were prepared, as in 
section 3.3.5, in a total volume of 10µl (refer to Table 3.1 for primer pair sequences).  The 
reactions were run on the 7500 real-time PCR system (Applied Biosystems) with the 
following thermal cycling parameters: an initial incubation step at 50°C for 2 minutes, a 
hot start step at 95°C for 10 minutes, followed by 40 cycles of denaturation at 95°C for 15 
seconds and 40 cycles of primer annealing/extension at 65°C for 1 minute.  A H2O control 
was included to rule out reagent contamination.  For gel electrophoresis, 5µl of PCR 
product was mixed with 2µl loading dye, and was run on a 1.5% agarose gel for 
approximately one hour at 100V in 1X TBE buffer (Appendix A.3).  The gel was analysed 
on the Bio-Rad Gel Doc EZ Imager system, together with the Image Lab software (version 
5).  A dissociation/melt curve was generated on the 7500 real-time PCR system (Applied 
Biosystems) with the remaining 5µl of PCR products.   
Having confirmed the presence of the SOX2 gene in HT29 and DLD1 putative CSCs, and 
in their parental cell lines, a subsequent PCR assay was carried out to evaluate its 
expression in these cells.  RNA was extracted from the HT29 and DLD1 putative CSCs, 
and from their parental cell lines, as previously described in Chapter 3.3.3.  The RNA from 
each of the samples was standardised to 50ng/µl and reverse transcribed (see Chapter 
3.3.4).  Next, PCR reactions with primers to SOX2 and ACTB (positive control) were 
prepared, as in Chapter 3.3.5, in a total volume of 10µl.  The reactions were run on the 
7500 real-time PCR system (Applied Biosystems) with the same thermal cycling 
parameters described above.  Negative/minus RT controls and H2O controls were included 
to rule out gDNA contamination and reagent contamination, respectively.  For gel 
electrophoresis, 5µl of PCR product was mixed with 2µl loading dye, and run on a 1.5% 
agarose gel for approximately one hour at 100V in 1X TBE buffer (Appendix A.3). The 
gel was analysed on the Bio-Rad Gel Doc EZ Imager system, together with the Image Lab 
software (version 5). As previously, a dissociation curve was generated on the 7500 real-
time PCR system (Applied Biosystems) with the remaining 5µl of PCR products. 
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4.2 Results 
As there was no amplification in the minus RT and H2O controls, cDNA samples were 
neither compromised by gDNA/reagent contamination, nor by primer dimer formation.  
The PCR analysis of the gDNA confirmed the presence of the SOX2 gene in both the HT29 
and DLD1 putative CSC lines, and in their parental cell lines, with an amplicon of 176bp 
(Figure 4.1 A).  The dissociation curve analysis produced a reproducible melting 
temperature of 87.12°C for each sample analysed (Figure 4.1 B).  A subsequent PCR study 
using cDNA as a template, together with gel electrophoresis and melt curve analysis, 
shows that SOX2 was not expressed at detectable levels in either HT29 or DLD1 putative 
CSC lines.  Whereas, in the HT29 and DLD1 parental cell lines it was expressed at low 
levels when compared to ACTB (Figure 4.2 A).  
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Figure324.1. A 1.5% agarose gel (A), and its corresponding dissociation/melt curve (B) 
showing the presence of the SOX2 amplicon (176bp) in gDNA isolated from DLD1 and 
HT29 cells, and from their associated putative CSCs.  In Figure 4.1 A, lane 1 is a 100bp 
DNA ladder (Fermentas); lane 2 is a SOX2 H2O control; lanes 3, 4 are SOX2 amplicons in 
DLD1 and HT29 cells respectively; lanes 5, 6 are SOX2 amplicons in DLD1 and HT29 
putative CSCs, respectively.  In Figure 4.1 B, the melt curve shows that SOX2 amplicons 
melt consistently at 87.12°C. 
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Figure334.2. A 1.5% agarose gel (A), and its corresponding dissociation/melt curve (B) 
showing the presence of the ACTB (192bp) and SOX2 amplicons (176bp) in DLD1 and 
HT29 cells, and the absence of the SOX2 amplicon in DLD1 and HT29 putative CSCs.  In 
Figure 4.2 A, lane 1 is a 100bp DNA ladder (Fermentas); lanes 2-5 are ACTB amplicons in 
DLD1 cells, HT29 cells, DLD1 putative CSCs and HT29 putative CSCs respectively; lanes 
6-9 are ACTB minus RTs for all cell types; lane 10 is an ACTB H2O control; lanes 11-12 
are SOX2 amplicons from DLD1 and HT29 cells, respectively; lanes 13-14 show SOX2 
amplicons from DLD1 and HT29 putative CSCs; and lane 15 is a SOX2 H2O control.  In 
Figure 4.2 B, the melt curve shows ACTB amplicons melt at ~85.3°C in DLD1 and HT29 
putative CSCs, and in their parental cells lines; whereas SOX2 amplicons melt at ~87.12°C 
in DLD1 and HT29 cells only.  
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4.3 Discussion 
The present findings indicate that the apparent lack (or at least, undetectable levels) of 
SOX2 mRNA is characteristic of the HT29 and DLD1 putative CSCs, and not of their 
corresponding parental cell lines.  The absence of SOX2 mRNA transcripts in putative 
CSCs was unusual as the SOX2 protein was previously shown to localise subcellularly in 
these cells.  This deficiency cannot be accounted for by the genotype of these cells, as the 
SOX2 gene sequence was confirmed to be present in both the HT29 and DLD1 putative 
CSC lines, and in their parental cell lines.  Moreover, the absence of SOX2 mRNA does 
not result from alternative splicing as the protein coding sequences of its two variants are 
the same (Flicek et al., 2014).  In this aspect of the study, the SOX2 primers used for the 
PCR assay spanned the protein coding sequence.  As SOX2 is known to regulate its own 
transcription via a negative feed-back loop (Ormsbee et al., 2013), it is possible that post-
translational modifications of SOX2 alter the negative regulatory feed-back mechanism in 
putative CSCs. 
In embryonic and adult SCs, post-translational modifications such as sumoylation, 
phosphorylation and acetylation are known to modulate SOX2 function in these cells 
(Tsuruzoe et al., 2006; Baltus et al., 2009; Jeong et al., 2010).  Post-translational 
modifications alter protein function by affecting DNA binding capability, localisation and 
stability (Jeong et al., 2012).  Sumoylation involves the conjugation of small ubiquitin-
related modifier (SUMO) proteins to cellular proteins and affects their ability to bind to 
target DNA.  Such alterations to the DNA-binding properties of proteins may either 
enhance or prohibit this interaction (Johnson, 2004; Baltus et al., 2009).  Sumoylation 
alters SOX2 function by reducing its binding affinity to DNA, thus inactivating its 
transcriptional activity and pluripotent function (Tsuruzoe et al., 2006).  Phosphorylation 
of SOX2 enhances its nuclear stability by blocking the ubiquitination process that would 
otherwise result in proteolysis (Jeong et al., 2010) whereas, acetylation of SOX2 results in 
its nuclear export to the cytoplasm where it can no longer maintain pluripotency (Baltus et 
al., 2009).   
As these post-translational modifications are known to modulate SOX2 function in 
embryonic and adult SCs, it is possible that these modifications are tailored to alter SOX2 
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function in putative CSCs.  The regulation of SOX2 gene expression and SOX2 function in 
HT29 and DLD1 putative CSCs, and in their parental cell lines, may be explained by the 
model developed through this study (Figure 4.3).  It is proposed here that in HT29 and 
DLD1 putative CSCs, post-translational modifications of SOX2 result in high levels of 
active/stable SOX2 in the nucleus. These modifications might include SOX2 
phosphorylation (Jeong et al., 2010).  It is here within the nucleus, that active SOX2 
associates with OCT4, where together they up-regulate the transcription of SC associated 
pluripotent genes to imbue cells with pluripotency potential (Boyer et al., 2005; Medvedev 
et al., 2008).  Moreover, a high level of active SOX2 in the nucleus prevents further SOX2 
transcription via a negative feed-back loop (Ormsbee et al., 2013).  Eventually, SOX2 
mRNA is degraded and this would account for its absence in these cells.  Alternatively, 
SOX2 transcription might occur at levels low enough to maintain a SOX2 threshold level 
however, these levels may be too low to detect with PCR assay. 
Conversely, in the HT29 and DLD1 cell lines, it is proposed here that post-translational 
modifications of nuclear SOX2 reduces its binding affinity to DNA (referred to as inactive 
SOX2) and/or results in its export to the cytoplasm.  These post-translational modifications 
might include sumoylation and acetylation, respectively (Tsuruzoe et al., 2006; Baltus et 
al., 2009).  Such SOX2 status would result in the reduced expression of pluripotency 
associated transcription factors followed by cell differentiation.  Moreover, a constant low 
level of active SOX2 in the nucleus would allow for continuous SOX2 transcription and 
this would account for its detection by PCR assay in the HT29 and DLD1 cell lines. 
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4.4 Conclusion 
In this chapter, the SOX2 gene and its expression at the mRNA level were further 
investigated in HT29 and DLD1 putative CSCs, and in their respective parental cell lines.  
PCR assay analyses showed that the SOX2 gene was present in all of these cell types 
although, its expression was restricted to the HT29 and DLD1 cell lines.  As the genotype 
of these cells did not account for the absence of SOX2 expression in HT29 and DLD1 
putative CSCs, and that alternative splicing was not responsible for its absence, a model 
involving post-translational modulation of SOX2 function in these cells was proposed.  In 
HT29 and DLD1 putative CSCs, it was hypothesised that selective post-translational 
modifications of SOX2, such as phosphorylation, result in high levels of active SOX2 in 
the nucleus.  Active SOX2 maintains pluripotency by increasing the transcription of 
pluripotent genes and by repressing its own transcription via negative feed-back.  
However, within the general population of HT29 and DLD1 cells, selective post-
translational modifications, including sumoylation and acetylation, may result in low levels 
of active nuclear SOX2.  This leads to reduced pluripotent gene expression and allows for 
increased SOX2 transcription.  Thus, post-translational modifications of SOX2 may 
possibly act as a bi-directional switch to modulate SOX2 expression. 
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CHAPTER 5 
CONCLUDING REMARKS AND FUTURE 
RESEARCH 
The possible generation of cancer stem cells (CSCs) from adult stem cells (SCs) during 
early carcinogenesis may involve epigenetic reprogramming leading to altered gene 
expression, wherein genes associated with cell differentiation may be silenced and SC 
specific genes up-regulated.  In cancer, the continued existence of treatment resistant 
tumour associated SCs poses a therapeutic challenge.  A better understanding of epigenetic 
events in cancer SC biology may lead to the development of new therapies, particularly 
since epigenetic changes are potentially reversible.    
The present study assessed the epigenetic modulation of key pluripotency genes in putative 
colorectal CSCs at both a protein and gene expression (mRNA) level.  The cells were 
selectively isolated from colorectal adenocarcinoma cell lines on the basis of their 
expression of the cell surface markers CD133 and EpCAM.  CD133 was found to be 
expressed at lower levels in the early stage colorectal adenocarcinoma cell line SW1116 
(Dukes’ stage A) and more abundantly in the later stage HT29 and DLD1 cell lines 
(Dukes’ stage B and C, respectively); whereas, EpCAM was expressed at high levels in all 
the cell lines representative of Dukes’ stages.  
The later stage putative CSCs derived from the HT29 and DLD1 cell lines showed 
clonality, a reproducible feature of SCs.  The effects of two epigenetic drugs, Valproic acid 
(VPA), a histone deacetylase inhibitor, and Zebularine (ZEB), a DNA methyltransferase 
inhibitor, were assessed on gene and protein expression of NANOG, OCT4 and SOX2, 
these being universal genes necessary for the maintenance of “stemness” and thus 
continued cell proliferation.  VPA and ZEB up-regulated nuclear NANOG and OCT4 
expression in the HT29 derived CSCs, while the effects of these drugs on nuclear NANOG 
and OCT4 expression in the DLD1 derived CSCs were unclear.  Nuclear SOX2 protein 
expression remained unchanged in either of the late stage derived CSCs.  The gene 
expression profiling studies indicated a lack of modulation of both NANOG and OCT4 in 
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both the HT29 and DLD1 sourced CSCs, while SOX2 mRNA was undetectable.  The lack 
of detectable SOX2 mRNA transcripts was a feature that was unusual yet unique to these 
cells and in this regard, a regulatory model was proposed to account for this observation.  
These findings however suggest a potential post-translational response of NANOG and 
OCT4 to epigenetic treatments in the HT29 derived CSCs, while SOX2 would appear to be 
unresponsive to either epigenetic drug in CSCs derived from both the HT29 and DLD1 cell 
lines.  Altering the expression of either transcription factor may possibly induce cell 
differentiation; however, further research would be needed to confirm this.  Should VPA 
and ZEB induce cell differentiation, these drugs when combined with current anti-cancer 
therapies, may result in tumour regression and prevent tumour relapse.  A model that 
captures the concept of combining CSC targeted therapy with current therapy is shown in 
Figure 5.1. 
 
Figure355.1. A conceptual model showing how combined CSC targeted therapy and 
conventional therapy results in tumour regression and prevents relapse (adapted from 
Figure 3 in Dalerba et al., 2007a, 279 p.). 
5.1 Future Directions  
In this study, CD133 was shown as a valuable marker to isolate and characterise putative 
CSCs from the HT29 and DLD1 colon adenocarcinoma cell lines.  However, as the sphere 
formation assay indicated that only 21% of these cells had clonogenic potential in vitro,  it 
would therefore be of future interest to determine whether additional markers, such as 
CD44, CD166 and CD24 could further enrich putative CSC isolation from these cell lines.  
It would also be relevant to further characterise CD133
+ 
HT29 and DLD1 cells based on 
their invasive potential and sensitivity to current chemotherapeutic drugs in vitro; and to 
evaluate the tumourigenic potential of these cells using a xenotransplantation assay, as this 
method is the gold standard for demonstrating “stemness” in vivo (Wolf et al., 2014).  
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Moreover, as some studies have shown that CD133
- 
cells show clonogenic potential in 
vitro and tumourigenic potential in vivo (Shmelkov et al., 2008; Kawamoto et al., 2010; 
Hsu et al., 2013), it would also be important to determine whether CD133
-
 HT29 and 
DLD1 cells also show features of “stemness”. 
The treatment of HT29 putative CSCs with VPA and ZEB were shown to up-regulate 
nuclear NANOG and OCT4 in these cells but their effects on transcription factor 
modulation in DLD1 putative CSCs were unclear.  Moreover, there was no clear evidence 
showing that these drugs modulate NANOG and OCT4 gene expression at the mRNA level 
in HT29 and DLD1 putative CSCs.  As sample size may have been a limiting factor in this 
study, it would be of future interest to increase the sample size and to verify the 
pharmacological effects of VPA and ZEB on NANOG and OCT4 gene expression in these 
cells.  It would be important to determine whether VPA and ZEB induce cell 
differentiation following NANOG and OCT4 modulation, in the HT29 and DLD1 derived 
CSCs, as these drugs may potentially prevent tumour relapse when combined with current 
anti-cancer therapies. An experimental approach would be to use flow 
cytometry/immunofluorescence microscopy together with antibodies to differentiation-
specific markers, such as CK20, a marker specific to differentiated colorectal cells (Wildi 
et al., 1999; Chen & Wang, 2004).   
Since pluripotency of embryonic and adult SCs is also maintained by the pluripotent genes, 
KLF-4 (Leng et al., 2013) and c-MYC (Takahashi & Yamanaka, 2006; Wang et al., 2008), 
as well as by a network of signalling pathways, including WNT and BMP4 (Medvedev et 
al., 2008; Roy & Majumdar, 2012), it would be relevant to investigate the potential effects 
of VPA and ZEB on these markers, and on signal transduction, in HT29 and DLD1 
putative CSCs.  The epigenetic status of these pluripotency associated genes, pre-and post-
treatment would also be of interest as epi-mutations are known to drive tumour initiation in 
the colon.   
Lastly, in the context of the previously proposed model, the regulation of SOX2 function in 
HT29 and DLD1 putative CSCs may be of some importance.  It would therefore be of 
future interest to elucidate the mechanism(s) that modulate SOX2 function in these cells.  
A relevant approach here would be to assess the interaction of SOX2 with partner binding 
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proteins, using chromatin immunoprecipitation (ChIP) assays.  It is suggested that 
elucidating the underlying cell biological mechanism(s) involved in SOX2 regulation, may 
well lead to the identification of potential targets for anti-cancer therapies.
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Appendix A 
Procedures 
All the chemicals used in this section of this study were sourced from Sigma Aldrich 
unless otherwise stated. 
A.1 Cell Culture 
Serum Free Cancer Stem Cell Selection Medium (Mather, 2008) 
The serum-free cancer stem cell selection medium (DMEM/F12) was supplemented with 
the following cell culture grade ingredients:  
6mg/ml glucose 
1mg/ml sodium bicarbonate 
2mM L-glutamine 
4μg/ml heparin 
4mg/ml BSA 
10ng/ml bFGF 
20ng/ml EGF 
100μg/ml apotransferrin 
25μg/ml insulin 
9.6μg/ml putrescine  
30nM sodium selenite anhydrous 
20nM progesterone 
Add 100μl 10000 IU penicillin and streptomycin (Lonza) per 50ml media 
Filter sterilise  
Only add bFGF and EGF, once needed 
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2% Agar 
2g Agar (Difco) 
100ml distilled water 
Autoclave 
Once cooled, add enough agar to cover the area of the growth surface of a dish (plate wells 
or flasks) 
A.2 Immunofluorescence Microscopy 
 
Phosphate Buffered Saline (PBS) 
5 PBS tablets in one litre distilled water (Sigma Aldrich) 
Autoclave 
Blocking Solution/Buffer 
PBS 0.5% BSA 
50ml PBS 
0.25g BSA 
Dissolve 
Fixing Solution/Buffer 
PBS 3% Formaldehyde 
16.5ml PBS 
1.5ml Formaldehyde (37%, Merck) 
Mix 
Permeabilisation Solution/Buffer 
PBS 0.5% BSA 0.25% Triton X-100 
20ml PBS 
0.1g BSA 
50μl Triton X 
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A.3 Gel Electrophoresis 
 
10X TBE (Tris, borate, ethylenediaminetetraacetic acid) buffer  
108g Tris (Merck) 
55g Boric acid (Merck) 
9.3g EDTA (Merck) 
Dissolve and make up to a total volume of 1l, adjust pH to 8.3 and store at room 
temperature. 
To make a one litre working solution of 1X TBE buffer, mix 100ml 10X TBE buffer with 
900ml distilled water. 
1.5% agarose gel 
1.5g agarose (Bio-Rad) 
100ml TBE buffer 
In a microwave, dissolve agarose in 1X TBE buffer, once slightly cooled add 5μl ethidium 
bromide (Promega), swirl to mix. Pour into a casting tray with a comb and allow to set. 
A.4 Flow Cytometry 
 
Wash Buffer 
PBS, 2mM EDTA and 0.5% BSA 
80ml PBS 
14.89mg EDTA (Merck) 
Adjust pH to 8.0 using 10N NaOH 
Add 0.5g BSA and dissolve 
Make up to 100ml 
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Appendix B 
Methods 
B.1 Thin Gel (non-gelling) Method for Three-dimensional Cell Culture 
(Matrigel/Geltrex) 
 
1. Thaw Matrigel/Geltrex (BD Biosciences/Gibco) on ice  
2. Gently pipette-mix the Matrigel/Geltrex and dilute 1ml into 29ml DMEM/F12 
3. Add enough diluted Matrigel/Geltrex to cover the area of the growth surface of a 
dish (plate wells or flasks) 
4. Incubate the coated plastics at 37°C for one hour, and remove the DMEM/F12 
medium 
5. Immediately plate cells, or alternatively seal the plastics with parafilm and store at 
2-8°C for up to 2 weeks. 
B.2 RNA Extraction and DNase Digestion  
 
Qiagen Easy Plus RNA Extraction and On-column DNase Treatment (Qiagen) 
This method of RNA extraction utilises a column wherein a silica-gel-membrane with 
selective binding properties, is placed.  The sample is lysed and homogenised.  Ethanol is 
added to provide appropriate binding conditions, and the sample is added to the column.  
RNA binds to the membrane and unbound sample is passed through by centrifugal force.  
The sample is washed and treated with DNase to ensure complete removal of DNA from 
the sample.  An appropriate elution buffer is applied to the column and purified RNA is 
eluted.  
1. Collect and disrupt cells in 600µl RLT Buffer containing 10μl/ml β-
mercaptoethanol (Sigma-Aldrich).  The lysates are stable for up to 6 months at -
70°C. 
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2. Thaw cell lysates and homogenise in QIAshredder spin columns centrifuged for 2 
minutes at 14 000rpm. 
3. Transfer the homogenised lysates to genomic DNA eliminator spin columns and 
centrifuge for 30 seconds at 10 900rpm. 
4. Add 600µl ice cold ethanol (70%) to the flow-through and pipette mix. 
5. Transfer up to 700µl of the sample to an RNeasy spin column and centrifuge for 15 
seconds at 10 900rpm.  Add the remainder of the flow-through and repeat. 
6. Discard the flow-through, add 350µl Buffer RW1 and centrifuge for 15 seconds at 
10 900rpm and discard the flow- through. 
7. Add 10µl of re-constituted DNase mixed in 70µl Buffer RDD onto the RNeasy spin 
column membrane and incubate at room temperature for 15 minutes followed by 
the addition of 350µl Buffer RW1.  Centrifuge the columns for 15 seconds at 
10 900rpm and discard the flow-through.  Add 500µl Buffer RPE to the column 
and centrifuge for 15 seconds at 10 900rpm followed by an additional wash with 
500µl Buffer RPE, centrifuged at 10 900rpm for 2 minutes.   
8. Place RNeasy spin columns in new 2ml collection tubes and centrifuge for 1 minute 
at 14 000rpm. 
9. Place spin columns in new 1.5ml collection tubes, add 30µl RNase-free water to the 
column membrane and incubate for 5 minutes followed by centrifugation at 
10 900rpm for 1 minute to elute RNA.   
10.  Add 5µl eluted RNA from step 9 to a 1.5ml eppendorf tube.  Add 85µl RNase-free     
water, 10µl 10X DNase I Reaction Buffer (New England Biolabs) and 2µl DNase I 
(RNase-free, 2000U/ml) (New England Biolabs). 
11. Incubate for 10 minutes at 37°C followed by the addition of 1µl 0.5M EDTA (filter 
sterilised).  Incubate for 10 minutes at 75°C and briefly centrifuge to remove 
droplets from the lid. 
12. Add 350µl RLT Buffer, mix and add 250µl ice cold ethanol (96-100%).  Pipette 
mix and apply 750µl of sample to a RNeasy column placed in a 2ml collection 
tube, followed by centrifugation at 10 900rpm for 15 seconds.   
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13. Transfer the column to a new 2ml collection tube and add 500µl Buffer RPE 
followed by centrifugation at 10 900rpm for 15 seconds.   
14. Discard the flow-through and add 500µl Buffer RPE followed by centrifugation at 
10 900rpm for 2 minutes. 
15. Repeat steps 8 and 9 to elute RNA. 
B.3 Genomic DNA Extraction (Qiagen) 
 
Qiagen QIAamp DNA Mini Kit 
This method of DNA extraction utilises a column wherein a silica-gel-membrane with 
selective binding properties, is placed.  The sample is lysed and ethanol is added to provide 
appropriate binding conditions.  The sample is added to the column and DNA is adsorbed 
onto the membrane during centrifugation.  The DNA is washed and purified DNA is eluted 
in an appropriate elution buffer. 
1. Collect and wash cells with 2ml PBS.  Centrifuge cells for 3 minutes at 800rpm, 
and discard the supernatant.  Repeat the wash and re-suspend the cell pellet in 
200µl PBS, in a 1.5ml microcentrifuge tube. 
2. Add 20µl Proteinase K and 200µl Buffer AL.  Pulse vortex for 15 seconds and 
incubate at 56°C for 10 minutes. 
3. Add 200µl ice cold ethanol (96-100%) and pulse vortex for 15 seconds.   
4. Apply the suspension to a QIAamp spin column placed in a 2ml collection tube, 
and centrifuge for 1 minute at 8000rpm. 
5. Place the column in a new 2ml collection tube and add 500µl Buffer AW1.  
Centrifuge for 1 minute at 8000rpm. 
6. Place the column in a new 2ml collection tube and add 500µl Buffer AW2.  
Centrifuge for 3 minutes at 14000rpm. 
7. Place the column in a new 2ml collection tube and centrifuge for 1 minute at 
14000rpm. 
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8. Place the column in a 1.5ml microcentrifuge tube and add 200µl Buffer AE to the 
column.  Incubate for 1 minute at room temperature, and centrifuge for 1 minute at 
8000rpm. 
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Appendix C 
Tables 
C.1 Flow Cytometric Characterisation of CD133 and EpCAM 
 
TableCC1: CD133
-
/EpCAM
-
, CD133
-
/EpCAM
+
 and CD133
+
/EpCAM
+
 expression in the 
SW1116, HT29 and DLD1 cell lines (N=3). 
 
 
 
 
 
 
 
 
 
 
 
 
  
Cell Line 
Marker Expression (%) 
CD133
-
/EpCAM
-
 CD133
-
/EpCAM
+
 CD133
+
/EpCAM
+
 
SW1116 
8.96 
12.80 
9.03 
88.70 
84.50 
88.70 
2.33 
2.65 
2.29 
Median 9.03 88.70 2.33 
HT29 
0.77 
0.58 
0.34 
94.10 
94.10 
94.70 
5.11 
5.31 
4.98 
Median 0.58 94.10 5.11 
DLD1 
0.19 
0.74 
0.05 
89.50 
88.60 
89.80 
10.30 
10.50 
10.10 
Median 0.19 89.50 10.30 
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C.2 Sphere Formation Assay 
 
TableDC2: Sphere-forming capacity of CD133
+
/EpCAM
+
 HT29 and DLD1 cells (N=3).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Replicate 
Number of Spheres/well 
HT29 DLD1 
Replicate 1 
23 
13 
18 
19 
17 
14 
29 
25 
16 
18 
21 
23 
Replicate 2 
14 
29 
24 
29 
16 
16 
13 
19 
23 
28 
21 
19 
Replicate 3 
24 
28 
29 
26 
17 
27 
25 
26 
18 
22 
21 
15 
Median 21 21 
Lower Quartile 16 18 
Upper Quartile 27 25 
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C.3 CD133 Expression in Colonic Tumours 
 
TableEC3: CD133 expression in colonic tumours with varying Dukes’ stages (adapted 
from Ricci-Vitiani et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case Dukes’ Stage CD133 Expression (%) 
1 C 2.40 
2 C 2.00 
3 D 2.50 
4 A 1.70 
5 C 1.40 
6 C 2.40 
7 C 1.80 
8 A 0.70 
9 A 2.40 
10 B 0.70 
11 A - 
12 C - 
13 B 2.60 
14 B 4.10 
15 C 2.70 
16 B 6.10 
17 A 1.70 
18 B 4.60 
19 D - 
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C.4 CD133 Expression in Colonic Tumours and Normal Tissues 
 
TableFC4: CD133 expression in 17 colonic tumours of varying stages, and in their 
corresponding normal tissues (adapted from O’Brien et al., 2007). 
 
 
 
 
 
 
 
 
Patient Number Tumour Stage CD133
+
 in tumour (%) CD133
+ 
in normal (%) 
1 IB 14.00 2.10 
2 IV 5.20 - 
3 IV 14.70 - 
4 IV 1.80 - 
5 IV 24.50 - 
6 IV 6.30 - 
7 I 9.30 1.20 
8 IIIC 7.50 0.40 
9 IV 12.10 - 
10 IIIC 8.90 1.30 
11 IV 19.00 - 
12 IIIC 15.90 0.85 
13 I 12.00 1.90 
14 IV 17.60 - 
15 IV 18.20 - 
16 IV 10.40 - 
17 IV 3.20 - 
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C.5 Pluripotent Marker Expression in HT29 putative CSCs 
TableGC5: Median pluripotent marker scores in HT29 putative CSCs (N=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key: NT=No treatment, VPA=Valproic acid, ZEB=Zebularine, 
DMSO=Dimethyl sulphoxide. 
  
Treatment Median 
HT29 NANOG Replicate 1 Replicate 2 Replicate 3 
NT 1.0 1.0 1.0 
1mM VPA 1.0 2.0 2.0 
2.5mM VPA 2.0 2.0 2.0 
5mM VPA 1.0 2.0 2.0 
DMSO 1.0 1.0 1.0 
100µM ZEB 1.0 2.0 2.0 
250µM ZEB 2.0 2.0 2.0 
500µM ZEB 2.0 2.0 2.0 
HT29 OCT4 Replicate 1 Replicate 2 Replicate 3 
NT 1.0 1.0 1.0 
1mM VPA 1.0 1.0 1.0 
2.5mM VPA 1.0 1.0 1.0 
5mM VPA 2.0 2.0 2.0 
DMSO 1.0 1.0 1.0 
100µM ZEB 2.0 1.5 1.0 
250µM ZEB 1.0 2.0 2.0 
500µM ZEB 2.0 2.0 2.0 
HT29 SOX2 Replicate 1 Replicate 2 Replicate 3 
NT 2.0 2.0 2.0 
1mM VPA 2.0 2.0 2.0 
2.5mM VPA 2.0 2.0 2.0 
5mM VPA 2.0 2.0 2.0 
DMSO 2.0 2.0 2.0 
100µM ZEB 2.0 2.0 2.0 
250µM ZEB 2.0 2.0 2.0 
500µM ZEB 2.0 2.0 2.0 
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C.6 Pluripotent Marker Expression in DLD1 putative CSCs 
 
TableHC6: Median pluripotent marker scores in DLD1 putative CSCs (N=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key: NT=No treatment, VPA=Valproic acid, ZEB=Zebularine, 
DMSO=Dimethyl sulphoxide. 
 
  
Treatment Median 
DLD1 NANOG Replicate 1 Replicate 2 Replicate 3 
NT 1.0 1.0 1.0 
1mM VPA 1.0 1.0 1.0 
2.5mM VPA 1.0 1.0 1.0 
5mM VPA 1.0 1.0 1.0 
DMSO 1.5 2.0 1.0 
100µM ZEB 2.0 2.0 1.5 
250µM ZEB 2.0 3.0 3.0 
500µM ZEB 2.0 2.0 3.0 
DLD1 OCT4 Replicate 1 Replicate 2 Replicate 3 
NT 2.0 2.0 1.0 
1mM VPA 2.0 2.0 1.0 
2.5mM VPA 2.0 2.0 1.0 
5mM VPA 2.5 3.0 2.0 
DMSO 1.0 1.0 1.0 
100µM ZEB 2.0 2.5 1.0 
250µM ZEB 2.0 2.5 2.0 
500µM ZEB 2.5 2.0 2.0 
DLD1 SOX2 Replicate 1 Replicate 2 Replicate 3 
NT 2.0 2.0 2.0 
1mM VPA 2.0 2.0 2.0 
2.5mM VPA 2.0 2.0 2.0 
5mM VPA 2.0 2.0 2.0 
DMSO 2.0 2.0 2.0 
100µM ZEB 2.0 2.0 2.0 
250µM ZEB 2.0 2.0 2.0 
500µM ZEB 2.0 2.0 2.0 
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C.7 Statistical Analyses of Pluripotent Marker Expression in HT29 Putative CSCs 
 
TableIC7: Kruskal-Wallis and Mann-Whitney tests of nuclear NANOG, OCT4 and SOX2 
expression in HT29 putative CSCs (N=3). 
 
*p≤0.05 is statistically significant; Key: NT=No treatment, VPA=Valproic acid, 
ZEB=Zebularine, DMSO=Dimethyl sulphoxide.  
 
 
 
 
 
 
HT29 putative CSCs 
Treatment Statistical Test NANOG OCT4 SOX2 
All treatments 
 
Kruskal-Wallis *p=0.038 *p=0.011 p=1.000 
NT  versus 1mM VPA Mann-Whitney   p=0.187   p=1.000 - 
NT  versus 2.5mM VPA Mann-Whitney *p=0.046   p=1.000 - 
NT  versus 5mM VPA Mann-Whitney   p=0.187 *p=0.046 - 
1mM versus 2.5mM VPA Mann-Whitney   p=0.505   p=1.000 - 
1mM versus 5mM VPA Mann-Whitney   p=0.792 *p=0.046 - 
2.5mM versus 5mM VPA Mann-Whitney   p=0.505 *p=0.046 - 
NT versus DMSO 
 
Mann-Whitney   p=1.000   p=1.000 - 
DMSO  versus  100µM ZEB Mann-Whitney   p=0.187   p=0.196 - 
DMSO  versus  250µM ZEB Mann-Whitney *p=0.046   p=0.187 - 
DMSO  versus  500µM ZEB Mann-Whitney *p=0.046 *p=0.046 - 
100µM  versus 250µM ZEB Mann-Whitney   p=0.505   p=0.813 - 
100µM  versus 500µM ZEB Mann-Whitney   p=0.505   p=0.196 - 
250µM  versus 500µM ZEB Mann-Whitney   p=1.000   p=0.505 - 
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C.8 Statistical Analyses of Pluripotent Marker Expression in DLD1 Putative CSCs 
 
TableJC8: Kruskal-Wallis and Mann-Whitney tests of nuclear NANOG, OCT4 and SOX2 
expression in DLD1 putative CSCs (N=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*p≤0.05 is statistically significant; Key: NT=No treatment, VPA=Valproic acid, 
ZEB=Zebularine, DMSO=Dimethyl sulphoxide.  
 
 
 
 
 
 
DLD1 putative CSCs 
Treatment Statistical Test NANOG OCT4 SOX2 
All treatments 
 
Kruskal-Wallis *p=0.004 *p=0.032 p=1.000 
NT  versus 1mM VPA Mann-Whitney   p=1.000   p=1.000 - 
NT  versus 2.5mM VPA Mann-Whitney   p=1.000   p=1.000 - 
NT  versus 5mM VPA Mann-Whitney   p=1.000   p=0.196 - 
1mM versus 2.5mM VPA Mann-Whitney   p=1.000   p=1.000 - 
1mM versus 5mM VPA Mann-Whitney   p=1.000   p=0.196 - 
2.5mM versus 5mM VPA Mann-Whitney   p=1.000   p=0.196 - 
NT versus DMSO 
 
Mann-Whitney   p=0.196 *p=0.046 - 
DMSO  versus  100µM ZEB Mann-Whitney   p=0.479   p=0.059 - 
DMSO  versus  250µM ZEB Mann-Whitney   p=0.115   p=0.063 - 
DMSO  versus  500µM ZEB Mann-Whitney   p=0.164   p=0.059 - 
100µM  versus 250µM ZEB Mann-Whitney   p=0.157   p=0.479 - 
100µM  versus 500µM ZEB Mann-Whitney   p=0.301   p=0.792 - 
250µM  versus 500µM ZEB Mann-Whitney   p=0.619   p=0.479 - 
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C.9 RNA Integrity Numbers (RINs) 
TableKC9: RNA integrity numbers of RNA extracted from HT29 and DLD1 putative 
CSCs. 
Treatment (N=3) RINs-HT29 CSCs RINs-DLD1 CSCs 
NT1 7.30 8.60 
NT2 8.10 8.10 
NT3 9.30 7.70 
1mM VPA1 9.00 9.20 
1mM VPA2 7.20 8.80 
1mM VPA3 8.70 8.50 
2.5mM VPA1 8.60 9.20 
2.5mM VPA2 8.00 9.00 
2.5mM VPA3 6.60 8.80 
5mM VPA1 7.20 9.50 
5mM VPA2 8.80 9.50 
5mM VPA3 8.60 7.40 
DMSO1 7.30 9.50 
DMSO2 8.90 9.00 
DMSO3 8.20 8.10 
100µM ZEB1 7.90 9.70 
100µM ZEB2 8.30 9.60 
100µM ZEB3 9.00 8.20 
250µM ZEB1 6.30 9.50 
250µM ZEB2 8.30 8.60 
250µM ZEB3 8.40 7.60 
500µM ZEB1 7.70 8.90 
500µM ZEB2 6.70 9.30 
500µM ZEB3 7.80 7.80 
 
Key: NT=No treatment, VPA=Valproic acid, ZEB=Zebularine, 
DMSO=Dimethyl sulphoxide.  
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C.10 Reverse Transcription Master Mix (Applied Biosystems) 
 
TableLC10: Stock concentrations and volumes of reagents used per 10µl reverse 
transcription reaction. 
 
 
 
 
 
 
 
 
 
C.11 Reverse Transcription Thermal Cycling Parameters 
 
TableMC11: Reverse transcription thermal cycling parameters (number of cycles=1). 
 
 
 
 
Reagent Volume and stock concentration 
Taq Man Buffer 1.00µl (10X) 
MgCl2 2.20µl (25mM) 
dNTPs 2.00µl (10mM) 
Random Hexamers/Oligo d(T)16s 0.50µl (2.5µM) 
RNase Inhibitor 0.20µl (20µM) 
Reverse Transcriptase 0.25µl (5U/µl) 
RNA + RNase free water 3.85µl (700-1000ng/µl) 
Total volume 10.00µl 
Step Temperature (°C) Time (minutes) Number of cycles 
Incubation 25 10 1 
Reverse Transcription 48 30 1 
Taq Inactivation 95 5 1 
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C.12 SYBR Green PCR Master Mix 
 
TableNC12: Stock concentrations and volumes of reagents used per 10µl real-time PCR 
reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Reagent Volume and Stock concentration 
SYBR green master mix 5.00µl (5X) 
Forward primer 1.00µl (2µM) 
Reverse primer 1.00µl (2µM) 
cDNA 3.00µl 
Total volume 10.00µl 
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C.13 Reference Gene Primers 
 
TableOC13: Primer sequences of reference genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Primer Sequence (forward and reverse, respectively) 
ACTB 
5’- ACC AAC TGG GAC GAC ATG GAG AAA -3’ 
5’- TAG CAC AGC CTG GAT AGC AAC GTA -3’ 
GUS 
5’- ACG AAC GCC CTG CCT ATC TGT ATT -3’ 
5’- ATG AGG AAC TGG CTC TTG GTG ACA -3’ 
β2M 
5’- TGC TGT CTC CAT GTT TGA TGT ATC T -3’ 
5’- TCT CTG CTC CCC ACC TCT AAG T -3’ 
GAPDH 
5’- TGC ACC ACC ACC TGC TTA GC -3’ 
5’- GGC ATG GAC TGT GGT CAT GAG -3’ 
HPRT 
5’- TGA CAC TGG CAA AAC AAT GCA -3’ 
5’- GGT CCT TTT CAC CAG CAA GCT -3’ 
TBP 
5’- TGA TGC CTT ATG GCA CTG GAC TGA -3’ 
5’- CTG CTG CCT TTG TTG CTC TTC CAA -3’ 
UBC 
5’- ATT TGG GTC GCG GTT CTT -3’ 
5’- TGC CTT GAC ATT CTC GAT GGT -3’ 
YWHAZ 
5’- ACT TTT GGT ACA TTG TGG CTT CAA -3’ 
5’- CCG CCA GGA CAA ACC AGT AT -3’ 
TR 
5’- GGC ACC ATC AAG CTG CTG AAT GAA -3’ 
5’- GTT GAT CAC GCC AGA CTT TGC TGA -3’ 
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C.14 Gene Expression (log10
 2-ΔΔCq) in HT29 putative CSCs 
 
TablePC14: ACTB, HPRT, NANOG, OCT4 and YWHAZ gene expression in HT29 putative 
CSCs. 
 
Key: NT=No treatment, VPA=Valproic acid, ZEB=Zebularine, DMSO=Dimethyl 
sulphoxide. 
Sample 
 
ACTB HPRT NANOG OCT4 YWHAZ 
HT29 CSC NT1 -0,01 0,06 -0,28 0,26 -0,05 
HT29 CSC NT2 -0,15 0,06 -0,53 0,00 0,09 
HT29 CSC NT3 0,10 -0,08 -0,22 0,12 -0,02 
HT29 CSC 1mM VPA1 -0,10 0,07 -0,18 -0,16 0,03 
HT29 CSC 1mM VPA2 -0,02 0,04 -0,03 -0,02 -0,03 
HT29 CSC 1mM VPA3 0,17 -0,14 0,22 -0,01 -0,03 
HT29 CSC 2.5mM VPA1 -0,11 -0,03 -0,30 -0,22 0,14 
HT29 CSC 2.5mM VPA2 -0,01 -0,04 0,11 -0,02 0,05 
HT29 CSC 2.5mM VPA3 0,02 -0,04 0,42 -0,07 0,02 
HT29 CSC 5mM VPA1 -0,13 0,06 0,00 0,37 0,07 
HT29 CSC 5mM VPA2 -0,20 0,10 0,07 0,02 0,10 
HT29 CSC 5mM VPA3 0,04 -0,02 0,03 0,02 -0,03 
HT29 CSC DMSO1 0,19 -0,08 -0,43 0,31 -0,12 
HT29 CSC DMSO2 -0,06 0,03 -0,32 -0,16 0,03 
HT29 CSC DMSO3 0,10 -0,01 -0,40 0,18 -0,09 
HT29 CSC 100uM  ZEB1 0,13 -0,15 -0,45 -0,06 0,02 
HT29 CSC 100uM  ZEB2 -0,03 0,02 -0,34 -0,51 0,01 
HT29 CSC 100uM  ZEB3 0,07 0,05 0,45 0,20 -0,12 
HT29 CSC 250uM  ZEB1 -0,11 0,14 0,07 0,14 -0,03 
HT29 CSC 250uM  ZEB2 -0,13 0,14 0,26 -0,05 -0,02 
HT29 CSC 250uM  ZEB3 0,00 0,07 0,01 0,30 -0,07 
HT29 CSC 500uM  ZEB1 -0,08 0,14 0,12 0,11 -0,06 
HT29 CSC 500uM  ZEB2 -0,02 0,03 0,07 0,12 -0,01 
HT29 CSC 500uM  ZEB3 0,18 -0,02 0,19 0,18 -0,16 
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C.15 Standard Error in Gene Expression (log10 
2-ΔΔCq) in HT29 putative CSCs 
 
TableQC15: Standard Error in ACTB, HPRT, NANOG, OCT4 and YWHAZ gene 
expression in HT29 putative CSCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key: NT=No treatment, VPA=Valproic acid, ZEB=Zebularine, DMSO=Dimethyl 
sulphoxide. 
Sample ACTB   HPRT  NANOG  OCT4  YWHAZ  
HT29 CSC NT1 6,28 0,87 0,09 0,34 1,23 
HT29 CSC NT2 0,08 0,26 0,01 6,30 0,44 
HT29 CSC NT3 1,52 0,48 0,12 0,52 2,99 
HT29 CSC 1mM VPA1 0,22 0,35 0,06 0,19 1,32 
HT29 CSC 1mM VPA2 1,64 1,93 2,98 1,35 2,36 
HT29 CSC 1mM VPA3 0,79 0,24 0,28 5,50 0,83 
HT29 CSC 2.5mM VPA1 0,27 1,45 0,12 0,14 0,92 
HT29 CSC 2.5mM VPA2 8,47 2,60 1,12 5,84 6,09 
HT29 CSC 2.5mM VPA3 0,58 0,39 0,49 0,56 1,31 
HT29 CSC 5mM VPA1 0,18 1,79 19,85 0,19 0,50 
HT29 CSC 5mM VPA2 0,27 0,77 0,65 1,79 1,16 
HT29 CSC 5mM VPA3 0,80 3,59 2,48 1,13 0,72 
HT29 CSC DMSO1 0,59 0,64 0,03 0,40 0,24 
HT29 CSC DMSO2 1,01 0,86 0,07 0,28 1,47 
HT29 CSC DMSO3 0,19 6,97 0,01 0,10 0,18 
HT29 CSC 100uM ZEB1 0,76 0,11 0,07 0,63 1,27 
HT29 CSC 100uM ZEB2 0,78 1,20 0,07 0,05 10,42 
HT29 CSC 100uM ZEB3 0,49 0,61 0,13 0,28 0,30 
HT29 CSC 250uM ZEB1 0,50 0,27 0,42 0,69 0,94 
HT29 CSC 250uM ZEB2 0,24 1,01 0,28 1,21 5,40 
HT29 CSC 250uM ZEB3 4,61 0,26 1,57 0,10 0,22 
HT29 CSC 500uM ZEB1 0,23 0,24 0,94 1,08 0,75 
HT29 CSC 500uM ZEB2 2,47 2,13 0,46 0,37 2,97 
HT29 CSC 500uM ZEB3 0,44 1,18 0,15 0,33 0,12 
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C.16 Gene Expression (log10 
2-ΔΔCq) in DLD1 putative CSCs 
 
TableRC16: ACTB, HPRT, NANOG, OCT4 and YWHAZ gene expression in DLD1 
putative CSCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key: NT=No treatment, VPA=Valproic acid, ZEB=Zebularine, DMSO=Dimethyl 
sulphoxide. 
Sample BA HPRT NANOG OCT4 YWHAZ 
DLD1 CSC NT1 0,00 0,00 -0,19 -0,10 0,00 
DLD1 CSC NT2 0,07 -0,16 -0,15 -0,40 0,09 
DLD1 CSC NT3 -0,05 -0,04 0,04 0,41 0,10 
DLD1 CSC 1mM VPA1 0,06 0,15 -0,11 -0,01 -0,21 
DLD1 CSC 1mM VPA2 0,07 -0,11 -0,02 -0,08 0,04 
DLD1 CSC 1mM VPA3 0,07 -0,10 0,27 0,31 0,03 
DLD1 CSC 2.5mM VPA 0,19 -0,11 -0,26 -0,21 -0,08 
DLD1 CSC 2.5mM VPA2 0,07 -0,12 -0,42 -0,34 0,05 
DLD1 CSC 2.5mM VPA3 0,02 -0,17 0,56 0,11 0,14 
DLD1 CSC 5mM VPA1 0,12 -0,13 -0,25 -0,16 0,01 
DLD1 CSC 5mM VPA2 0,04 -0,13 0,16 0,13 0,08 
DLD1 CSC 5mM VPA3 -0,02 -0,10 0,59 0,07 0,12 
DLD1 CSC DMSO1 -0,06 0,10 -0,27 -0,36 -0,04 
DLD1 CSC DMSO2 -0,37 0,16 -0,71 -0,51 0,22 
DLD1 CSC DMSO3 -0,14 0,06 0,26 0,19 0,08 
DLD1 CSC 100uM ZEB1 -0,06 0,15 0,02 -0,26 -0,09 
DLD1 CSC 100uM ZEB2 0,06 0,15 0,24 -0,46 -0,22 
DLD1 CSC 100uM ZEB3 0,03 -0,01 0,25 0,31 -0,01 
DLD1 CSC 250uM ZEB1 0,00 0,03 0,32 -0,22 -0,04 
DLD1 CSC 250uM ZEB2 -0,06 0,18 -0,01 -0,30 -0,12 
DLD1 CSC 250uM ZEB3 -0,03 0,00 0,48 0,38 0,03 
DLD1 CSC 500uM ZEB1 0,12 -0,02 0,15 0,32 -0,10 
DLD1 CSC 500uM ZEB2 0,01 -0,17 0,18 -0,11 0,16 
DLD1 CSC 500uM ZEB3 0,03 -0,03 0,36 0,23 0,00 
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C.17 Standard Error in Gene Expression (log10 
2-ΔΔCq) in DLD1 putative CSCs 
 
TableSC17: Standard Error in ACTB, HPRT, NANOG, OCT4 and YWHAZ gene 
expression in DLD1 putative CSCs. 
 
Key: NT=No treatment, VPA=Valproic acid, ZEB=Zebularine, DMSO=Dimethyl 
sulphoxide. 
Sample ACTB HPRT  NANOG OCT4 YWHAZ  
DLD1 CSC NT1  7,12 1,97 0,16 0,06 4,94 
DLD1 CSC NT2 0,54 0,40 0,22 0,05 0,60 
DLD1 CSC NT3 0,47 1,39 2,68 0,15 0,51 
DLD1 CSC 1mM VPA1 0,45 0,33 0,47 26,12 0,11 
DLD1 CSC 1mM VPA2 0,32 0,06 1,92 0,09 0,53 
DLD1 CSC 1mM VPA3 1,81 0,57 0,65 0,30 1,57 
DLD1 CSC 2.5mM VPA1 0,53 1,27 0,15 0,18 0,79 
DLD1 CSC 2.5mM VPA2 0,17 0,02 0,04 0,04 0,07 
DLD1 CSC 2.5mM VPA3 3,30 0,10 0,15 0,38 0,24 
DLD1 CSC 5mM VPA1 0,35 0,10 0,04 0,08 5,36 
DLD1 CSC 5mM VPA2 1,02 0,15 0,87 0,68 1,05 
DLD1 CSC 5mM VPA3 2,64 0,37 1,33 1,86 0,39 
DLD1 CSC DMSO1 1,09 0,34 0,19 0,05 1,05 
DLD1 CSC DMSO2 0,06 0,20 0,01 0,06 0,35 
DLD1 CSC DMSO3 0,30 0,99 0,48 0,42 1,28 
DLD1 CSC 100uM ZEB1 0,06 0,06 1,06 0,04 0,12 
DLD1 CSC 100uM ZEB2 1,08 0,27 0,62 0,03 0,21 
DLD1 CSC 100uM ZEB3 3,51 1,84 0,29 0,52 2,40 
DLD1 CSC 250uM ZEB1 39,31 0,96 0,36 0,09 1,11 
DLD1 CSC 250uM ZEB2 0,33 0,52 9,18 0,04 0,22 
DLD1 CSC 250uM ZEB3 2,59 13,85 0,50 0,49 2,13 
DLD1 CSC 500uM ZEB1 0,42 1,62 0,84 0,20 0,72 
DLD1 CSC 500uM ZEB2 4,49 0,43 0,37 0,70 0,65 
DLD1 CSC 500uM ZEB3 2,92 1,27 0,21 0,37 22,40 
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C.18 Statistical Analyses of Gene Expression Profiling 
 
TableTC18: Kruskal-Wallis and Mann-Whitney tests of NANOG and OCT4 mRNA 
expression in HT29 and DLD1 putative CSCs. 
 
 
*p≤0.05 is statistically significant; Key: NT=No treatment, VPA=Valproic acid, 
ZEB=Zebularine, DMSO=Dimethyl sulphoxide.  
  
 Statistical Test HT29 CSCs DLD1 CSCs 
NANOG    
NT versus VPA 
 
Kruskal-Wallis   p=0.204   p=0.621 
NT  versus 1mM VPA Mann-Whitney   p=0.080   p=0.382 
NT  versus 2.5mM VPA Mann-Whitney   p=0.382   p=0.662 
NT  versus 5mM VPA Mann-Whitney   p=0.080   p=0.662 
NT versus DMSO 
 
Mann-Whitney   p=0.662   p=0.662 
DMSO versus ZEB Kruskal-Wallis   p=0.218   p=0.496 
DMSO  versus  100µM ZEB Mann-Whitney   p=1.000   p=0.662 
DMSO  versus  250µM ZEB Mann-Whitney   p=0.080   p=0.190 
DMSO  versus  500µM ZEB Mann-Whitney   p=0.080   p=0.382 
OCT4    
NT versus VPA Kruskal-Wallis *p=0.037   p=0.679 
NT  versus 1mM VPA Mann-Whitney   p=0.080   p=0.662 
NT  versus 2.5mM VPA Mann-Whitney   p=0.080   p=1.000 
NT  versus 5mM VPA Mann-Whitney   p=1.000   p=1.000 
NT versus DMSO 
 
Mann-Whitney   p=1.000   p=0.662 
DMSO versus ZEB Kruskal-Wallis   p=0.739   p=0.361 
DMSO  versus  100µM ZEB Mann-Whitney   p=0.662   p=0.662 
DMSO  versus  250µM ZEB Mann-Whitney   p=1.000   p=0.382 
DMSO  versus  500µM ZEB Kruskal-Wallis   p=0.662   p=0.190 
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C.19 SOX2 Splice Variants   
 
TableUC19: SOX2 transcript and protein accession numbers (Flicek et al., 2014). 
 
  
Name Transcript ID Length  Protein ID Length  CCDS 
SOX2-001 ENST00000325404 2500bp ENSP00000323588 317aa CCDS3239 
SOX2-201 ENST00000431565 1318bp ENSP00000439111 317aa CCDS3239 
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Appendix D 
Figures 
D.1 Immunofluorescence Microscopy-CD133 and EpCAM Negative Staining 
Controls 
 
 
 
Figure36D.1. Immunofluorescence images showing primary and secondary antibody 
negative control staining for CD133 and EpCAM in HT29 and DLD1 putative CSCs.  
Cells were stained with Phalloidin-Alexa Fluor 488 conjugate (F-actin) indicated in green 
and DAPI (nuclei) indicated in blue.  The cells are also stained with CD133 and EpCAM 
primary antibodies only, and with Alexa Fluor 594, donkey anti-rabbit IgG (H+L) and with 
Alexa Fluor 568 donkey anti-goat IgG, respectively.  (Original magnification 63X). 
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D.2 Immunofluorescence Microscopy-Drug Treatments 
 
 
Figure37D.2. Immunofluorescence images showing NANOG expression in HT29 putative 
CSCs treated with varying concentrations of VPA.  Cells were stained with DAPI (nuclei) 
indicated in blue and NANOG detected with Alexa Fluor 568 donkey anti-goat IgG 
indicated in red.  (Original magnification 63X) (N=1). 
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Figure38D.3. Immunofluorescence images showing NANOG expression in HT29 putative 
CSCs treated with varying concentrations of ZEB.  Cells were stained with DAPI (nuclei) 
indicated in blue and NANOG detected with Alexa Fluor 568 donkey anti-goat IgG 
indicated in red.  (Original magnification 63X) (N=1). 
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Figure39D.4. Immunofluorescence images showing OCT4 expression in HT29 putative 
CSCs treated with varying concentrations of VPA.  Cells were stained with DAPI (nuclei) 
indicated in blue and OCT4 detected with Alexa Fluor 568 donkey anti-goat IgG indicated 
in red.  (Original magnification 63X) (N=1). 
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Figure40D.5. Immunofluorescence images showing OCT4 expression in HT29 putative 
CSCs treated with varying concentrations of ZEB.  Cells were stained with DAPI (nuclei) 
indicated in blue and OCT4 detected with Alexa Fluor 568 donkey anti-goat IgG indicated 
in red.  (Original magnification 63X) (N=1). 
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Figure41D.6. Immunofluorescence images showing SOX2 expression in HT29 putative 
CSCs treated with varying concentrations of VPA.  Cells were stained with DAPI (nuclei) 
indicated in blue and SOX2 detected with Alexa Fluor 488 donkey anti-mouse IgG 
indicated in green.  (Original magnification 63X) (N=1). 
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Figure42D.7. Immunofluorescence images showing SOX2 expression in HT29 putative 
CSCs treated with varying concentrations of ZEB.  Cells were stained with DAPI (nuclei) 
indicated in blue and SOX2 detected with Alexa Fluor 488 donkey anti-mouse IgG 
indicated in green.  (Original magnification 63X) (N=1). 
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Figure43D.8. Immunofluorescence images showing NANOG expression in DLD1 putative 
CSCs treated with varying concentrations of VPA.  Cells were stained with DAPI (nuclei) 
indicated in blue and NANOG detected with Alexa Fluor 568 donkey anti-goat IgG 
indicated in red.  (Original magnification 63X) (N=1). 
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Figure44D.9. Immunofluorescence images showing NANOG expression in DLD1 putative 
CSCs treated with varying concentrations of ZEB.  Cells were stained with DAPI (nuclei) 
indicated in blue and NANOG detected with Alexa Fluor 568 donkey anti-goat IgG 
indicated in red.  (Original magnification 63X) (N=1). 
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Figure45D.10. Immunofluorescence images showing OCT4 expression in DLD1 putative 
CSCs treated with varying concentrations of VPA.  Cells were stained with DAPI (nuclei) 
indicated in blue and OCT4 detected with Alexa Fluor 568 donkey anti-goat IgG indicated 
in red.  (Original magnification 63X) (N=1). 
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Figure46D.11. Immunofluorescence images showing OCT4 expression in DLD1 putative 
CSCs treated with varying concentrations of ZEB.  Cells were stained with DAPI (nuclei) 
indicated in blue and OCT4 detected with Alexa Fluor 568 donkey anti-goat IgG indicated 
in red.  (Original magnification 63X) (N=1). 
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Figure47D.12. Immunofluorescence images showing SOX2 expression in DLD1 putative 
CSCs treated with varying concentrations of VPA.  Cells were stained with DAPI (nuclei) 
indicated in blue and SOX2 detected with Alexa Fluor 488 donkey anti-mouse IgG 
indicated in green.  (Original magnification 63X) (N=1). 
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Figure48D.13. Immunofluorescence images showing SOX2 expression in DLD1 putative 
CSCs treated with varying concentrations of ZEB.  Cells were stained with DAPI (nuclei) 
indicated in blue and SOX2 detected with Alexa Fluor 488 donkey anti-mouse IgG 
indicated in green.  (Original magnification 63X) (N=1). 
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Figure49D.14. Immunofluorescence images showing primary and secondary antibody 
control staining for NANOG, OCT4 and SOX2 in HT29 and DLD1 putative CSCs.  Cells 
are stained with DAPI (nuclei) indicated in blue.  The cells are also stained with a 
combination of NANOG, OCT4 and SOX2 primary antibodies only, and with Alexa Fluor 
568, donkey anti-goat IgG and with Alexa Fluor 488 donkey anti-mouse IgG.  (Original 
magnification 63X). 
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D.3 Mapped NANOG Primers  
 
1    ATGAGTGTGGATCCAGCTTGTCCCCAAAGCTTGCCTTGCTTTGAAGCATCCGACTGTAAAGAATCTTCAC 
71   CTATGCCTGTGATTTGTGGGCCTGAAGAAAACTATCCATCCTTGCAAATGTCTTCTGCTGAGATGCCTCA 
141  CACGGAGACTGTCTCTCCTCTTCCTTCCTCCATGGATCTGCTTATTCAGGACAGCCCTGATTCTTCCACC 
      F primer 
211  AGTCCCAAAGGCAAACAACCCACTTCTGCAGAGAAGAGTGTCGCAAAAAAGGAAGACAAGGTCCCGGTCA 
281  AGAAACAGAAGACCAGAACTGTGTTCTCTTCCACCCAGCTGTGTGTACTCAATGATAGATTTCAGAGACA 
      R primer 
351  GAAATACCTCAGCCTCCAGCAGATGCAAGAACTCTCCAACATCCTGAACCTCAGCTACAAACAGGTGAAG 
421  ACCTGGTTCCAGAACCAGAGAATGAAATCTAAGAGGTGGCAGAAAAACAACTGGCCGAAGAATAGCAATG 
491  GTGTGACGCAGAAGGCCTCAGCACCTACCTACCCCAGCCTTTACTCTTCCTACCACCAGGGATGCCTGGT 
561  GAACCCGACTGGGAACCTTCCAATGTGGAGCAACCAGACCTGGAACAATTCAACCTGGAGCAACCAGACC 
631  CAGAACATCCAGTCCTGGAGCAACCACTCCTGGAACACTCAGACCTGGTGCACCCAATCCTGGAACAATC 
701  AGGCCTGGAACAGTCCCTTCTATAACTGTGGAGAGGAATCTCTGCAGTCCTGCATGCAGTTCCAGCCAAA 
771  TTCTCCTGCCAGTGACTTGGAGGCTGCCTTGGAAGCTGCTGGGGAAGGCCTTAATGTAATACAGCAGACC 
841  ACTAGGTATTTTAGTACTCCACAAACCATGGATTTATTCCTAAACTACTCCATGAACATGCAACCTGAAG 
911  ACGTGTGA 
 
Figure50D.15. NANOG mRNA sequence showing the forward (F) and reverse (R) primer 
binding sites, amplicon size: 158bp (NCBI accession number: NM_024865.2). 
D.4 Mapped OCT4 Primers  
  
1    ATGGCGGGACACCTGGCTTCGGATTTCGCCTTCTCGCCCCCTCCAGGTGGTGGAGGTGATGGGCCAGGGG 
71   GGCCGGAGCCGGGCTGGGTTGATCCTCGGACCTGGCTAAGCTTCCAAGGCCCTCCTGGAGGGCCAGGAAT 
141  CGGGCCGGGGGTTGGGCCAGGCTCTGAGGTGTGGGGGATTCCCCCATGCCCCCCGCCGTATGAGTTCTGT 
211  GGGGGGATGGCGTACTGTGGGCCCCAGGTTGGAGTGGGGCTAGTGCCCCAAGGCGGCTTGGAGACCTCTC 
281  AGCCTGAGGGCGAAGCAGGAGTCGGGGTGGAGAGCAACTCCGATGGGGCCTCCCCGGAGCCCTGCACCGT 
                                                                   F primer 
351  CACCCCTGGTGCCGTGAAGCTGGAGAAGGAGAAGCTGGAGCAAAACCCGGAGGAGTCCCAGGACATCAAA 
421  GCTCTGCAGAAAGAACTCGAGCAATTTGCCAAGCTCCTGAAGCAGAAGAGGATCACCCTGGGATATACAC 
          R primer 
491  AGGCCGATGTGGGGCTCACCCTGGGGGTTCTATTTGGGAAGGTATTCAGCCAAACGACCATCTGCCGCTT 
561  TGAGGCTCTGCAGCTTAGCTTCAAGAACATGTGTAAGCTGCGGCCCTTGCTGCAGAAGTGGGTGGAGGAA 
631  GCTGACAACAATGAAAATCTTCAGGAGATATGCAAAGCAGAAACCCTCGTGCAGGCCCGAAAGAGAAAGC 
701  GAACCAGTATCGAGAACCGAGTGAGAGGCAACCTGGAGAATTTGTTCCTGCAGTGCCCGAAACCCACACT 
771  GCAGCAGATCAGCCACATCGCCCAGCAGCTTGGGCTCGAGAAGGATGTGGTCCGAGTGTGGTTCTGTAAC 
841  CGGCGCCAGAAGGGCAAGCGATCAAGCAGCGACTATGCACAACGAGAGGATTTTGAGGCTGCTGGGTCTC 
911  CTTTCTCAGGGGGACCAGTGTCCTTTCCTCTGGCCCCAGGGCCCCATTTTGGTACCCCAGGCTATGGGAG 
981  CCCTCACTTCACTGCACTGTACTCCTCGGTCCCTTTCCCTGAGGGGGAAGCCTTTCCCCCTGTCTCCGTC 
1051 ACCACTCTGGGCTCTCCCATGCATTCAAACTGA 
 
Figure51D.16 OCT3/4 (POU5F1) mRNA sequence showing the forward (F) and reverse 
(R) primer binding sites, amplicon size: 127bp (NCBI accession number: NM_002701.5). 
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D.5 Mapped SOX2 Primers 
 
1    ATGTACAACATGATGGAGACGGAGCTGAAGCCGCCGGGCCCGCAGCAAACTTCGGGGGGCGGCGGCGGCA 
        F primer 
71   ACTCCACCGCGGCGGCGGCCGGCGGCAACCAGAAAAACAGCCCGGACCGCGTCAAGCGGCCCATGAATGC 
141  CTTCATGGTGTGGTCCCGCGGGCAGCGGCGCAAGATGGCCCAGGAGAACCCCAAGATGCACAACTCGGAG 
          R primer 
211  ATCAGCAAGCGCCTGGGCGCCGAGTGGAAACTTTTGTCGGAGACGGAGAAGCGGCCGTTCATCGACGAGG 
281  CTAAGCGGCTGCGAGCGCTGCACATGAAGGAGCACCCGGATTATAAATACCGGCCCCGGCGGAAAACCAA 
351  GACGCTCATGAAGAAGGATAAGTACACGCTGCCCGGCGGGCTGCTGGCCCCCGGCGGCAATAGCATGGCG 
421  AGCGGGGTCGGGGTGGGCGCCGGCCTGGGCGCGGGCGTGAACCAGCGCATGGACAGTTACGCGCACATGA 
491  ACGGCTGGAGCAACGGCAGCTACAGCATGATGCAGGACCAGCTGGGCTACCCGCAGCACCCGGGCCTCAA 
561  TGCGCACGGCGCAGCGCAGATGCAGCCCATGCACCGCTACGACGTGAGCGCCCTGCAGTACAACTCCATG 
631  ACCAGCTCGCAGACCTACATGAACGGCTCGCCCACCTACAGCATGTCCTACTCGCAGCAGGGCACCCCTG 
701  GCATGGCTCTTGGCTCCATGGGTTCGGTGGTCAAGTCCGAGGCCAGCTCCAGCCCCCCTGTGGTTACCTC 
771  TTCCTCCCACTCCAGGGCGCCCTGCCAGGCCGGGGACCTCCGGGACATGATCAGCATGTATCTCCCCGGC 
841  GCCGAGGTGCCGGAACCCGCCGCCCCCAGCAGACTTCACATGTCCCAGCACTACCAGAGCGGCCCGGTGC 
911  CCGGCACGGCCATTAACGGCACACTGCCCCTCTCACACATGTGA 
 
Figure52D.17. SOX2 mRNA sequence showing the forward (F) and reverse (R) primer 
binding sites, amplicon size: 176bp (NCBI accession number: NM_003106.3). 
D.6 Mapped ACTB Primers 
 
1    ATGGATGATGATATCGCCGCGCTCGTCGTCGACAACGGCTCCGGCATGTGCAAGGCCGGCTTCGCGGGCG 
71   ACGATGCCCCCCGGGCCGTCTTCCCCTCCATCGTGGGGCGCCCCAGGCACCAGGGCGTGATGGTGGGCAT 
141  GGGTCAGAAGGATTCCTATGTGGGCGACGAGGCCCAGAGCAAGAGAGGCATCCTCACCCTGAAGTACCCC 
       F primer 
211  ATCGAGCACGGCATCGTCACCAACTGGGACGACATGGAGAAAATCTGGCACCACACCTTCTACAATGAGC 
281  TGCGTGTGGCTCCCGAGGAGCACCCCGTGCTGCTGACCGAGGCCCCCCTGAACCCCAAGGCCAACCGCGA 
            R primer 
351  GAAGATGACCCAGATCATGTTTGAGACCTTCAACACCCCAGCCATGTACGTTGCTATCCAGGCTGTGCTA 
421  TCCCTGTACGCCTCTGGCCGTACCACTGGCATCGTGATGGACTCCGGTGACGGGGTCACCCACACTGTGC 
491  CCATCTACGAGGGGTATGCCCTCCCCCATGCCATCCTGCGTCTGGACCTGGCTGGCCGGGACCTGACTGA 
561  CTACCTCATGAAGATCCTCACCGAGCGCGGCTACAGCTTCACCACCACGGCCGAGCGGGAAATCGTGCGT 
631  GACATTAAGGAGAAGCTGTGCTACGTCGCCCTGGACTTCGAGCAAGAGATGGCCACGGCTGCTTCCAGCT 
701  CCTCCCTGGAGAAGAGCTACGAGCTGCCTGACGGCCAGGTCATCACCATTGGCAATGAGCGGTTCCGCTG 
771  CCCTGAGGCACTCTTCCAGCCTTCCTTCCTGGGCATGGAGTCCTGTGGCATCCACGAAACTACCTTCAAC 
841  TCCATCATGAAGTGTGACGTGGACATCCGCAAAGACCTGTACGCCAACACAGTGCTGTCTGGCGGCACCA 
911  CCATGTACCCTGGCATTGCCGACAGGATGCAGAAGGAGATCACTGCCCTGGCACCCAGCACAATGAAGAT 
981  CAAGATCATTGCTCCTCCTGAGCGCAAGTACTCCGTGTGGATCGGCGGCTCCATCCTGGCCTCGCTGTCC 
1051 ACCTTCCAGCAGATGTGGATCAGCAAGCAGGAGTATGACGAGTCCGGCCCCTCCATCGTCCACCGCAAAT 
1121 GCTTCTAG 
 
Figure53D.18. ACTB mRNA sequence showing the forward (F) and reverse (R) primer 
binding sites, amplicon size: 192bp (NCBI accession number: NM_001101.3). 
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D.7 Mapped HPRT Primers 
 
1    ATGGCGACCCGCAGCCCTGGCGTCGTGATTAGTGATGATGAACCAGGTTATGACCTTGATTTATTTTGCA 
71   TACCTAATCATTATGCTGAGGATTTGGAAAGGGTGTTTATTCCTCATGGACTAATTATGGACAGGACTGA 
141  ACGTCTTGCTCGAGATGTGATGAAGGAGATGGGAGGCCATCACATTGTAGCCCTCTGTGTGCTCAAGGGG 
211  GGCTATAAATTCTTTGCTGACCTGCTGGATTACATCAAAGCACTGAATAGAAATAGTGATAGATCCATTC 
281  CTATGACTGTAGATTTTATCAGACTGAAGAGCTATTGTAATGACCAGTCAACAGGGGACATAAAAGTAAT 
          F primer 
351  TGGTGGAGATGATCTCTCAACTTTAACTGGAAAGAATGTCTTGATTGTGGAAGATATAATTGACACTGGC 
421  AAAACAATGCAGACTTTGCTTTCCTTGGTCAGGCAGTATAATCCAAAGATGGTCAAGGTCGCAAGCTTGC 
   R primer 
491  AGCTTGCTGGTGAAAAGGACC TTTGTTGGATTTGAAATTCCAGACAAGTT 
561  TGTTGTAGGATATGCCCTTGACTATAATGAATACTTCAGGGATTTGAATCATGTTTGTGTCATTAGTGAA 
631  ACTGGAAAAGCAAAATACAAAGCCTAA 
 
Figure54D.19. HPRT mRNA sequence showing the forward (F) and reverse (R) primer 
binding sites, amplicon size: 130bp (NCBI accession number: NM_000194.2). 
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D.8 Mapped YWHAZ Primers 
 
1    CTTTCTCCTTCCCCTTCTTCCGGGCTCCCGTCCCGGCTCATCACCCGGCCTGTGGCCCACTCCCACCGCC 
71   AGCTGGAACCCTGGGGACTACGACGTCCCTCAAACCTTGCTTCTAGGAGATAAAAAGAACATCCAGTCAT 
141  GGATAAAAATGAGCTGGTTCAGAAGGCCAAACTGGCCGAGCAGGCTGAGCGATATGATGACATGGCAGCC 
211  TGCATGAAGTCTGTAACTGAGCAAGGAGCTGAATTATCCAATGAGGAGAGGAATCTTCTCTCAGTTGCTT 
281  ATAAAAATGTTGTAGGAGCCCGTAGGTCATCTTGGAGGGTCGTCTCAAGTATTGAACAAAAGACGGAAGG 
351  TGCTGAGAAAAAACAGCAGATGGCTCGAGAATACAGAGAGAAAATTGAGACGGAGCTAAGAGATATCTGC 
421  AATGATGTACTGTCTCTTTTGGAAAAGTTCTTGATCCCCAATGCTTCACAAGCAGAGAGCAAAGTCTTCT 
491  ATTTGAAAATGAAAGGAGATTACTACCGTTACTTGGCTGAGGTTGCCGCTGGTGATGACAAGAAAGGGAT 
561  TGTCGATCAGTCACAACAAGCATACCAAGAAGCTTTTGAAATCAGCAAAAAGGAAATGCAACCAACACAT 
631  CCTATCAGACTGGGTCTGGCCCTTAACTTCTCTGTGTTCTATTATGAGATTCTGAACTCCCCAGAGAAAG 
701  CCTGCTCTCTTGCAAAGACAGCTTTTGATGAAGCCATTGCTGAACTTGATACATTAAGTGAAGAGTCATA 
771  CAAAGACAGCACGCTAATAATGCAATTACTGAGAGACAACTTGACATTGTGGACATCGGATACCCAAGGA 
841  GACGAAGCTGAAGCAGGAGAAGGAGGGGAAAATTAACCGGCCTTCCAACTTTTGTCTGCCTCATTCTAAA 
911  ATTTACACAGTAGACCATTTGTCATCCATGCTGTCCCACAAATAGTTTTTTGTTTACGATTTATGACAGG 
981  TTTATGTTACTTCTATTTGAATTTCTATATTTCCCATGTGGTTTTTATGTTTAATATTAGGGGAGTAGAG 
1051 CCAGTTAACATTTAGGGAGTTATCTGTTTTCATCTTGAGGTGGCCAATATGGGGATGTGGAATTTTTATA 
         F primer 
1121 CAAGTTATAAGTGTTTGGCATAGTACTTTTGGTACATTGTGGCTTCAAAAGGGCCAGTGTAAAACTGCTT 
     R primer 
1191 CCATGTCTAAGCAAAGAAAACTGCCTACATACTGGTTTGTCCTGGCGGGGAATAAAAGGGATCATTGGTT 
1261 CCAGTCACAGGTGTAGTAATTGTGGGTACTTTAAGGTTTGGAGCACTTACAAGGCTGTGGTAGAATCATA 
1331 CCCCATGGATACCACATATTAAACCATGTATATCTGTGGAATACTCAATGTGTACACCTTTGACTACAGC 
1401 TGCAGAAGTGTTCCTTTAGACAAAGTTGTGACCCATTTTACTCTGGATAAGGGCAGAAACGGTTCACATT 
1471 CCATTATTTGTAAAGTTACCTGCTGTTAGCTTTCATTATTTTTGCTACACTCATTTTATTTGTATTTAAA 
1541 TGTTTTAGGCAACCTAAGAACAAATGTAAAAGTAAAGATGCAGGAAAAATGAATTGCTTGGTATTCATTA 
1611 CTTCATGTATATCAAGCACAGCAGTAAAACAAAAACCCATGTATTTAACTTTTTTTTAGGATTTTTGCTT 
1681 TTGTGATTTTTTTTTTTTTGATACTTGCCTAACATGCATGTGCTGTAAAAATAGTTAACAGGGAAATAAC 
1751 TTGAGATGATGGCTAGCTTTGTTTAATGTCTTATGAAATTTTCATGAACAATCCAAGCATAATTGTTAAG 
1821 AACACGTGTATTAAATTCATGTAAGTGGAATAAAAGTTTTATGAATGGACTTTTCAACTACTTTCTCTAC 
1891 AGCTTTTCATGTAAATTAGTCTTGGTTCTGAAACTTCTCTAAAGGAAATTGTACATTTTTTGAAATTTAT 
1961 TCCTTATTCCCTCTTGGCAGCTAATGGGCTCTTACCAAGTTTAAACACAAAATTTATCATAACAAAAATA 
2031 CTACTAATATAACTACTGTTTCCATGTCCCATGATCCCCTCTCTTCCTCCCCACCCTGAAAAAAATGAGT 
2101 TCCTATTTTTTCTGGGAGAGGGGGGGATTGATTAGAAAAAAATGTAGTGTGTTCCATTTAAAATTTTGGC 
2171 ATATGGCATTTTCTAACTTAGGAAGCCACAATGTTCTTGGCCCATCATGACATTGGGTAGCATTAACTGT 
2241 AAGTTTTGTGCTTCCAAATCACTTTTTGGTTTTTAAGAATTTCTTGATACTCTTATAGCCTGCCTTCAAT 
2311 TTTGATCCTTTATTCTTTCTATTTGTCAGGTGCACAAGATTACCTTCCTGTTTTAGCCTTCTGTCTTGTC 
2381 ACCAACCATTCTTACTTGGTGGCCATGTACTTGGAAAAAGGCCGCATGATCTTTCTGGCTCCACTCAGTG 
2451 TCTAAGGCACCCTGCTTCCTTTGCTTGCATCCCACAGACTATTTCCCTCATCCTATTTACTGCAGCAAAT 
2521 CTCTCCTTAGTTGATGAGACTGTGTTTATCTCCCTTTAAAACCCTACCTATCCTGAATGGTCTGTCATTG 
2591 TCTGCCTTTAAAATCCTTCCTCTTTCTTCCTCCTCTATTCTCTAAATAATGATGGGGCTAAGTTATACCC 
2661 AAAGCTCACTTTACAAAATATTTCCTCAGTACTTTGCAGAAAACACCAAACAAAAATGCCATTTTAAAAA 
2731 AGGTGTATTTTTTCTTTTAGAATGTAAGCTCCTCAAGAGCAGGGACAATGTTTTCTGTATGTTCTATTGT 
2801 GCCTAGTACACTGTAAATGCTCAATAAATATTGATGATGGGAGGCAGTGAGTCTTGATGATAAGGGTGAG 
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2871 AAACTGAAATCCCAAACACTGTTTTGTTGCTTGTTTTATTATGACCTCAGATTAAATTGGGAAATATTGG 
2941 CCCTTTTGAATAATTGTCCCAAATATTACATTCAAATAAAAGTGCAATGGAGAAAAAAAAAAA 
 
Figure55D.20. YWHAZ mRNA sequence showing the forward (F) and reverse (R) primer 
binding sites, amplicon size: 94bp (NCBI accession number: NM_003406.3). 
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Appendix E 
Ethics Waiver 
 
